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Abstract 
Risk Prediction Modelling in Head and Neck Cancer:  Development and 
Validation of a Model using the UK Biobank.                                                            
Caroline Elizabeth McCarthy 
Introduction and Aims 
Head and Neck Cancer (HNC) is the sixth most common cancer worldwide and it causes 
significant morbidity and mortality.  A risk prediction model could help to stratify patients 
according to risk of disease and be used in the design of clinical trials to aid selection of 
participants.  This thesis concerns the development and validation of a risk prediction 
model for absolute risk of HNC, using the UK Biobank dataset.  The changes in incidence of 
HNC in England between 2002-2011 will be explored and novel female-specific risk factors 
will be reviewed. 
Methods 
The model has been developed within the UK Biobank dataset, using logistic regression.  
The internal validity of the model was assessed using discrimination and calibration 
statistics.  The model was externally validated within a cohort of the UK Biobank not used 
to develop the original model.   
Results 
The risk model developed contains variables for age, smoking, gender, alcohol, diet, 
household income, BMI, number of sexual partners, fruit consumption and exercise.  The 
c-statistic was 0.67 and the model displayed good calibration.  On external validation, the 
c-statistic was 0.64 with good calibration.   
Conclusions 
Methods for assessing the implementation and impact of the model are discussed.         
The model has shown reasonable performance through internal and external validation 
methods.  Risk prediction models have the potential to inform the design of future clinical 
trials in HNC and this could be translated to work in OED.  
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Chapter 1 
 
Introduction 
 
 
 
This chapter discusses Head and Neck Cancer (HNC) and summarises the incidence 
of the disease according to geographical regions, gender and age (section 1.1).  It 
then goes on to discuss potential risk factors (section 1.2) and, briefly, cancer 
screening for other cancers (1.3.1).  Risk prediction modelling is introduced in 1.3.2 
with two examples of risk models developed for related conditions.  
1.1 Head and Neck Cancer 
The term ‘Head and Neck Cancer’ [HNC] refers to a heterogenous group of cancers 
affecting various sites of the head and neck, including the lip and oral cavity, salivary 
glands, pharynx, larynx, nasal cavity and paranasal sinuses (1), each with its own risk 
factor profile.   Figure 1.1 shows these anatomical sub-sites. 
 
 
 
 
 
 
 
 
Figure 1.1. Diagram showing sub-sites of Head and Neck Cancer.                            
Image from https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet 
2 
 
  
 According to the United Kingdom Association of Cancer Registries (UKACR), in their 
Library of recommendations on cancer coding and classification policy and practice 
(2), HNC includes cancers of the following sub-sites (International Classification of 
Diseases (ICD) codes are shown in parenthesis): oral cavity (C00-06), salivary glands 
(C07-08), tonsil and oropharynx (C09-10), nasopharynx (C11), piriform sinus (C12), 
hypopharynx (C13), base of tongue (C02.9), nasal cavity and middle ear (C30), 
accessory sinuses (C31) and larynx (C32).  The term “oropharyngeal cancer” includes 
cancers of the base of tongue, tonsil, soft palate and pharyngeal walls.   
There has been wide variation in the definition of HNC in the literature, with some 
papers including cervical oesophagus or thyroid gland (3, 4). 
In the UK, there were 12,061 cases of HNC in 2015 and 4,047 deaths in 2016 (5).  Over 
90% of HNC are thought to be preventable.  HNC is the eighth most common cancer 
in the UK and incidence rates have risen by 30% over the last 30 years (5). 
An overall incidence for HNC of 19.9 per 100,000 persons was reported in the UK in 
2015, by Cancer Research UK.  Incidence varies depending on sub-site, with 
nasopharyngeal cancer and oral cavity cancer having incidences of 0.49 and 3.13 per 
100,000 persons respectively (data from 2000-2004, South East England; Thames 
Cancer Registry) (1). 
1.1.1 Geographical Variation 
There is wide geographical variation in incidence, worldwide, with the highest 
incidence in South and Southeast Asia (Sri Lanka, India, Pakistan and Taiwan).  Oral 
cancer is the most common cancer in males in Sri Lanka (incidence 10.2 per 100,000) 
and this is likely to be due to specific risk factors such as chewing of smokeless 
tobacco (6).  In India, an average of 100,000 new cases of oral cancer per year are 
reported, in comparison to 4,564 in the UK in 2010 (5).  Parts of Western Europe (e.g. 
France), Eastern Europe (e.g. Hungary and Slovakia), Latin America and the Caribbean 
(e.g. Brazil, Uruguay and Puerto Rico) and the Pacific regions (e.g. Papua New Guinea 
and Melanesia) also have high incidences of oral cancer (6).   
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Within the UK, there are variations in incidence, with Scotland reporting a higher 
incidence of HNC than the rest of the UK; the incidence in Scotland increased from 
12.57 to 22.04 per 100,000 between 1975 and 2012 (7).  Up to 2010, the middle super 
output area (MSOA) of Liverpool experienced a peak incidence of HNC of 35 per 
100,000, which is higher than less economically developed areas of the Indian 
subcontinent for example (8).  
1.1.2 Gender 
Gender differences in incidence of HNC are marked, with 64.3-78.6% of HNC patients 
being male (1, 9-12), however, an increasing incidence in females has been noted 
(13, 14).  Males are three times more likely than females to develop HNC in the UK 
(incidence 12.7 per 100,000 vs 4.9 per 100,000) (1).  In the USA, the percentage of 
women affected increased from 40% to 45% between 1990 and 2004 and this is 
thought to be due to changes in smoking habits between men and women (13). 
1.1.3 Age 
HNC has higher incidence in older age groups; most tumours develop in persons in 
the fifth and sixth decade (1, 10, 11, 15).  60% of HNC patients in the UK are aged 
between 40 and 69 years and this is similar for the rest of the world (1).  Canada 
reports 60% of HNC patients are over the age of 60 years (11).  In the Middle East, 
51% are in the 50-69 years age category (10) and 50% are aged 60-79 years in 
Germany (15).  More recently, a trend for younger individuals developing HNC has 
been noticed, particularly in the USA and Scotland (13, 16).  In Scotland, where this 
trend was first reported, the incidence rate in males under 45 years of age more than 
doubled, from 0.6 to 1.3 per 100,000, between 1990 and 1999 (7).  
1.1.4 Global changes in Incidence of HNC 
Changes in incidence of HNC/oral cancer, over different time periods, have been 
reported (1, 10, 11, 17, 18).  In the UK, between 2002 and 2006, certain sub-types of 
HNC demonstrated a significant increase in incidence: oropharyngeal cancer doubled 
in incidence and oral cancer has been rising by 2.7% per year for the last twenty years 
(19). There has been an increase of 12% in males and 11% in females in the UK 
between 1995-1999 and 2000-2004 (1).  In the same period, the incidence of 
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laryngeal cancer decreased by 16% in males and 14% in females, possibly due to a 
decrease in smoking (1).   
In Europe, the incidence of oral cancer has been steadily increasing over the last two 
decades, although reports vary in whether or not they include the sub-site of the 
oropharynx (5).  In the Netherlands, a 0.5-2% annual increase in oral cavity cancer 
and 2.3-3% annual increase in oropharyngeal cancer was noted between 1989 and 
2006 (17).  Canada reported a decrease in incidence from 10.7 to 8.8 per 100,000 for 
oral cancer between 1992 and 2009 and an increase in oropharyngeal cancer from 
1.6 to 2.6 per 100,000 in the same period (11).  Croatia reported a 24% decrease in 
HNC from 1988 to 2008 (18) whilst Denmark reported an increase of 5 per 100,000 
between 1982-2007 (10).  In Australia, between 1982 and 2005, cancers of the base 
of tongue and tonsil increased in incidence by 1.39% and 3.02% respectively in males 
(20).  Oral cavity cancers decreased by 1.69% in the same time-frame (20).  The 
general trend is that the incidence of oropharyngeal cancer is rapidly increasing.  
Human papillomavirus (HPV) infection is strongly implicated as a risk factor for 
oropharyngeal cancer and will be discussed in section 1.2.4 (20).   
 
1.2 Risk Factors 
Smoking and alcohol are significant risk factors for HNC and will be discussed in 1.2.1.  
Other risk factors will be considered in sections 1.2.3 – 1.2.8, including diet, HPV, 
periodontal disease and socio-economic status. 
1.2.1 Tobacco and Alcohol 
Tobacco smoking, chewing tobacco and alcohol cause 75% of HNC (21).  Tobacco and 
alcohol act synergistically, as well as independently (21).  The relative risk for heavy 
smokers who consume 100-180g/ethanol per day (a heavy drinker) is 50.1 (95% CI 
33.54 – 74.91), compared to 6.21 (95% CI 3.76–10.24) for heavy smokers who only 
drink 0 – 24g ethanol/day and 2.27 (95% 1.11–4.63) for a heavy drinker who does not 
smoke (22).  The risk of HNC related to smoking increases with increasing frequency, 
duration and pack years (23). (Pack years is calculated as: number of cigarettes 
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smoked per day/20 × number of years smoked).  Earlier age of starting smoking is 
also associated with increased risk (23).  It is known that mortality rates from HNC 
are higher amongst smokers (19).   
The main risk factor in non-smokers is alcohol consumption and in those who do not 
consume alcohol, the main risk factor is smoking (23). Alcohol increases mucosal 
permeability and therefore allows increased uptake of carcinogens (24).  As with 
smoking tobacco, the risk of HNC attributed to alcohol increases with daily quantity, 
duration of consumption and lifetime cumulative consumption (23).  Research has 
been carried out into the effects of different types of alcohol, with varying results 
(25, 26); it appears that the quantity and the alcoholic content of the beverage 
consumed is most important (23). 
1.2.1.1 Smokeless Tobacco 
Smokeless tobacco is widely used in certain populations (27, 28).  Betel quid 
(paan/areca nut) is popular amongst Bangladeshi women and this extends to ethnic 
groups in the UK (28). Risk increases with quantity used and duration of use (23). The 
betel nut is held against the oral mucosa for long periods and may or may not be 
mixed with tobacco. Adding tobacco increases carcinogenesis, and in Asia, the use of 
betel quid is a stronger risk factor for oral cancer than smoking (23).  It seems to exert 
strongest effect on the gingivae, with a markedly increased risk of gingival carcinoma 
amongst users when compared to tongue cancer (23).   
1.2.3 Diet 
Poor diet is thought to account for 10-15% of oral/pharyngeal cancers (23).  Intake 
of fruits and vegetables may protect against HNC (29). A large prospective study 
conducted by the National Institute of Health, in a cohort of 490,802 members of the 
American Association of Retired Persons (NIH-AARP) followed-up from 1995/1996 to 
2000, showed that intake of vegetables had a more profound effect (Hazard Ratio 
[HR] 0.65, 95% CI 0.50-0.85) in reducing the risk of developing HNC than fruits (HR 
0.87, 95%CI 0.68-1.11)(29).  Cereals, butter, olive oil, grilled meat, fresh fish, pork and 
shellfish have all been explored with varying results regarding protective and harmful 
effects (23).  Consuming Maté (a herbal tea from South America) is known to increase 
6 
 
risk of oral cancer by 2.5 to 3.7 times (23).  Salted fish, consumed by Chinese 
populations, has also been found to increase the risk of nasopharyngeal carcinomas 
(28). 
1.2.4 Human papillomavirus 
Human papillomavirus infection [HPV] is rapidly emerging as a major cause of 
oropharyngeal cancer (OPC) and is thought to account for 20-25% of HNC (11, 20, 
21).  It is sexually transmitted and, therefore, individuals most at risk are those with 
early-age sexual activity and a high number of sexual partners (30).  A UK multi-centre 
study of HPV status of oropharyngeal cancers revealed that 51.8% (95% CI:49.3 - 
54.4) were HPV positive (31), whilst figures for oral cancer and laryngeal cancer were 
23.5% and 24% respectively (32). Some studies report HPV detection in over 80% of 
oropharyngeal cancers, however it is important to remember that detection does not 
imply causation (10% of benign oral samples were found to be HPV positive) (23).  
Interestingly, the rapid increase in the incidence of OPC (section 1.1.4) is not 
paralleled with an increase in the proportion of HPV-positive cases of OPC (31).  This 
demonstrates the need for further work into the underlying reasons for the 
increasing incidence of OPC cancers. 
1.2.5 Ethnic-Specific Risk Factors 
Ethnicity alone is not considered a risk factor for HNC, however ethnic-specific risk 
factors (such as betel quid use, discussed in 1.2.4) are very important (23). 
Interestingly, oropharyngeal cancer has much lower incidence in ethnic groups 
compared to white males and the incidence is lowest amongst black Africans (28).  
Incidence rates for cancer of the hypopharynx and salivary glands, which are not 
influenced as much by traditional risk factors, are very similar for ethnic minority 
groups and non-ethnic minority groups, which further supports the argument that 
ethnic-specific risk factors are responsible for the higher incidence of other HNC’s in 
ethnic-minority groups, rather than ethnicity alone (28). 
1.2.6 Periodontal Disease 
Periodontal disease and poor oral health have been investigated as possible risk 
factors for HNC. Eliot et al. reported an Odds Ratio [OR] of 1.09 (95%CI 1.02-1.16) for 
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periodontal disease, controlling for smoking, in a case-control study of 513 cases and 
567 controls (33).  This supports the findings of another study which found that 
increasing alveolar bone loss is associated with an increased risk of HNC (34).  
Periodontal disease involves a shift in the bacterial flora in the gums, accompanied 
by a potentially pathogenic inflammatory response, which may lead to alterations in 
the immune system, increased cellular proliferation and the generation of DNA-
damaging free radicals (33). 
1.2.7 Socio-economic Status 
Low socio-economic status (SES) is known to be a risk factor for many diseases and 
has been recognised as a significant risk factor for HNC (35). Although SES is highly 
correlated with other risk factors, such as smoking and alcohol consumption (16), 
there remains a significant proportion of risk associated with social deprivation that 
cannot be attributed to other risk factors (35).   
HNC is more common in low socio-economic groups and those with lower 
educational attainment (OR 1.9, 95%CI 1.6-2.3) (23).  Low educational attainment 
remained as a risk factor for HNC, when controlling for age, sex, smoking, alcohol and 
diet (OR 1.34 95% CI 1.04 – 1.73) in a meta-analysis of 16 studies with 4,395 cases of 
HNC (35).  Low household income was also associated with an increased risk of HNC, 
in a meta-analysis of 8 studies with 1,048 cases of HNC (OR 1.56 95% CI 1.29 – 1.88), 
controlling for age, sex, smoking and alcohol (35).   
A meta-analysis of 41 case-control studies (15,344 cases and 33, 852 controls) 
investigated the impact of SES on oral / oropharyngeal cancer risk. Low income, low 
occupational social class, and low educational attainment were all associated with 
HNC (36). Compared with individuals who were in high SES strata, the pooled ORs for 
the risk of developing oral cancer were 1.85 (95%CI 1.60- 2.15) in 37 studies for those 
with low educational attainment, 1.84 (95%CI 1.47-2.31) in 14 studies for those with 
low occupational social class,  and 2.41 (95%CI 1.59-3.65) in 5 studies for those with 
low income (36).  
 The effect of poor education on health, lack of access to healthcare, hygiene, poor 
nutrition, unfavourable working environments and poor living conditions may 
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contribute to causation of oral cancer via complex interactions with well-established 
risk factors such as smoking and alcohol (35, 36).  The high incidence in Liverpool 
(described in section 1.1.1) is likely to be linked, in part, to social deprivation; 
Liverpool was rated the most deprived local authority in England in 2010 (8). 
1.2.8 Occupational Risk Factors 
The International Agency for Research on Cancer (IARC) consider wood dust and 
leather dust-exposure as risk factors for sino-nasal cancers (37).  A systematic 
review of occupational risk factors for HNCs, based on 14 eligible studies (38), 
concluded that there was an association between exposure to formaldehyde and 
nasopharyngeal (39) and hypopharyngeal cancers (40) (OR 2.7 (95% CI 1.2-6.0) and 
OR 3.78 (95% CI 1.50-9.49) respectively) , wood dust and nasopharyngeal cancer 
(41), coal particles and hypopharyngeal cancer (40), asbestos and pharyngeal 
cancer (42) and leather dust and HNC (42). However, each of these associations is 
only based on an individual study and two of these studies did not control for 
alcohol consumption (39, 41), which increases the risk of confounding.  Seven of the 
included studies did not control for all relevant risk factors such as age, smoking 
and alcohol, therefore the results should be interpreted with caution. 
1.3 The Benefit of Early Detection of HNC 
It is known that early detection of HNC improves outcome, with 5 year survival rates 
of around 80%, compared to those diagnosed with nodal metastases, in whom this 
figure falls to 20% (19, 43, 44).   Presently, most HNCs are TNM (Tumour size, Nodal 
spread, distant Metastasis; TNM Classification of Malignant Tumours) stages 3 or 4 
at diagnosis; in a Danish study of nearly 10,000 HNC cases, 58% were diagnosed at 
late stage.  Risk factors for late stage diagnosis of oral cancer included male gender 
(female gender was protective): OR 0.63 95% CI 0.62 – 0.65), low income (OR 1.83 
95% CI 1.59 – 2.10) and shorter length of education (OR 1.80 95% CI 1.58 – 2.05)(45), 
which supports the role of social deprivation in HNC. 
Treatment of HNC is often multi-modal, including surgery, radiotherapy and/or 
chemoradiotherapy in the curative setting.  For recurrent or metastatic disease 
chemotherapy or immunotherapy may be offered.  Treatment carries significant 
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morbidity; early detection is crucial to the survival of cancer patients and enables less 
invasive treatments, which are associated with less morbidity, such as speech or 
swallowing impairment (46). 
1.3.1 Cancer Screening     
The aim of cancer screening is to detect patients with a high risk of having the disease 
in question.  These individuals would then be offered a diagnostic test to confirm if 
they have the disease.  The hope is that screening would identify cases at an earlier 
stage, which maximises survival.  Cancer screening can also reduce the incidence of 
disease through the accurate detection and treatment of pre-malignant conditions, 
before a cancer develops.  For example, the cervical cancer screening programme in 
the UK has resulted in a large decrease in incidence (OR 0.18 95% CI 0.16 – 0.20; 
females aged 35-64 years regularly screened) (47). 
Despite increased incidence of some cancer types, there has been a decreased 
incidence in age standardised mortality rate from all cancers (US data) (48). This has 
been attributed to the combined effect of early detection due to screening and the 
availability and provision of improved treatment (48).  In the UK there are screening 
programmes in place for breast cancer, bowel cancer and cervical cancer.  Breast 
cancer mortality is 35% lower amongst those who attend for breast screening 
compared to those who do not (OR 0.65 95% CI 0.53 – 0.80) (49) and cervical cancer 
screening prevents 70% (95% CI: 66–73%) of deaths from cervical cancer (47).  
Regular bowel cancer screening reduces the risk of dying from bowel cancer by 15% 
(50, 51). 
There is no current lung cancer screening programme in the UK, although results 
from randomised controlled trials are favourable (52-54).  The European position 
statement on lung cancer screening was published in 2017 and recommends 
European countries should begin planning their respective lung cancer screening 
programmes (55); this statement suggests only high- risk individuals are selected for 
screening and the use of risk prediction modelling to identify such patients.   
No screening programme is currently in place for HNC in the UK and this is partly due 
to the low detection rates demonstrated in studies (56).  Most  screening studies for 
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oral cancer have been completed in India, with varying results (57). It has been 
suggested that more research into targeted screening of high risk individuals is 
needed (58).  The U.S Preventive Task Force published recommendations regarding 
oral cancer and recommended that future research should aim to clearly define high 
risk individuals that will allow the efficacy of screening programmes to be accurately 
assessed.  They also stated that screening high-risk individuals may be cost-effective 
(59).  Screening for oral cancer is usually non-invasive, involving a clinical oral 
examination, whereas screening for other smoking-related cancers, such as lung 
cancer, involves exposure to radiation using a computerised tomographic (CT) scan. 
With any screening programme, there is a risk of false positive diagnosis, unnecessary 
surgery for benign lesions and associated psychological harm, and these effects must 
be carefully balanced against the benefits of screening (55).   
Often, individuals are selected for screening for cancers based on age or gender, e.g. 
the UK bowel cancer screening programme offers flexible sigmoidoscopy at age 55 
years, with two-yearly faecal occult blood test (FOBT) from age 60-74 years (60). 
However, cancers for which an invasive test is required may be targeted though 
screening of high-risk individuals, to balance the risk of harm and benefit (55).  High-
risk individuals can be identified using risk prediction models (section 1.3.2).   
1.3.2 Risk Prediction Models 
In recent years, epidemiological research has played a prominent role in predicting 
individual risk of developing chronic diseases. The potential public health benefits of 
individualised estimates of the probability of developing a disease cannot be 
overemphasised. Because of the public health significance, the National Cancer 
Institute has recognised risk prediction as an area of extraordinary opportunity (58).  
Risk prediction models for cancer are statistical models that estimate the probability 
of developing cancer over a defined period. Risk prediction for HNC would involve 
identifying the risk factors (so-called predictive or prognostic factors) of HNC and 
combining them into probability estimates of predicting HNC, either over a discrete 
time period or over a lifetime. The risk factors included in the model can be 
environmental, behavioural, genetic or psychological attributes of individuals, or any 
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combination of these. The development of a simple-to-use, validated, statistical 
model that estimates the probability of developing HNC over a defined period will 
help clinicians identify individuals at higher risk; this could allow more frequent 
screening in general dental practice and counselling of behavioural changes to 
decrease risk. These types of models will also be useful for designing future 
chemoprevention and screening intervention trials in individuals at high risk of HNC 
in the general population. Although risk models have been developed for cardio-
vascular disease (61), lung (62), breast (58, 63, 64) and colorectal cancer (65), a model 
incorporating oral cancer does not exist. 
Once a risk prediction model has been developed in a sample population, it must be 
validated in independent samples from the same population (internal validation) and 
ideally, within samples from different populations (external validation), to ensure its 
reliability and transportability to different populations.  Results of these internal and 
external validation studies may stimulate the modification of the original model, 
leading to new or modified models being gradually developed over time (66). 
There are a variety of ways of assessing the performance of a model, such as 
sensitivity, specificity and the AUC (area under the receiver operating curve [ROC]) 
(66).  The E/O statistic and c statistic are the most commonly reported statistics in 
relation to risk model performance (67, 68).  The E/O statistic measures the 
calibration performance of the model.  It compares the expected (E) numbers to 
observed (O) numbers of events, so a well-fitting model should have a value close to 
1 (67).  The c-statistic is equivalent to the AUC and it measures the discrimination 
performance of the model.  A value of 0.5 indicates no discrimination between those 
who develop the disease and those who do not, whereas a value of 1 indicates 
perfect discrimination (68).  
1.3.2.1 A risk model for Barrett’s oesophagus 
Barrett’s oesophagus is a pre-malignant oesophageal disease.  A risk model for 
predicting an individual’s risk of Barrett’s oesophagus, as detected by endoscopic 
screening, has been developed (69).  This study included 393 cases and 313 controls 
with non-Barrett inflammation of the oesophagus.  64% of cases were male and >95% 
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of cases and controls were Caucasian.  Variables included in the model were selected 
by a review of the literature and participants were required to complete a 
standardised health and lifestyle questionnaire, to collect information on these 
variables.  Variables included in the final model were selected by 2 phases of stepwise 
backward logistic regression.  The accuracy of the model was then assessed by using 
AUC (c-statistic) and calibration was assessed by using the Hosmer–Lemeshow 
goodness-of-fit test.  An AUC of 0.70 (95% CI, 0.66–0.74) was reported from the 
development dataset.  This was reduced to 0.61 (95% CI 0.56–0.66) in the external 
validation dataset. Performance of the model was good as shown by the goodness-
of-fit test (Hosmer–Lemeshow test, p=0.75).  This model compares favourably with 
the Gail model for breast cancer risk and other cancer risk models (43). 
 
1.3.2.2 A risk model for oesophageal cancer 
Kunzmann et al published a risk model for oesophageal adenocarcinoma, developed 
using the UK Biobank dataset (70), a cohort of over 500,000 adults over the age of 40 
years, recruited and followed up in the United Kingdom (described in detail in Section 
4.3.2).  They used a group of 355,034 adults over the age of 50 years with no cancer 
history at baseline, and identified 220 cases of oesophageal cancer during the 5-year 
follow-up period.  They developed a risk prediction model using Cox regression 
modelling and included variables for age, sex, smoking, body mass index and history 
of oesophageal conditions or treatments.  The discrimination performance was 
excellent with an AUC of 0.80.  They defined a cut off point for high-risk individuals 
and demonstrated that the model had a sensitivity of 77.4% and specificity of 70.4% 
for identifying those with disease. 
1.4 Aims: A Risk Model for Head and Neck Cancer using The UK 
Biobank Dataset 
Head and Neck cancer is a disease that is increasing in incidence and carries 
significant morbidity and mortality.  Efforts must be made to accurately identify high 
risk individuals to inform the design of future trials and to investigate the possibility 
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of screening of high-risk individuals.  Therefore, this thesis centres around building a 
risk model for head and neck cancer using a large, UK based dataset, containing 
extensive information on over 500,000 participants. 
The model was developed using logistic regression modelling (Chapter 6), using data 
from a section of the database containing participants from all areas of the UK 
excluding the North West; the model was validated in the North West cohort 
(Chapter 7).  Further details of the dataset can be found in Chapter 4, along with 
details of the methodology used to develop the model. Chapter 7 presents the 
external validation of the model in the North West Cohort. 
Prior to development and validation of the model, the trends in incidence of the 
disease in the UK will be investigated using data from the Office for National Statistics 
(Chapter 2).  Novel risk factors for head and neck cancer will be explored via a 
systematic review in Chapter 3.    The penultimate chapter will discuss Oral Dysplasia 
(a potentially malignant oral disease) and the potential for the use of risk modelling 
to guide management of this condition (Chapter 8).  The thesis will conclude by 
considering various applications of risk modelling to the field of HNC (Chapter 9). 
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Chapter 2 
 
Trends in the Incidence of Head and 
Neck Cancer in England:  2002 to 
2011 
 
 
 
The work within this Chapter was published in the International Journal of Oncology 
(Appendix 8). 
Trends and Regional Variation in the Incidence of head and neck cancers in England: 
2002-2011.   
McCarthy CE, Field JK, Rajlawat BP, Field EA, Marcus MW. 
Int J Oncol. 2015 Jul;47(1):204-10. doi: 10.3892/ijo.2015.2990. Epub 2015 May 7 
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2.1 Introduction 
Chapter 1 introduced Head and Neck Cancer (HNC) as a disease and described, 
briefly, the problems of increasing incidence and the known risk factors.  Risk 
prediction modelling was also introduced as a method to identify individuals at high 
risk of the disease.  This chapter investigates the incidence of HNC in England 
between 2002 and 2011 using data from the Office for National Statistics (ONS), 
looking specifically at trends for age groups, regions of England and gender. 
2.2 Background 
Head and Neck Cancer (HNC) is the fifth most common cancer worldwide, with over 
550,000 cases reported in 2012, and 12,061 cases in the UK in 2015 (71, 72).  
Incidence of laryngeal cancers has remained stable in recent years, whilst dramatic 
increases in incidence of oropharyngeal cancers have been reported (73).  For a 
definition of HNC sub-sites see Section 1.1. and Fig. 1.1. 
Cancer statistics form part of the evidence base to inform decisions regarding public 
health measures and resource planning.  They can also help to define the need for 
further research in particular areas.  In England, cancer registrations are validated by 
the Office for National Statistics (ONS) following submission of data by the Regional 
cancer registries. The validated data are freely available from the ONS for analysis.  
Regional differences in cancer incidence in England have been reported, with the 
North of England having higher incidence in both males and females, which may be 
linked to increased levels of deprivation (8, 74). 
By 2041, it is estimated that there will be 3.2 million people, in the UK, over the age 
of 85, which is double the amount of 2016 (75).  This ageing population will develop 
more cancers and the analysis of trends in incidence will form an important part of 
health-care planning. 
The aim of this study was to assess overall incidence of HNC in England in 2002-2011.  
The distribution and trends in incidence of HNC’s at specific anatomical subsites have 
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been analysed and trends have been identified in the different Regions of England.  
Trends in incidence between gender and age-categories were also considered. 
2.3 Methods 
Cases of HNC were identified from the Office for National Statistics (ONS) database.  
The ONS collects and publishes data related to the economy, population and society 
in the United Kingdom (UK).  Cancer registration has been conducted in parts of the 
UK since 1929 but national coverage was not achieved until 1962.  Cancer registries 
are now responsible for collecting data on cancer incidence, mortality and survival.  
In England, there are nine cancer registries and each uploads their regional data to a 
repository for validation by the ONS.  The validation process is based on process 
recommended by the International Agency for Research on Cancer.  Following 
internal validation by the ONS, detailed results of annual incidence of all cancers are 
published, categorised by age, gender and region of residence. 
Head and Neck Cancer cases were identified using ICD codes C00-C14 and C30-C32 
(see section 1.1).  The data available included raw numbers and age-
standardised/age-specific rates for males and females in 19 five-year age categories, 
from <1 to 85 years+.  Raw numbers and age-standardised rate ratios were available 
for the Regions (former “Government Offices for the Regions”) of England (Table 2.1).  
Incidence was calculated using cancer registration data and sex- and age-specific 
population data for each region of England, which was available from ONS.   A ten-
year period (2002-2011) was chosen in order to have sufficient data to allow 
examination of recent trends in the incidence of HNC. 
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Table 2.1.  Regions used to Categorise Cancer Statistics, by the Office for National Statistics.  Data on incidence of 
HNC and the sub-groups were analysed according to these Regions. 
Regions used to categorise Cancer Statistics 
North East 
North West 
Yorkshire and Humber 
East Midlands 
West Midlands 
East 
London 
South East 
South West 
 
Data were analysed to look for trends between age categories, gender, region and 
HNC subtypes within this period.  Combinations of these variables were also 
analysed.  There has been a reported increase in the incidence of Human 
papillomavirus-related HNC in recent years, therefore oropharyngeal (C09), base of 
tongue (C01) and tonsillar cancers (C10) were analysed as a subgroup, as these sites 
have most frequently been associated with HPV-infection (31, 32).  This group will be 
referred to as oropharyngeal squamous cell carcinomas (OPSCC).  The HPV status of 
these cancers is not known, however it has been reported that 36-80% of cancers at 
these sites are HPV-associated (31, 32).  This is discussed in more detail in section 
2.5.1.1. 
 Oral Cancer included ICD codes C00, C02-06 and C12-14.  Laryngeal cancers were 
also analysed separately (C32) as they account for a significant proportion of HNC 
(72).  Salivary gland cancers (C07-08), nasopharynx (C11), nasal cavity and middle ear 
(C30) and accessory sinuses (C31) have the lowest incidence of HNC, therefore were 
not analysed separately but included in the overall HNC figures. 
Incident rates are reported as number of new cases per 100,000 person-years and 
are age-standardised according to the 2013 European Standard population.  The ESP 
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is an artificial population structure which allows weighting of incidence or mortality 
data to produced age-standardised rates. This provides an estimate of what the 
incidence rate would be if the age-distribution was the same as the ESP, which allows 
comparison between countries with different population structures.  The study 
population was categorised according to age, region of residence, gender and cancer 
sub-types.   
2.3.1 Statistical Analysis 
Poisson regression models were used to examine time trends in the overall incidence 
of HNCs and time trends in the five-year age categories, region of residence, gender 
and HNC subtypes, between 2002 and 2011.  Poisson regression determines if 
changes occurring across a time series are significant, whilst adjusting for an 
independent variable such as age.   The dependent variable is ‘incidence of head and 
neck cancer’ (or sub-category) and the independent variables were year, age 
category, region of residence and gender. 
 
The Poisson regression equation can be written as  
𝑃(𝑦𝑖|𝑥𝑖; 𝛽) =  
exp(− 𝑒𝑥𝑝(𝑥𝑖
′ 𝛽)) exp (𝑥𝑖
′𝛽)𝑦
𝑦!
 
where 𝑦𝑖 is the incidence of HNC and 𝑥𝑖  is an independent variable (age, region or 
gender).  𝛽 represents the coefficient associated with the independent variable, 𝑥. 
Stata statistical software (StataCorp. 2013 (Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP) was used to analyse the data and p-values <0.05 
were considered statistically significant. 
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2.4 Results 
In the period 2002-2011, 71,457 HNC’s were reported (69% men, 31% women).  
30,651 were oral cancers, 12,849 were OPSCC and 17,496 were laryngeal cancers.  
62.8% of HNC patients were 60 years or older. 
The number of cases of HNC and the incidence, in 2002 and 2011, are displayed in 
Table 2.2; full data for each year are in Appendix 1. The results are displayed 
graphically in Figure 2.1 for HNC and each sub-type (oral cancer, oropharyngeal 
cancer and laryngeal cancer). 
The average annual incidence in HNC increased by 30.3% from 2002-2011, from 12.2 
to 15.9 per 100,000.  There was a 27% increase in males (17.4 to 22.1 per 100,000; 
p=0.003) and 32% increase in females (7.4-9.8 per 100,000; p=0.004). 
The incidence of OPSCC cancer increased by 45.5% from 1.8 to 3.3 per 100,000 
between 2002-2011 (p<0.001).  In males, the increase was 47.1% (2.7 to 5.1 per 
100,000; p=0.003) and in females 37.5% (1.0 – 1.6 per 100,000; p=0.003).  
Oral Cavity cancer showed a 24.6% increase from 5.2 to 6.9 per 100,000.  For males, 
the increase was 24.1%, from 6.6 to 8.7 per 100,000 (p=0.005) and for females there 
was an increase of 25.5% (3.8 to 5.1 per 100,000) (p=0.004).  
The incidence of laryngeal cancer was stable in comparison, increasing by only 2.9% 
from 3.4 to 3.5 per 100,000 (p=0.32).  
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Table 2.2. Incidence and number of cases of HNC in England from 2002 to 2011 (see Appendix 1 for full data). P-
values for significance of the trend in incidence are presented, with <0.05 considered statistically significant. 
 
 
 
 
 
 
Year         Men         Women  
  2002 2011   2002 2011  
Number of Cases         
         
Head and Neck  4215 5788   1867 2636  
Oral  1611 2271   971 1376  
Oropharyngeal  654 1338   245 434  
Larynx  1374 1506   300 342  
         
Incidence per 100,000    p 
value 
   p value 
Head and Neck  17.4 22.1 0.003  7.4 9.8 0.004   
Oral  6.6 8.7 0.005  3.8 5.1 0.004 
Oropharyngeal  2.7 5.1 0.003  1.0 1.6 0.003 
Larynx  5.7 5.8 0.400  1.2 1.3 0.400 
  
 
2
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  The incidence of Head and Neck Cancer (combined), OPSCC, Oral Cancer and Laryngeal Cancer in England: 2002-2011.                     Incidence per 
100,000 persons.  The incidence of HNC, oral cancer and oropharyngeal cancer increased throughout the period 2002-2011, whereas laryngeal cancer 
incidence remained stable. 
                      Males                                             Females 
                       
Oropharyngeal SCC 
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2.4.1 Age 
Figure 2.2 compares incidence rates of HNC and the subtypes, for males and females, 
aged over 40 years, in five-year age-categories between 2002 and 2011.  Age is 
presented in 5-year groups by the ONS and this method of categorisation has been 
used in several other epidemiological studies (76, 77).  
96% of patients with HNC were aged forty years or older (range 96.0-96.7%).  53% of 
cases occurred in persons aged 55 to 75 years.  The highest incidence of HNC 
occurred in those aged 80 years and older (67.3 per 100,000 males and 30.0 per 
100,000 females) but the highest average number of cases occurred in the 60 to 64-
year age category (males: n=783; females: n=279). (See Figure 2.2 “HNC”). 
Oral Cancer also had highest incidence in males and females aged 80-years and older 
(25.4 and 18.7 per 100,000 respectively).  The greatest number of oral cancer cases 
occurred in males aged 55-65 years (n=299) and in females aged 65-75 years (n=136), 
with 31% and 23% of oral cancer cases occurring in these age groups respectively.  
Incidence continued to rise sharply through all age categories for females, whereas 
for males there was no significant increase in incidence beyond 80 years. (See Figure 
2.2 “Oral Cancer”). 
Laryngeal cancer incidence was highest in males and females aged 75 to 85 years 
(24.2 and 4.1 per 100,000 persons respectively), although the greatest number of 
cases was found in those aged 60-70 years (males: n=236 and females: n= 45), with 
20.7% and 32.4% of cases occurring in these age groups respectively.  After a sharp 
increase in incidence between 45 and 74 years, there is a slight decrease in incidence 
in the oldest age categories, although this is non-significant. (See Figure 2.2 
“Laryngeal Cancer”). 
The incidence and total number of OPSCC were highest in males and females age 55 
to 65 years (incidence 11.9 and 3.6 per 100,000 and n=349 and 110 respectively). 
There is a sharp rise in incidence between ages 40 and 60 years, followed by a 
statistically significant decrease in incidence from age 60 years upwards, for both 
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males and females (p=0.002).  16.4% of cases were in the 40 to 49-year age category 
(range 14.2-18.3%), compared to 9.3% (8.7-9.7%) for oral cancer.  (See Figure 2.2 
“Oropharyngeal SCC”). 
2.4.1.1 Trends within Age Categories 
From 2002 to 2011, there was a significant increase in incidence of HNC for males in 
all age categories from 25 to 75 years, although this was most marked for males aged 
55-74 years (incidence increased from 49.7 to 63.6 per 100,000 males).  The largest 
increase was seen in the 55-59-year age category, particularly the second half of the 
ten-year period, with incidence of 41.4 in 2002, 45.0 in 2006 and 67.3 per 100,000 in 
2011. (See Table 2.3). 
Significant increases were also seen in females aged 30 to 40 (Appendix 2) and 50 to 
85 years (Table 2.3), with the largest increase in incidence found in females aged 65-
84 years: the incidence increased from 21.6 to 29.2 per 100,000 females between 
2002 and 2011.  The largest percentage increase was found in females aged 65-69 
(17.4 to 25.5 per 100,000); however, the largest change in incidence was found in the 
80-84-year age category (25.1 to 33.3 per 100,000). 
For OPSCC, in males there was a significant increase in incidence over the ten-year 
period for those aged 40 to 79 years and for females aged 35 to 79 (Table 2.3 and 
Appendix 2).  The incidence more than doubled in males aged 55-59 years (8.3 to 
17.6 per 100,000) and 65-69 years (6.2 to 13.6 per 100,000), which was the highest 
percentage increase for any age group and any HNC subsite. Incidence almost 
doubled in females aged 65-69 years (2.0 to 3.9 per 100,000). 
For oral cancer, the incidence increased significantly for females aged 50 to 84 years 
and males aged 50 to 74 years (Table 2.3).   The highest percentage increase in the 
ten-year period was seen in males aged 60-64 years (18.1 to 26.5 per 100,000) and 
females aged 65-69 years (8.3 to 13.6 per 100,000). 
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No statistically significant increase or decrease was found in any age category for 
laryngeal cancer, for either females or males.  Incidence rates remained relatively 
stable throughout the ten-year period (Appendix 2). 
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Figure 2.2.  Mean incidence, by age category, of Head and Neck Cancer, Oral Cancer, OPSCC and Laryngeal Cancer (per 100,000 persons). (mean of 
incidence per year from 2002-2011).  Incidence of HNC (combined) and oral cancer increases with increasing age. For oropharyngeal caner the incidence 
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Table 2.3. Incidence of Head and Neck, Oral, OPSCC and Laryngeal Cancer in 5 year age-categories, from 2002-2011.   
Significant p values are highlighted in bold. Significant increases in incidence are seen for HNC, oral cancer and OPSCC. The incidence of laryngeal cancer in stable in all age categories. 
Age Category Gender Head and Neck 
 
Oral 
 
OPSCC 
 
Laryngeal 
(years)   2002 2011 p value   2002 2011 p value   2002 2011 p value   2002 2011 p value 
                 
40-44 M 8.1 8.7 0.035 
 
3.5 3.4 0.410 
 
2.1 2.8 0.027 
 
1.2 1.0 >0.05 
 
F 3.0 3.5 0.076 
 
1.2 1.4 0.159 
 
0.5 0.9 0.014 
 
0.4 0.2 >0.05 
  
  
   
  
   
  
   
  
  
45-49 M 18.5 21.3 0.015 
 
7.6 8.5 0.220 
 
5.2 7.3 0.006 
 
3.2 3.3 >0.05 
 
F 5.6 7.3 0.129 
 
2.6 3.1 0.674 
 
1.2 2.0 0.005 
 
0.5 0.8 >0.05 
  
  
   
  
   
  
   
  
  
50-54 M 29.8 33.4 0.022 
 
12.4 13.1 0.027 
 
6.6 12.5 0.005 
 
7.5 5.2 >0.05 
 
F 9.8 14.3 0.006 
 
4.5 7.1 0.032 
 
2.2 3.5 0.010 
 
1.2 1.7 >0.05 
 
 
  
       
  
   
  
  
55-59 M 41.4 57.3 0.004 
 
16.2 22.3 0.007 
 
8.3 17.6 0.004 
 
13.5 12.6 >0.05 
 
F 13.7 19.1 0.009 
 
6.1 8.8 0.005 
 
2.9 5.2 0.009 
 
2.8 1.8 >0.05 
  
  
   
  
   
  
   
  
  
60-64 M 48.2 63.1 0.012 
 
18.1 26.5 0.008 
 
7.7 16.2 0.005 
 
18.1 15.6 >0.05 
 
F 15.9 20.6 0.006 
 
8.4 10.3 0.029 
 
2.6 4.8 0.022 
 
2.6 3.2 >0.05 
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Table 2.3 continued 
Age Category Gender Head and Neck  
 
Oral  OPSCC  Laryngeal 
(years)   2002 2011 Pvalue   2002 2011 pvalue   2002 2011 pvalue   2002 2011 pvalue 
65-69 M 51.9 64.7 0.008 
 
19.5 24.0 0.018 
 
6.2 13.6 0.003 
 
20.8 20.9 >0.05 
 
F 17.4 25.5 0.010 
 
8.3 13.6 0.004 
 
2.0 3.9 0.010 
 
4.1 4.1 >0.05 
  
  
   
  
   
  
   
  
  
70-74 M 57.0 69.3 0.018 
 
18.9 26.9 0.015 
 
6.0 12.5 0.007 
 
24.8 22.7 >0.05 
 
F 22.0 29.1 0.018 
 
11.6 15.9 0.029 
 
3.1 3.5 0.076 
 
4.2 4.6 >0.05 
  
  
   
  
   
  
   
  
  
75-79 M 55.4 66.6 0.120 
 
19.8 24.7 0.207 
 
5.4 7.9 0.022 
 
22.9 24.7 >0.05 
 
F 21.8 29.0 0.006 
 
12.8 17.1 0.010 
 
1.3 2.6 0.032 
 
3.7 4.6 >0.05 
  
  
   
  
   
  
   
  
  
80-84 M 65.0 67.5 0.370 
 
25.7 25.8 0.410 
 
4.6 5.9 0.076 
 
23.4 24.0 >0.05 
 
F 25.1 33.3 0.014 
 
14.8 20.9 0.012 
 
1.9 2.3 0.571 
 
5.0 4.7 >0.05 
  
  
   
  
   
  
   
  
  
85+ M 68.9 79.7 0.546 
 
28.7 30.0 0.596 
 
5.6 4.8 0.499 
 
18.6 26.2 >0.05 
 
F 26.8 32.5 0.076 
 
15.7 19.7 0.096 
 
2.2 1.8 0.784 
 
3.2 3.3 >0.05 
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2.4.2 Gender 
Between 2002 and 2011, on average, 69% of HNC patients were male, giving a 
male:female ratio of 2.1:1.  The ratio of males to females did not change significantly 
between 2002 and 2011 (range 2.1:1 – 2.2:1).  The percentages of male oral cancer 
patients, OPSCC patients and laryngeal cancer patients were 61% (M:F = 1.6:1), 72% 
(2.6:1) and 82% (4.6:1) respectively.  Values quoted relate to patients aged 40 years 
or over. 
Figure 2.3 shows the percentage of male and female cases in each age category for 
each of the HNC types; the mean percentage for 2002-2011 for each age category 
has been used. 
The ratio of males:females with HNC, in terms of total number of cases, increases 
with age up to 55-59 years and then gradually decreases until the oldest age 
category, where there are fractionally more female cases than males (n=234 and 228 
respectively). This trend is more marked for oral cancer, where the proportion of 
males peaks in the 55-59-year age category (70%) and gradually falls, with increasing 
age, to 36.6% in the 85 years and over category, giving a female:male ratio of 1.7:1 
(n=149 and n=85 for females and males respectively).  Laryngeal cancer is the only 
subtype of HNC analysed that did not display a significant decrease in the proportion 
of male:female cases in the older age categories. 
Although the relative number of males affected falls in the older age categories for 
HNC, OPSCC and Oral Cancer, the incidence in males remains higher throughout all 
age categories (Figure 2.3).   
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2.4.3 Regional Variation 
Table 2.4 contains incidence data for all Regions of England.  The North East of 
England has the highest incidence of HNC in England; in 2011 the incidence was 27.6 
and 10.2 per 100,000 for males and females respectively, compared to the lowest 
incidence in London of 17.3 per 100,000 males and 6.8 per 100,000 females.  The 
North East also recorded the highest incidence for the subtypes analysed (OPSCC, 
oral and laryngeal cancers). 
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Figure 2.3. Percentage of Male and Female cases in each age category for HNC, OPSCC, Oral cancer and Laryngeal cancer; results show a 
decline in the male:female ratio with increasing age.  There are more females than males with oral cancer in those aged 80y and over. 
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The North West consistently records the second highest incidence of HNC (24.1 per 
100,000 males and 9.9 per 100,000 females). The greatest number of cases of HNC 
in England are recorded in the North West; an average of 813 male and 348 female 
cases of HNC were recorded each year from 2002-2011, compared to 325 and 132 
respectively in the North East.   
Table 2.4.  Mean Incidence of HNC and each sub-type, per 100000 persons, by Region of England.                                                        
(Mean of values from 2002-2011).  The North East and North West have the highest incidence of HNC and all sub-
groups. 
Region  Head and Neck  OPSCC  Oral  Laryngeal 
 
 Male Female  Male Female  Male Female  Male Female 
North East  26.0 10.0  4.8 1.6  10.2 4.8  8.3 1.8 
North West  24.1 9.9  4.7 1.4  9.2 5.1  7.4 1.7 
Yorkshire&Humber  20.5 8.8  3.9 1.1  7.7 4.5  6.5 1.4 
East Midlands  19.7 9.3  3.7 1.3  7.7 4.9  5.8 1.2 
West Midlands  19.5 8.1  3.8 1.3  7.6 4.5  5.9 1.2 
East  17.2 8.0  3.7 1.2  6.3 4.3  4.9 0.9 
London  16.4 6.8  3.1 1.1  6.4 3.6  4.8 0.9 
South East  17.3 8.2  3.4 1.2  6.7 4.5  4.7 0.8 
South West  20.6 9.0  4.0 1.3  7.8 4.7  5.7 1.0 
 
 
  
 
  
 
  
 
  
From 2002-2011, there was a significant increase in the incidence of HNC in all 
Regions of England.  Figure 2.4 shows the incidence of HNC in the Regions of England 
from 2002-2011, with p-values for significance of the trend.  The most consistent 
increases were found in the South West and Yorkshire & Humber for males, with an 
average annual percentage increase of 3.7% and 3.1% respectively.  The East 
Midlands and North West reported the most consistent increases for females 
(average APC 8.1% and 4.3% respectively). 
The North East showed a statistically significant decrease for Laryngeal cancer in 
males from 2002-2011 (incidence 9.2 per 100,000 to 7.6 per 100,000).  However, the 
East Midlands report a statistically significant increase in incidence for females, from 
0.8 to 1.5 per 100,000.  All other regions display non-significant trends, indicating 
that the incidence of laryngeal cancer is relatively stable. 
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The incidence of Oral Cancer increased significantly in all regions except Yorkshire & 
Humber and the North East, for males and females.  There was no significant increase 
in the East of England for female oral cancers. The East Midlands and South West 
displayed the most consistent increases each year for males and females 
respectively, with average annual percentage change of 5.1% (incidence increased 
from 6.2 to 9.2 per 100,000 from 2002-2011) and 5.7% (incidence increased from 3.5 
to 5.6 per 100,000). 
The incidence of OPSCC significantly increased in males and females in all regions 
except for females in the East and London.   The East Midlands and Yorkshire & 
Humber display the most consistent increases in incidence, in males, between 2002 
and 2011 with average APC of 14.3% (incidence increased from 1.9 to 5.9 per 
100,000) and 8% (incidence increased from 2.6 to 5.1 per 100,000).  In females, the 
most consistent increase was found in the South West, with average APC of 14.1%; 
incidence increased from 0.9 to 2.1 per 100,000 between 2002 and 2011. 
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significant increase in incidence of HNC for males.  All regions except the North East display a statistically significant increase in incidence of HNC in females. 
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2.5 Discussion 
Results of an increasing trend in the incidence of HNC in England, between 2002 and 
2011, have been presented in section 2.4.   
Over 96% of patients were aged over 40 years and 68% of HNC patients were male, 
which is similar to figures reported in other studies from England and internationally 
(1, 9, 10, 12, 15, 78). 
The incidence of HNC increased significantly during the study period, as did the 
incidence of OPSCC and oral cancer.  These findings were also observed by Dobaree 
et al in their study of HNC in the South East of England between 1995 and 2004 (1).  
Conway et al observed an increase in oral and pharyngeal cancer rates (C00-C06, C09, 
C10) in England between 1990 and 1999, with incidence in males increasing from 6.5 
to 8.3 per 100,000 and in females from 2.6 to 3.6 per 100,000 (79).  Although our 
results cannot be directly compared due to differences in classification, the trend 
appears to be similar over the two decades. 
There was no significant increase in the incidence of laryngeal cancer between 2002 
and 2011; this finding is also reported by the Oxford Cancer Intelligence Unit in a 
report detailing the profiles of HNC in England.  They found that the incidence of 
laryngeal cancer reduced by 20%, from 3.6 per 100,000 to 3.0 per 100,000, between 
1990 and 2006 but stabilised in the latter five years (73).  This is supported by 
Coupland et al, who found that incidence has decreased from the early 1990’s, 
particularly in those aged over 70 (80).  A reduction in laryngeal cancer incidence in 
males and stable incidence in females has been reported in France, Finland, Norway, 
Denmark, Spain and the Netherlands (10, 17, 71).  The highest incidence of laryngeal 
cancer was found in 75-84 year olds, which is similar to findings reported from the 
Netherlands that 21% of patients are in the 75-85 year age group and 32% are in the 
60-70 year age group (17).   
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2.5.1 Age 
Over half of all HNC patients in England, between 2002-2011, were in the 55-75 year 
age group.    Dobaree et al. reported that 60% of HNC patients in South East England 
were aged 40-69 years between 2000 and 2004 whereas Germany report a slightly 
higher age at diagnosis, with 50% of HNC patients aged 60-79 years (1, 15).  The USA 
report mean age at diagnosis of 62 years (44). 
Over the ten-year period studied, the most marked increases in HNC incidence were 
found in the 55-59 year age category for males and 65-69 year age category for 
females, which is mostly due to the increase in oropharyngeal, base of tongue and 
tonsil cancer as discussed below. 
The highest incidence of oral cancer was found in the over 80’s, for both males and 
females.  The most significant increases in incidence of oral cancer were found in 
males aged 60-64years and females aged 65-69 years.  Results from Portugal show 
that the highest incidence of oral cancer in females is in the over 75 year age group, 
whereas for males the 60-64 year age group has highest incidence, further 
supporting the concept that females with oral cancer tend to be older than males 
(12). 
Oral cancer incidence is increasing in the Netherlands in females, however rates are 
stable in males, which are findings similar to those reported from France (17, 81).  
Other studies have reported reducing incidence of oral cancer; a reduction of 1.5% 
per year was found between 1995 and 2004 in the USA (81), however in the time 
period 2003-2010, there was an annual percentage increase in oral cancers in males 
of 0.2% (44).  In fact, cancers of the tongue increased in males by 2.4% annually 
between 1999 and 2010 and in females by 0.6% annually between 1992 and 2010; 
therefore the trend may have been reversed (44).  This is unlikely to be due to HPV, 
as oral cancers are less commonly associated with HPV infection than oropharyngeal 
cancers (82), and is more likely to be due to smoking and alcohol habits.  The original 
reports of a declining incidence were for the USA as a whole, which is a vast, culturally 
and geographically diverse nation.  Incidence within some states continued to rise 
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during the period of general decline in oral cancer incidence (83) and it may be that 
the increasing incidence in these states has now reversed the general trend. 
2.5.1.1 Oropharyngeal SCC 
Information on HPV-status was not available from the ONS.  However, we classified 
oropharynx, base of tongue and tonsil as a sub-group (OPSCC) in order to study 
trends in incidence at these sub-sites, based on reports in the literature that between 
36% and >80% of cancers at these sites are infected by HPV, implying, but not 
proving, causation (32).  Studies have confirmed 50-55% of oropharyngeal cancers 
are HPV-infected (31) and HPV infection poses an increased risk of developing 
oropharyngeal cancer: OR 3.5 (95%CI 2.1 – 5.9) (84, 85).   
OPSCC affect younger individuals, with the highest incidence found in those aged 55-
65 years; it also affects proportionally more people aged 40-49 years than other head 
and neck cancers.  Higher incidence in older age categories is noted in the other HNC 
sub-types, however incidence of OPSCC decreases in persons aged over 65 years.  The 
incidence of OPSCC doubled in males aged 55-59 and 65-69 years, and almost 
doubled in females aged 65-69 years between 2002 and 2011.  This is in agreement 
with National Cancer Information Service data, which shows that the incidence of 
oropharyngeal cancer doubled in England between 1990 and 2006 (73); this rise is 
thought to be due to HPV-infection.  Forte et al have also reported a marked increase 
in tonsil and base of tongue cancer in Canada, again believed to be due to HPV 
infection (11).  Forte et al report the largest increase in persons aged 50-59 years 
(incidence 4.4 to 8.9 per 100,000 between 1997 and 2009), which is similar to our 
findings in England.  Monteiro et al reported that oropharyngeal cancer in men 
increased by 3.5% per year and in females by 2% per year between 1998 and 2007 in 
Portugal (12); the USA report increasing incidence of oropharyngeal and tonsillar 
cancer of 2.3% annually for males between 1992 and 2010 (13, 44).  Interestingly, a 
0.4% annual reduction in female oropharyngeal and tonsil cancers is reported in the 
USA in the period 1992-2010 (44); the reason for this is unclear.  This HPV-epidemic 
is under intensive research, and cancer statistics will form an important part of public 
health campaigns and health-care planning. 
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2.5.2 Gender 
The ratio of males:females remained relatively stable over the study period 
(approximately 2:1).  The incidence of head and neck cancers in males is higher than 
females throughout all age groups, however the relative proportion of females 
affected increases in the older age categories, probably due to a larger female 
population.  The male:female ratio is most consistent for cancers of the oral cavity; 
there are more female oral cancer patients over 80 years of age than male patients 
(58% and 42% respectively). Females have longer life-expectancy than males and as 
the population of females is much larger in this age group (1,564,400 and 920,700 
respectively in 2011), it is reasonable to expect a higher number of oral cancer cases. 
Laryngeal cancer had the highest ratio of male:female cancers (4.6:1) and this ratio 
is very similar throughout all age groups, even the most elderly, which is different to 
the trend observed with oral cancer:  Coupland reports a male:female ratio of 4.8:1 
for laryngeal cancer in the South East of England between 1985 and 2004 (80). In 
other countries, the ratio is much higher: Lithuania and Portugal have a male:female 
ratio of 25:1 and 36:1 respectively (71).  This is likely to be due to historical differences 
in smoking habits: 50% of men in Lithuania were smokers from the 1990’s to 2002, 
whereas only 10-20% of women smoked (86).  Alcohol consumption is also much 
higher in men in both Lithuania and Portugal (87). 
The incidence in males varies widely from country to country, from 11.9 per 100,000 
in Hungary to 1.8 per 100,000 in Sweden (71).  Smoking and alcohol are major risk 
factors for all HNC, however for laryngeal cancer the Population Attributable Risk 
(PAR) has been found to be 89% compared to 64% for oral cavity cancer. PAR is the 
proportion of the incidence of a disease in a population that can be attributed to a 
particular exposure, in this case smoking and alcohol.  Males also have a higher PAR 
for smoking and alcohol compared to women (74% compared to 57% respectively) 
(88); this may help to explain the much higher incidence in males than females. 
2.5.3 Region 
The North East and North West have the highest incidence of HNC and all subtypes 
analysed, with incidence rates that are consistently above the national average. 
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For HNC overall (C00-14, C30-32), all Regions of England showed a significant 
increase in incidence in the period 2002-2011.  Not all Regions had a statistically 
significant increase in Oral Cancer, but none displayed a decrease in incidence.  
Incidence of OPSCC increased in all Regions for males, particularly the East Midlands 
and Yorkshire & Humber; interestingly Yorkshire & Humber was one of the regions 
with no statistically significant increase in oral cancer incidence.  For females, it was 
the South West with the most marked increase in OPSCC. 
Laryngeal cancer incidence significantly decreased in the North East, although even 
with the decrease, the incidence is still the highest in the country.  A previous report 
has found a decreasing incidence in laryngeal cancer from the North to the South of 
England, thought to be due to the changes in the industrial landscape  and supporting 
the concept of the “North-South divide”, which is a term used to describe gross 
differences in socio-economic status for individuals living in the North and South of 
England (73).   
2.5.3.1 The Relationship between Social Deprivation, Smoking and Alcohol 
It has previously been reported that there is increased incidence of HNC in lower 
socio-economic groups and a link with deprivation has been established (16).  
Smoking and alcohol are the two most significant risk factors for head and neck 
cancer, and differences in the rates of smoking and alcohol consumption could help 
to explain the regional variations in incidence of the disease.  Smoking rates in the 
UK reduced dramatically between 1974 and 2011 (51% to 20% of men and 41% to 
18% of women) but regional variations still exist: in 2011 smoking rates were higher 
in the North West (22%) than the rest of England (20%), although this is not 
statistically significant (89).  Residential area deprivation is a strong independent 
predictor for smoking (OR 1.85 CI 1.57-2.13) and the North West contains over half 
of the 1% most deprived areas of England (90, 91).  Social deprivation is also 
considered as a risk factor for HNC in Section 5.2.2. 
Smoking is more prevalent in the routine and manual occupations than managerial 
and professional (29% vs 14% for males; 26% vs 12% for females) and the percentage 
of never smokers is lower.  It is known that people in lower socio-economic groups 
   
 
 
39 
are not only more likely to take up smoking but generally start younger, smoke more 
heavily and are less likely to quit smoking, each of which increases their risk of HNC 
(89).   
Heavy drinking on at least one day in the week (>8 units for men, >6 units for women) 
was most common in the North West and Yorkshire & Humber in 2011 (23% vs 18%).  
In contrast to smoking, regular alcohol consumption (at least 5 days per week) is 
more prevalent amongst the managerial/professional group than the 
routine/manual group (19% vs 13% for males) and in those who are in employment 
compared to the unemployed (15% vs 6% for males) (89).   
Smoking and drinking are also closely linked:  according to ONS data (2011), 14% of 
male smokers consumed greater than 12 units of alcohol on one day in the preceding 
week compared to 8% of non-smokers. It has also been found that amongst young 
people aged 11-15 years, occasional and regular smokers are much more likely to 
drink alcohol (OR 2.85 and 3.65 respectively) than non-smokers (92).  
Ethnicity has also been considered as a risk factor, due to the marked differences in 
incidence of HNC around the world.  Incidence of HNC is highest in South and South 
East Asia and the incidence of HNC amongst South East Asians living in the UK is 
higher than in other ethnic groups (3, 93); Csikar et al report incidence of 7.2 per 
100,000 and 6.0 per 100,000 respectively.  They conclude that in areas in which many 
South Asian women live, there may be a higher incidence of head and neck 
(particularly oral) cancer.  However, London has the highest percentage of Indian, 
Bangladeshi and Pakistani persons in England (1.8% of the population) and our study 
shows the incidence of HNC was the lowest of all the Regions (16.4 per 100,000 males 
and 6.8 per 100,000 females) (Figure 2.4).     
Smokeless tobacco use is highest in Bangladeshi women (16% of the Bangladeshi 
population) and this is thought to account for the higher incidence of oral cancer in 
this group (3).  Interestingly, there appears to be no link with deprivation for either 
male or female South Asians, in terms of oral and pharyngeal cancer risk, which 
supports the concept that ethnic-specific risk factors account for the higher incidence 
of oral/HNC in this group of the population (93). 
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2.6 Conclusion 
This study has confirmed that the incidence of HNC continues to rise in England.  
Between 2002 and 2011, incidence increased from 12.2 to 15.9 per 100,000.  Oral 
cancer incidence is also increasing, in males and females, whereas incidence of 
laryngeal cancer is stable.  The incidence of OPSCC doubled, in males and females in 
high-risk age-groups, in this ten-year period.  Regional variation exists and further 
work is needed to establish the role of deprivation and socioeconomic status on HNC 
incidence.  Cancer statistics form an important part of healthcare planning and this 
information may be used to inform researchers when planning studies and screening 
programmes in different Regions of England.  
This work has demonstrated a significant increase in the incidence of oral cancers in 
older females, which justifies exploration of novel, female-specific, risk factors for 
HNC.  Chapter 3 will explore female-specific risk factors for head and neck cancer, 
including age at menopause and hormone replacement therapy.    
   
 
 
41 
 
 
Chapter 3 
 
Exploring Novel Risk Factors for 
Head and Neck Cancer 
 
 
 
 
The work within this chapter was published in Oncology Reports (Appendix 8): 
Age at Menopause and Hormone Replacement Therapy as risk factors for Head and 
Neck and Oesophageal Cancer. A systematic review. 
McCarthy CE, Field JK, Marcus MW 
Oncol Rep. 2017 Oct;38(4):1915-1922. doi: 10.3892/or.2017.5867. Epub 2017 Aug 1 
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3.1 Introduction 
Chapter 2 explored the increasing incidence of HNC in England between 2002 and 
2011 and identified an increasing incidence in older females.  This chapter will 
explore novel female-specific risk factors for HNC, using a systematic review of the 
literature. 
3.2 Background 
The ratio of male: female cases of HNC in persons aged 50-60 years is close to 3:1, 
however the gender disparity reduces in the elderly population, with a male:female 
ratio of 1.5:1 in the over-eighties (94). For oesophageal SCC, the male:female ratio is 
lower, at 1.1:1.  
There have been reports of young women with no classic risk factors, developing oral 
cancer (95, 96) and some efforts have been made to explore this (96).  A review of 
risk factors in young adults (<45years) was conducted in the INHANCE consortium (a 
collaboration of HNC researchers, including over 40 member studies) in 2015; a lower 
attributable fraction for smoking and alcohol was detected (19.9% for women <45y 
vs 48.9% for women >45y).  There were proportionally more female HNC cases with 
tongue cancer who were never smokers and never drinkers, across all age categories 
(97).  This contrasts with the commonly accepted fact that smoking and alcohol 
account for most cases of HNC (see Section 1.2.1). 
Hormones are known to play an important role in several cancers, such as breast, 
ovarian and uterine, endometrial, prostate, testis and thyroid cancers.  There have 
also been reports of hormone-related risk factors for squamous cancers, such as 
oesophageal, cervical and lung cancer (98). Whilst hormone-replacement therapy 
(HRT) is a known risk factor for certain cancers (e.g. breast cancer), a recent meta-
analysis found that use of HRT is protective against oesophageal squamous cell 
carcinoma (SCC) (99). Early-menopause has also been linked to increased risk of 
oesophageal SCC (RR 1.32 (95% CI 1.11-1.56) per 5 years younger at menopause) 
(100). Another meta-analysis suggested decreased risk of lung cancer in never-
smoker females who use Hormone Replacement Therapy (HRT) (OR 0.86 (95% CI 
0.75-0.99)) (101).  
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This leads to the hypothesis that hormone levels have a role as a risk factor for 
squamous cancers. There is uncertainty surrounding the role of female hormones 
and the risk of head and neck oesophageal SCC; no systematic review has been 
conducted to address this uncertainty.  
3.3 Aims 
 
The aim of this review is to explain the role of female hormones in relation to the risk 
of head and neck and oesophageal SCC.   
The squamous histology and strong similarities in their epidemiology and aetiology 
justify their combination in this project (102-105), which will address two specific 
questions:  
(i) Is early menopause a risk factor for HNC or oesophageal SCC?  
(ii) Is Hormone Replacement Therapy protective against HNC or oesophageal 
SCC? 
 
3.4 Methods 
3.4.1 Search Strategy  
Electronic databases Medline, Web of Science, Embase and Cochrane were searched 
up to February 11, 2016. Search strategies were developed using medical subject 
headings (MeSH): ("head and neck neoplasms"[MeSH Terms] OR ("head"[All Fields] 
AND "neck"[All Fields] AND "neoplasms"[All Fields]) OR "head and neck 
neoplasms"[All Fields] OR ("head"[All Fields] AND "neck"[All Fields] AND "cancer"[All 
Fields]) OR "head and neck cancer"[All Fields] OR “HNC”[All Fields])) AND 
"oesophageal cancer"[All Fields] OR "esophageal neoplasms"[MeSH Terms] OR 
("esophageal"[All Fields] AND "neoplasms"[All Fields]) OR "esophageal 
neoplasms"[All Fields] OR ("esophageal"[All Fields] AND "cancer"[All Fields]) OR 
"esophageal cancer"[All Fields] AND "hormone replacement therapy"[MeSH Terms] 
OR ("hormone"[All Fields] AND "replacement"[All Fields] AND "therapy"[All Fields]) 
OR "hormone replacement therapy"[All Fields] AND ("female"[MeSH Terms] OR 
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"female"[All Fields]) AND ("hormones"[Pharmacological Action] OR 
"hormones"[MeSH Terms] OR "hormones"[All Fields] OR "hormone"[All Fields]) AND 
"early menopause"[All Fields]) and text words related to hormones and HNC or 
(o)esophageal cancer.  Reference lists were also extensively searched and relevant 
papers obtained.  
3.4.2 Eligibility Criteria 
Randomised controlled trials (RCTs), controlled (non-randomised) clinical trials 
(CCTs) or cluster trials, prospective and retrospective comparative cohort studies, 
case-control or nested case-control studies and cross-sectional studies, addressing 
the question of female hormones as a risk factor for HNC or oesophageal SCC, were 
considered. Studies were included if they:  
(i) Examined the general adult population (age >18 years), specifically 
studies with at least 50 cases of HNC/oesophageal SCC and any number 
healthy controls.  
(ii) Addressed the question of hormone replacement therapy or reproductive 
factors (menopause) and HNC/oesophageal SCC 
(iii) Administered HRT as an intervention for prevention of cancer or being 
taken therapeutically due to symptoms of menopause.  
(iv) Collected data on age at menopause, smoking, alcohol, age and socio-
economic status or educational attainment. 
(v) Reported odds ratios, risk ratios or incidence/prevalence of HNC or 
oesophageal SCC defined using the World Health Organisation (WHO) 
classification of diseases ICD-10 codes, C00-15 and C30-31 (see Section 
1.1) 
Cohort studies were only eligible if follow up time was at least 5 years.  Case series 
and case reports were excluded.  Only studies published in peer-reviewed 
journals, from 1948 to 2016, were considered. These criteria were applied to 
maximise the quality of the evidence considered.   
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3.4.3 Data Extraction 
Titles and/or abstracts of studies retrieved using the search strategy and those from 
additional sources were screened independently by two review authors (Caroline 
McCarthy and Dr. Michael Marcus) to identify studies that potentially met the 
inclusion criteria outlined above. Studies combining HNC with oesophageal 
squamous cell cancers were considered but data were extracted separately for HNC 
and oesophageal cancer where possible. Data were extracted in all forms (e.g. 
dichotomous, continuous) as reported in the included studies. The full texts of these 
potentially eligible studies were independently assessed for eligibility by the same 
authors. Any disagreement over the eligibility of particular studies was resolved 
through discussion with a third reviewer. A data extraction form was developed to 
assess the characteristics and findings of the primary studies (Appendix 3).  
3.4.4 Risk of Bias 
The risk of bias in each study was assessed using the Newcastle-Ottawa Scale (NOS).  
The NOS evaluates risk of bias based on methods used to select patients, 
comparability of groups in the study, methods for assessing outcomes, proof of 
exposure and appropriate follow-up. Studies are categorised as low, medium, high 
or unclear risk of bias, using a star-based scoring system. 8 categories are considered 
in total (see Table 3.1) with one star allocated if the criteria are met (two stars are 
available for the “control” category, as indicated). 
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Table 3.1. Categories for scoring studies using the Newcastle Ottawa Scale.  One star is available for each category 
except ‘Control’ as indicated with *, where two stars are available.  The maximum score is 9 stars.  
Newcastle Ottawa Scale Categories Scores one star if criteria 
fulfilled 
Selection 
1. Representativeness of the exposed cohort  
 
Truly OR somewhat 
representative 
2. Selection of controls  Drawn from same 
community as cohort 
3. Ascertainment of exposure  Secure record OR structured 
interview 
4. Demonstration that outcome of interest 
was not present at start of study  
Yes 
Comparability 
5. Study includes control for confounders  
*two stars available if 
general plus disease-specific 
factors included as control 
Outcome 
6. Assessment of outcome  
 
Independent blind assessment OR 
record linkage 
7. Was follow-up long enough for outcomes 
to occur  
Yes 
8. Adequacy of follow-up cohorts  Complete follow-up OR those 
lost to follow up unlikely to 
introduce bias: description of 
those lost suggests no 
different from those 
followed up OR <20% loss to 
follow up 
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A maximum of 9 stars are available; the higher the number of stars the lower the risk 
of bias. For ease of interpretation, a score of 7 or greater is considered ‘low-risk’ of 
bias, 4-6 is ‘medium-risk’ and 3 or below is considered ‘high-risk’ of bias.  
 
3.5 Results 
The search identified 13 potentially eligible studies following the review of titles and 
abstracts identified from the initial search. One study considered HNC and 
Oesophageal cancer separately, therefore this paper was included in both arms of 
the review. Five papers were excluded, based on insufficient number of cases (n=2), 
failure to report an effect estimate/confidence intervals (n=2) and lack of 
categorisation by histopathological subtype (n=1). Eight studies met the inclusion 
criteria, 3 for HNC and 6 for oesophageal cancer, with one being in both arms (100, 
106-112). The literature search results and selection process are presented in Figure 
3.1 and 3.2, for HNC and Oesophageal cancer respectively.  
 
Figure 3.1. Flow diagram of literature search results and selection process: Head and Neck Cancer 
 
 
257 papers identified from literature 
search 
252 excluded based on title/abstract 
5 potentially relevant papers 
2 excluded after full text review due 
to lack of reporting of effect estimate 
 
3 eligible for inclusion in systematic 
review 
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Figure 3.2. Flow diagram of literature search results and selection process: Oesophageal Cancer 
 
The systematic review includes two cohort studies (one oesophageal/HNC and one 
oesophageal cancer only) (100, 106) with follow-up time of 7.5 and 9.1 years 
respectively. Six case-control studies (four oesophageal cancer and two HNC) (107-
112) were also included. Studies covered the UK (100, 112), USA (106, 107), European 
continent (108, 113) and China (110, 111). 
The mean number of cases per study for the HNC papers was 214 (range 149-297). 
For oesophageal cancer, the mean case number per study was 163 (range 56-578). A 
summary of the demographic data for each study is presented in Table 3.2. 
A summary of the findings regarding use of hormone replacement therapy and risk 
of HNC/Oesophageal SCC is shown in Table 3.3.  Table 3.4 summarises the findings 
regarding age at menopause.  
 
293 papers identified from 
literature search 
278 excluded based on 
title/abstract 
9 potentially relevant papers 
3 excluded after full text review: 
 2 due to insufficient number of cases (<50) 
 1 due to lack of analysis by histopathological subtype 
6 eligible for inclusion in systematic 
review 
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Table 3.2. Demographic characteristics of the studies included in the Systematic Review of Hormone Replacement Therapy and Early Menopause, as risk factors for Head and 
Neck Cancer (HNC) and Oesophageal Cancer. 
 
Cancer Type Studied Author (Year) Country Study Type Participant demographics Time period 
      
HNC/Oesophageal Freedman (2010) USA Cohort 
NIH-AARP Diet and Health Study Cohort, aged 50-71years (median 
follow up 7.5 years) 
1995-2003 
HNC Langevin (2011) USA Case-Control 
Cases of primary HNC and complaint-free hospital controls attending 
ENT department, University of Pittsburgh Medical Center.  
2006-2010 
HNC Bosetti (2000) Italy/Switzerland Case-Control 
Cases of histologically confirmed oral/pharyngeal cancer age <75 
years attending hospitals in Italy/Switzerland and hospital controls 
with acute, non-neoplastic conditions 
1984-1997 
      
Oesophageal Lindblad (2006) UK 
Nested Case-
Control 
UK General Practice Research Database (UK GPRD) Cohort aged 50-
84 years 
1994-2001 
      
Oesophageal Gallus (2001) Italy/Switzerland Case-Control 
Cases aged < 79years of histologically confirmed oesophageal SCC 
admitted to study hospitals; hospital controls admitted to the same 
hospitals for acute, non-neoplastic conditions 
1984-1999 
      
Oesophageal Yu (2011) China Case-Control 
Cases of histopathologically confirmed oesophageal SCC; hospital 
based controls confirmed not to have oesophageal cancer. 
2008-2010 
      
Oesophageal Chen (2011) China Case-Control 
Cases of newly diagnosed primary oesophageal cancer; Hospital 
controls with no history of cancer 
2004-2010 
      
Oesophageal Green (2012) UK Cohort 
Million Women Study Cohort (women aged 50-64 years) with mean 
9.1 years follow up 
1996-2008 
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Table 3.3. Results for Hormone Replacement Therapy as a risk factor for HNC and Oesophageal cancer.  Significant Odds Ratios or Hazard Ratios are shown in bold. 
Outcome of Interest Author (Year) Type of Study 
Number of 
cases 
Relative Effect (Odds Ratio 
(OR) or Hazard Ratio (HR)) 
95% 
Confidence 
interval 
Risk of Bias 
(Newcastle Ottawa Scale) 
       
HNC Freedman (2010) Cohort 297 HR 0.78 0.61 – 0.99 Low (8/9) 
HNC Langevin (2011) Case-Control 149 OR 0.47 0.20 – 1.08 Medium (6/9) 
HNC Bosetti (2000) Case-Control 195 OR 0.88 0.45 – 1.72 Medium-High (4/9) 
Oesophageal SCC Lindblad (2006) Nested Case-Control 74 OR 0.93 0.40 - 2.16 Low (9/9) 
Oesophageal SCC Gallus (2001) Case-Control 114 OR 0.32 0.09 – 1.13 Medium-High (4/9) 
Oesophageal SCC Freedman (2010) Cohort 56 HR 0.74 0.42 – 1.26 Low (8/9) 
Oesophageal SCC Yu (2011) Case-Control 88 OR 0.94 0.53 – 1.70 Medium-high (4/9) 
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Outcome of 
Interest 
Author (Year) Type of Study 
Number of 
cases 
Age Relative Effect 
95% Confidence 
interval 
Risk of Bias 
(Newcastle Ottawa 
Scale) 
        
HNC Freedman (2010) Cohort 297 >55 years HR 0.92 0.50-1.71 Low (8/9) 
HNC Bosetti (2000) Case-Control 195 > 50 years OR 0.46 0.30 – 0.70 Medium-High (4/9) 
        
Oesophageal SCC Gallus (2001) Case-Control 114 > 50 years OR 0.43 0.22 – 0.83 Medium-High (4/9) 
Oesophageal SCC Freedman (2010) Cohort 56 increasing age P trend = 0.019  Low (8/9) 
Oesophageal SCC Yu (2011) Case-Control 88 <45 years OR 2.27 1.03 – 4.97 Medium-high (4/9) 
Oesophageal SCC Green (2012) Cohort 578 
Per 5 years 
younger 
RR 1.32 1.11 – 1.56 Low (7/9) 
Oesophageal SCC Chen (2011) Case-Control 68 >48 years OR 0.94 0.31-2.85 Medium (5/10) 
Table 3.4. Age at menopause and risk of HNC and Oesophageal cancer.  Significant Odds Ratios and Hazards Ratios are shown in bold. 
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3.5.1 Hormone Replacement Therapy (HRT) 
3.5.1.1 Head and Neck Cancer 
Three papers (one cohort study and two case-control studies) addressed the question 
of the use of HRT and incidence of HNC.  Only the Freedman et al study (8) was 
considered at ‘low-risk’ of bias, with a Newcastle Ottawa score of 7/9 stars.  This was 
a cohort study conducted in the USA, using the NIH-AARP Diet and Health Cohort of 
125 887 women. 297 cases of HNC were identified with mean follow-up of 7.5 years. 
The risk of HNC was 22% lower for people who had ever used HRT (HR 0.78;95% CI 
0.61-0.99). 44.1% of cases (n=127) had ever used HRT compared to 54.6% of controls 
(n=106934).  
Further analysis by hysterectomy status revealed that the risk reduction was greatest 
for women with an intact uterus who were current users of HRT for >5 years (HR 
0.23;95% CI 0.09-0.57). Interestingly, use of HRT other than oestrogen-alone or 
oestrogen-progesterone therapy conferred a greater risk of HNC (HR 2.31;95% CI 
1.15-4.65); however, this analysis was based on only 9 cases who used an alternative 
HRT.   
Two case-control studies were considered at medium/high risk of bias; they reported 
a non-significant reduction in risk of HNC for ever-users of HRT (107, 108). 
3.5.1.2 Oesophageal SCC 
Four studies analysed HRT use and risk of oesophageal SCC. Two were considered 
low-risk of bias (106, 112) and two were medium/high risk of bias (109, 110). 
Although all studies reported an effect estimate of <1 for users of HRT, implying a 
protective effect, none of the results were statistically significant. 
3.5.2 Age at Menopause 
3.5.2.1 Head and Neck Cancer 
Two studies (106, 108) assessed the link between age at menopause and risk of HNC. 
Bosetti et al (108) found a protective effect of later age at menopause (>50 years), 
with an OR of 0.46 (95% CI 0.30-0.70), although the study was medium-high risk of 
bias (NOS 4/9 stars). Freedman et al (106) found no significant effect on risk of HNC 
with later age at menopause (>55 years) and this study was scored as low risk of bias 
(7/9 stars). 
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3.5.2.2 Oesophageal SCC 
Four out of five studies reported a significant effect of age at menopause and risk of 
oesophageal SCC. The method of reporting varied: Gallus et al (109) reported an OR 
of 0.43 (95% CI 0.22-0.83) for age at menopause of >50 years vs menopause at age 
<45 years. Yu et al. (110) reported an increased risk of oesophageal SCC for women 
entering menopause at <45 years (OR 2.27;95% CI 1.03-4.97) and for 45-49 years (OR 
2.16; 95% CI 1.14-4.78) compared to menopause at age >50 years.  Both of these 
studies were scored as medium-high risk of bias (NOS 4/9 stars).  Green et al (100) 
reported increased risk of oesophageal SCC for every 5 years younger a woman was 
at time of menopause (RR 1.32;95% CI 1.11 – 1.56). Although Freedman et al (106) 
found no significant effect for individual age categories, they did observe a significant 
trend (p=0.019) for lower risk of oesophgeal SCC with older age at menopause.  Green 
(100) and Freedman’s (106) studies were considered low risk of bias, with NOS scores 
of 7/9 and 8/9 respectively (see Table 3.4).  Chen et al (111) (NOS score 5/9; medium 
risk of bias) observed no significant effect for age at menopause, although these 
authors classified older age at menopause as >48 years.  
3.6 Discussion 
This systematic review has considered evidence from a total of eight studies 
investigating the risk of HNC or oesophageal SCC in relation to age at menopause and 
use of hormone replacement therapy: five papers investigated oesophgeal SCC, two 
papers investigated HNC and one paper included both cancers. 
3.6.1 Early Menopause  
The evidence suggests that earlier age at menopause is associated with a higher risk 
of oesophageal cancer, based on 4 studies with a total of 836 cases of oesophageal 
SCC.  
Most women experience the menopause between the ages of 45 and 55 years; the 
median age at menopause is 47.2 years, according to a prospective cohort study of 
over 5000 women enrolled on the Royal College of GP’s Oral Contraception study 
(114). Menopause is ‘early’ in women aged 40-45 years (~5% of women) and 
‘premature’ in women <40years (~1% of women) (115). 
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3.6.1.1 Risk Factors for Early Menopause 
Early menopause is more frequent in women with certain genetic or autoimmune 
disorders, infections or a history of chemotherapy/radiotherapy or surgery to remove 
the ovaries (115). Mean age of menopause for smokers is significantly lower than 
non-smokers (45.6 years vs 46.9 years) (114). Women with early natural menopause 
are more likely to be smokers, ever-users of the oral contraceptive pill, undergone 
tubal ligation, have at least one episode of endometriosis and are less likely to use 
HRT. No association with alcohol, BMI, physical activity or parity (number of children) 
is reported (114).  
Women with diabetes have also been found to be at risk of early menopause (OR 
2.76;95% CI 1.32-5.66) (116). In a pooled analysis of case-control studies, diabetes 
diagnosed at age < 50 years conferred a greater risk of HNC (OR 1.37;95% CI 1.07-
1.74) when analysing 6448 cases of HNC and 13747 controls (117), but no link with 
age at menopause was considered in this study.  
3.6.1.2 Early Menopause and Oesophageal Cancer 
A recent systematic review and meta-analysis by Zhu et al of oesophageal squamous 
cell carcinoma and reproductive factors also found a protective effect for older age 
at menopause (RR=0.70; 95% CI 0.51-0.95) (118). The authors concluded that 
“properly extending the time of menstruation for pre-menopausal women is a 
possible way to reduce the risk of oesophageal SCC” (118).  However, this meta-
analysis was only able to consider evidence from case-control and cohort studies, 
several of which did not report adjusted risk ratios, therefore the authors calculated 
crude risk ratios from the reported data, which may have introduced bias.   
Another meta-analysis, by Wang et al, of eight oesophageal SCC studies, found 
menopausal status was associated with higher risk of oesophageal SCC (RR 1.66; 95% 
CI 1.12-2.48) but age at menopause was not significant (6).  
3.6.1.3 Early Menopause and HNC 
Hashim et al published a pooled analysis of hormone factors in female HNC in 
2017(119).  They used data from 11 studies from around the world, including 1572 
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cases of HNC and 4343 controls.  They report a 69% increased risk for all HNC for 
menopause at less than 52 years (OR 1.69 95% CI 1.06 – 2.71) compared to 
menopause over the age of 52 years, which conferred a non-statistically significant 
increased risk of HNC (OR 1.54 95%CI 0.93 – 2.57).  
 
3.6.2 Hormone Replacement Therapy (HRT) 
Hormone replacement therapy is long-established in the management of symptoms 
of the menopause and has also been shown to reduce risk of osteoporotic fractures, 
cardio-vascular disease, Alzheimer’s, depression, stroke, and colon cancer. 
Approximately 30% of UK women aged 50-74 years used HRT in 2001-2002 (120). 
Following this, a large US-based trial (Women’s Health Initiative - WHI) was 
prematurely stopped due to concerns over evidence of increased risk of breast 
cancer, coronary heart disease, stroke and pulmonary embolism amongst users of 
HRT (121). The UK-based Million Women Study (MWS) also reported increased risk 
of breast cancer with HRT in 2003 (122). Following media coverage of the results of 
these trials, use of HRT declined steadily in the UK for the next 3-4 years. In 2005, 
only 10-11% of menopausal women were using HRT (120).  
However, concerns have been raised by some authors surrounding the reporting of 
the WHI and MWS trial results and the fact little coverage was given to the evidence 
of reduced incidence of osteoporotic fractures and colon cancer (123). Both trials 
recruited women aged over 50 years, therefore the results cannot be applied to 
women who undergo premature menopause (124). HRT for women with premature 
menopause (primary ovarian insufficiency), prescribed up to the age of natural 
menopause (~51 years), is endorsed by the British Menopause Society and NICE 
guidelines. The NICE guidelines also recommend the development of a collaborative 
‘primary ovarian insufficiency’ registry to allow data collection to clarify, amongst 
other factors, the long-term risk of cancers in this group (125).  
3.6.2.1 HRT and Oesophageal Cancer 
The systematic review in this chapter did not find evidence of a significant risk 
reduction for oesophageal cancer amongst users of HRT.  However, all effect 
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estimates were <1 and the studies included contained only modest numbers of 
oesophageal cancer cases: the Freedman et al cohort study included 297 cases of 
HNC and was the only study to report a significant relative risk reduction for HNC in 
users of HRT (HR 0.78; 0.61-0.99).   
In a recent meta-analysis of oesophageal cancer and reproductive factors, the 
authors reported a 33% relative risk reduction with HRT use (RR 0.67; 95% CI 0.56-
0.81) (118). Similar results were reported for reduced risk of gastric cancers (RR 0.77; 
95% CI 0.64-0.92) (126).  
3.6.2.2 HRT and HNC 
The review presented in this chapter found a protective effect of HRT for HNC but 
this was based on one study at low risk of bias (106); Freedman et al report a 22% 
protective effect (HR 0.78;95% CI 0.61-0.99) for ever-users of HRT. 
Hashim et al (119) reported a striking protective effect of HRT for HNC, in their pooled 
analysis (described in 3.6.1.3).  For HNC they report a 42% protective effect (OR 0.58 
95% CI 0.34-0.77) when considering a total of 626 cases and 1,351 controls who had 
ever used HRT.   
The relationship between HRT and female HNC is assessed using the UK Biobank data, 
in Section 5.2.11. 
3.6.2.2 HRT: Confounding Factors 
Confounding factors must be considered: users of HRT tend to be of higher socio-
economic status and have higher levels of education. Both factors would reduce risk 
of HNC. To address this, only studies controlling for a measure of SES or education 
were eligible for inclusion in the review presented in this chapter.  Freedman et al (8) 
controlled for education, alcohol, BMI, tobacco smoking, physical activity and diet 
(fruit and vegetable intake), although residual confounding could still be relevant.  
3.6.3 The Role of Oestrogen deficiency 
3.6.3.1 The Female Survival Advantage 
Females have been found to have survival advantage in head and neck cancer, 
oesophageal, gastric and pancreatic cancer, as well as cancers at 11 other sites. For 
all cancers combined, women have a 5% lower risk of death than men; for head and 
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neck cancer, 12% improved survival is reported (39). This finding is consistent across 
all European regions in the EUROCARE-4 cohort of 1.6 million population-based 
cancer cases (127). The advantage is most pronounced in younger women and 
declines with age, with a marked decline beyond the age of menopause. It is possible 
that female hormones play a part in this 12% improvement in survival. 
3.6.3.2 Oestrogen and Cancer 
Oestrogen is known to promote cancer in oestrogen-responsive tissues, such as 
breast, endometrium and cervix, however evidence from mouse models suggests 
that oestrogen has an inhibitory role in oesophageal SCC growth (128). Oestrogen 
receptors have been found in oesophageal SCC tissue samples and HNCs (128-130). 
Oesophageal SCC cells with oestrogen receptors have been shown to be inhibited by 
oestrogen exposure and this may initiate apoptosis (131). Oestrogen appears to have 
both tumour-promoting and anti-tumour properties, depending on the tissue and 
presence of oestrogen receptors.  Head and neck cancer cell lines, from males and 
females, have been found to contain oestrogen receptors, and laboratory studies 
appear to show that oestrogen promotes growth of HNC cells (132, 133).  
3.6.3.3 Cumulative Oestrogen Exposure 
If oestrogen is responsible for inhibiting the growth of some cancer cells, oestrogen 
deficiency could be considered a risk factor for certain cancers. A woman who 
undergoes premature menopause has less oestrogen exposure over her lifetime and 
this may increase risk of cancers such as oesophageal SCC or HNC. However, further 
high-quality basic science studies are required to confirm the role of oestrogen in 
HNC and oesophageal SCC. 
3.6.4 Limitations 
The studies included in this review were all assessed for risk of bias, using the 
Newcastle Ottawa scale.  Only three of the eight papers included were low risk for 
bias.  This does limit the significance of our findings and is an indication of the need 
for further, high quality studies addressing the issue of female hormones and 
squamous cancers. 
We have only included studies that control for significant potential confounding 
factors, such as smoking and socio-economic status, however, the risk of residual 
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confounding remains.  Smokers are at risk of early menopause, so this is something 
that needs to be properly controlled for in future studies in this area.  Equally, users 
of HRT are likely to be of higher socio-economic status, which is a protective factor 
for HNC; studies should collect data on deprivation so that this might be controlled 
for. 
The rationale for combining head and neck cancer and oesophageal squamous cell 
carcinoma is based on the strong similarities in their epidemiology and aetiology.  We 
have deliberately excluded oesophageal adenocarcinomas as these cancers have 
quite different aetiology.  One of the papers included in our review by Bosetti et al 
(9) fails to clarify the histology of the oral/pharyngeal cancer cases included, which 
introduces a potential source of bias.  However, over 90% of oral cancers and more 
than 80% of pharyngeal cancers are of squamous histology (46), therefore the bias is 
unlikely to be significant.   
3.7 Conclusion 
Earlier age at menopause is a risk factor for oesophageal squamous cell carcinoma, 
with women entering menopause at <45 years having double the risk of those 
entering menopause age >50 years.  Similar, but less striking, results were observed 
for HNC.  Hormone replacement therapy was found to reduce the risk of 
HNC/Oesophageal SCC but the evidence is not conclusive.   
Strict eligibility criteria were used and only studies that controlled for other risk 
factors were considered, however there is still risk of residual bias.   
Data on reproductive factors and exposure to HRT should be collected, as routine 
practice, in future epidemiological and clinical studies of these cancers. The concept 
of oestrogen deficiency as a risk for HNC/oesophageal SCC deserves further 
exploration in appropriate laboratory and clinical studies.  Chapters 2 and 3 have 
demonstrated an increasing incidence of HNC in England and explored novel, female-
specific risk factors.  Chapter 4 describes the methodology used to develop and 
validate a risk prediction model for HNC, using the UK Biobank dataset.  
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Chapter 4 
 
Methodology for developing the 
first risk prediction model for Head 
and Neck Cancer 
 
 
4.1 Introduction 
Chapters 2 and 3 have presented results on the increasing incidence of HNC in 
England and explored novel risk factors for female HNC.  The role of risk modelling in 
cancer prediction was discussed in Chapter 1 (section 1.3 and 1.4).  This chapter will 
describe the methodology used to develop the first risk prediction model for absolute 
risk of HNC, using data from the UK Biobank.  Study design is considered in 4.3 and 
the UK Biobank dataset is described in 4.3.2.  Methods for data cleaning and handling 
of missing data are discussed in 4.3.3, as well as the issue of handling of continuous 
predictors (section 4.3.5).  Logistic regression is discussed in 4.4.4 and the issue of 
number of events per variable (EPV) is considered in 4.4.5.2.  Methods for assessment 
of model performance are briefly covered in 4.5 and expanded later in Chapter 6.    
Finally, the TRIPOD guidelines (Transparent Reporting of a multivariable prediction 
model for Individual Prognosis or Diagnosis) are discussed in 4.6 as an essential 
framework for ensuring that this HNC risk prediction model is robustly developed, 
validated and presented (134, 135). 
4.2 Research Question  
The aim of this study is to develop an internally and externally validated prognostic 
model for predicting an individual’s risk of developing HNC.  This would inform the 
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organisation of future screening programmes for HNC to ensure their efforts and 
finances are focussed on the highest risk individuals. 
The question being addressed is: “Can a large-scale dataset, containing data from 
500,000 individuals, be used to create a risk prediction model, which will accurately 
predict an individual’s risk of developing head and neck cancer?” 
 
4.3 Research Design 
4.3.1 Options for Study Design: Observational Studies 
Observational studies are frequently used to study risk factors and for predicting risk 
of disease.  Randomised controlled trials are not feasible for this type of project as it 
would be unethical to expose people to harmful risk factors (e.g. smoking) in order 
to determine which diseases they develop.  Equally, due to strict inclusion and 
exclusion criteria, the population enrolled may not be representative of the general 
population (136). 
Prospective cohort studies, case-control studies and cross-sectional studies are all 
valid types of observation study, through which to collect data for development of a 
risk prediction model (137).  Time available, budget and rarity of the disease will 
influence the type of study chosen to collect the necessary data. As pre-existing 
databases can be used for developing a risk prediction model, these considerations 
are not relevant, rather it is the quality of the study used to develop the database 
that should be considered. 
4.3.1.1 Prospective Cohort Studies 
Prospective cohort studies have an advantage that participants are disease-free at 
recruitment, therefore the researcher knows that the exposure of interest precedes 
the outcome.  This allows calculation of incidence, rather than simply prevalence (as 
is the case with cross-sectional studies) (137).  The researcher is also able to 
determine cause and effect, rather than simply reporting an ‘association’ between a 
risk factor and a disease, although one must be aware of the risk of confounding, 
even with prospective cohort studies.  Prospective studies also allow the study of rare 
exposures and allow examination of multiple effects of a single exposure (137); for 
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example, one can study the effect of smoking on incidence of cardiovascular disease, 
lung cancer and HNC.   
However, prospective cohort studies are often not appropriate when studying rare 
diseases or those with a long latency period, such as head and neck cancer (138) ; to 
develop a dataset with enough numbers of individuals with the outcome of interest, 
to provide an appropriately powered study, would take many years (137).  
Prospective studies are time-consuming and expensive and there is often an issue of 
differential loss to follow up between those who develop disease and those who do 
not, which introduces bias (139, 140).   
4.3.1.2 Retrospective Cohort Studies 
Retrospective cohort studies involve going back to existing data, developing a cohort 
within this and determining which risk factors were present in those who developed 
the disease. As the study will have been designed without the present question in 
mind (for example risk factors for HNC), it is possible that the dataset will not contain 
all relevant information related to the disease in question, which means that 
potentially relevant risk factors may not be included in the model (136, 141); 
however, retrospective cohort studies are preferred to case-control studies as the 
risk of recall bias is reduced (137).  Recall bias describes the situation whereby those 
with a disease are more likely to remember exposure to risk factors than those 
without the disease.   
4.3.1.3. Case-Control Studies 
Case-control studies compare separate groups of cases and controls retrospectively 
and seek to identify predictors of outcome.  They are particularly useful when 
studying rare diseases, when a cohort study would take too long.  New hypotheses 
can be generated with the findings of case-control studies, which can be tested in 
future prospective studies.  Cases are recruited from a particular population, for 
example patients attending a head and neck cancer clinic; controls may be recruited 
from the general population but are often recruited from hospital patients who do 
not have the disease in question. This introduces selection bias as they may not be 
representative of the general population.  Controls are usually matched to cases in 
terms of age and sex to reduce confounding.  Case-control studies are cost-efficient 
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and allow calculation of odds ratios; they examine the relative importance of a 
predictor (risk factor) in relation to the presence or absence of disease.  A case-
control study is often the only feasible option when there is a long latency period 
between the exposure and outcome (142), e.g. smoking and head and neck cancer. 
4.3.1.4 Nested Case-Control Studies 
Nested case-control studies provide an alternative study design when developing risk 
prediction models.  The ‘nested’ design, whereby the case and control groups are 
nested within an existing cohort database, overcomes some of the disadvantages of 
case-control studies and has some of the advantages of cohort studies (143, 144).  
Those who have developed the disease are ‘cases’ and those who have not are used 
as ‘controls’.  This should mean the cases and controls are more representative of the 
population, when compared to recruiting from a single centre, for example (145).  
The issue of recall bias is also reduced as the data were collected prospectively; 
however, some ‘cases’ may have already had the disease at recruitment.  As with 
retrospective cohort studies, the problem of incomplete data or failure to record 
details of all pertinent risk factors could be a problem with nested case-control 
studies (141). 
4.3.1.5 Existing Databases 
Pre-existing databases are a  convenient source of data (141); data has been collected 
by people other than the researcher and independently of any hypothesis, thereby 
reducing observer bias and standardising data collection.  The main disadvantage is 
that the type of data collected may not be ideally suited to the current hypothesis 
(141).  
4.3.2 The UK Biobank Dataset: a nested case-control study 
To answer the research question posed (“Can we reliably predict an individuals’ risk 
of developing head and neck cancer?”), a nested case-control study design is used 
here.  The case-control study is nested within the UK Biobank dataset, a prospective 
cohort study of over 500,000 individuals.   
The UK Biobank is a UK-based project, which has involved collecting large amounts of 
data from over half a million people from the general population of the United 
Kingdom.  It provides a uniquely rich resource for the study of risk factors, with the 
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aim of helping researchers to understand the causes of diseases and to find better 
ways of preventing and treating many conditions.    
The UK Biobank recruited over 500,000 persons aged 40-69 years between 2006 and 
2010.  These participants have provided detailed information about themselves and 
have agreed to have their health followed; this will develop a powerful resource for 
scientists to discover why some people develop diseases and others do not.  Data on 
a wide range of exposure and health-related outcomes have been collected.   
The UK Biobank was established by the Wellcome Trust (www.wellcome.ac.uk) and 
is supported by many other charities, government bodies and the NHS.   The biobank 
links to several electronic records, including cancer registries, death registers, 
hospital episode statistics and general practice records.  As time goes on, more health 
events will occur, and the resource will become increasingly valuable. 
Researchers can apply to have access to the dataset for a clearly-defined research 
programme and can select which information they receive from several categories 
(e.g. genetic data, population characteristics, health-related outcomes etc.)   The 
application is a two-stage process, preliminary and main application, including a lay 
summary, scientific rationale for the project, feasibility, security protocols for the 
data, funding details and a timeframe for the project.  The application is reviewed by 
the UK Biobank application sub-committee and when approved, charges must be 
paid in full.  
4.3.2.1 Data Protection 
Prior to release of anonymised data to researchers, the principal investigator, their 
institution and any collaborators are required to complete a Material Transfer 
Agreement.  This details the specific purpose for which the data will be used and 
standard terms relating to the dissemination and exploitation of results. See 
Appendix 4. 
In this case, the application process took over one year up to the point the data were 
released, and the cost was £2500,  
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4.3.2.2 Participants 
Researchers within UK Biobank planned to recruit 500,000 participants from the UK; 
this number was based on power calculations, assuming the dataset would mainly be 
used for nested case-control studies.  Further details of the power calculations can 
be found in the UK Biobank Protocol (146). 
Eligible participants were identified from population-based registers, held by the 
NHS.  35 assessment centres were set up around the UK, with 10 million eligible 
people living within 10 miles of an assessment centre.  The importance of good 
transport links, disabled access and availability of evening appointments were 
considered when setting up the assessment centres.   A pilot study of 300 individuals 
was conducted to allow refinement of the protocol.  Based on this, it was estimated 
that around 5 million primary invitations would need to be sent to achieve 
recruitment of 500,000 individuals. 
 
4.3.2.3 Data Collection and Validity of Data 
Participants first completed the consent process via a touch-screen electronic 
system, allowing for direct data entry.  A touch-screen self-administered 
questionnaire was used to collect most data, which has ensured good response-rates 
to sensitive questions, as privacy is maintained when compared to interview.   
A subsequent computer-assisted personal interview was completed, based on 
‘screening’ questions asked as part of the touch-screen questionnaire; for example, 
patients who indicated they had a particular medical condition would be asked 
follow-up questions during the interview.   The full assessment lasts around 90 
minutes.   
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Questions can be divided into the following categories:  
 Sociodemographic factors  
 Smoking and alcohol 
 Family history and early life exposures 
 General health and disability 
 Environmental factors 
 Dietary habits 
 Physical activity 
 Psychological and cognitive state 
The findings of a review of questionnaires used in previous scientific studies and 
trials, as well as consultation with international experts in each area, were used to 
develop the questionnaire used in UK Biobank (146). 
Baseline physical measurements were also recorded by trained staff at the 
recruitment centres; the measurements were chosen based on relevance, reliability 
and resources:  blood pressure, weight, height, waist and hip circumference, bio-
impedance (body-fat), hand-grip strength and bone densitometry were measured 
(146). 
 
4.3.3 Data Cleaning  
Due to the large file size (1.7GB), it was necessary to access the dataset via a 
University of Liverpool virtual machine.  The dataset was imported to R statistical 
software (147).  The UK Biobank dictionary of variables (n=7,800) was then reviewed 
to determine which variables could be removed from the outset, using prior clinical 
knowledge.  Variables that are very unlikely to be risk factors for HNC, for example 
‘number of falls in the last year’ and ‘plays computer games – yes or no’ were 
removed.  
4.3.3.1 Missing Data 
The remaining variables were then assessed for amount of missing data.  Many of the 
questions were only asked to a smaller number of participants, based on answers to 
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previous questions, e.g. specific smoking-related questions were only asked to 
participants who disclosed they had previously smoked.  For this reason, it was not 
possible to create a rule whereby variables were discarded based on amount of 
missing data; variables had to be assessed individually to determine their relevance 
to the research question, based on clinical knowledge and literature.  Missing data is 
discussed in more detail in section 4.4.3.  
As this study requires only baseline characteristics, rather than repeated measures, 
it was necessary to drop a large number of variables representing repeated 
measures; it was noted that these variables had a large amount of missing data (over 
90%) in some cases and therefore would have added little to the analysis. 
A working dataset containing 233 variables, with some relevance to HNC and with 
less than 20% missing data, was created by discarding variables as described.  The full 
list of variables included in the development dataset is presented in Appendix 5.  The 
rationale for retaining these variables in the dataset is discussed in Chapter 5.2.  
4.3.3.2 Inconsistencies in the Data 
Data were assessed for inconsistencies and outliers.  Cancer Registers often have the 
same cancer registered twice, with slightly different/updated information.  Many of 
the HNC cases within the dataset appeared to have had two HNC at the same 
anatomical site, days apart; obvious errors like these were corrected by removing the 
details of the ‘second’ HNC.  The rules applied for managing variables are presented 
in Appendix 6. 
 
4.3.4 Identification of Head and Neck Cancer cases 
International Classification of Disease-10 codes (148) were used to identify patients 
within the dataset who had HNC.  ICD-10 codes C00-C14 and C30-31 were used to 
represent HNC.  Laryngeal cancer was excluded from the initial model; it would be 
useful to consider building a separate model for this disease, due to the differences 
in epidemiology and risk factors.  The male:female for laryngeal cancer ranges from 
4:1 (80) up to 36:1 (71) , compared to 2:1 for oral cancer (149) (see sections 2.4.2 and 
2.5.2).  Smoking and drinking alcohol account for 90% of cases compared to 64% for 
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oral cavity (88).  There have also been differences identified at the molecular level, in 
the pathway of carcinogenesis, when comparing laryngeal cancer and oral cancer 
(150).  Laryngeal lesions are not visible via oral examination, therefore General Dental 
Practitioners (GDPs) are not involved in the detection of laryngeal cancer.  Given that 
the model will be aimed at GDPs it would not be appropriate to include laryngeal 
cancers in this context.  As described, oral and OPSCC have a mixed-aetiology, 
whereas laryngeal cancer has a high PAR for smoking and alcohol, therefore it is 
possible that other relevant risk factors for oral and OPSCC would be masked by 
including laryngeal cancers in the model. For these reasons, a separate model for 
laryngeal cancer can be considered in the future.   
4.3.5 Handling of Continuous Variables: Categorisation and Fractional 
Polynomials 
One of the assumptions of a logistic regression model is that the relationship between 
the log odds of the predictor variable and the outcome variable is linear (151).  There 
are three main options for addressing a non-linear relationship: variables can be 
categorised at arbitrary cut-off points, or fractional polynomials or cubic splines can 
be used (152).  Categorisation of continuous variables reduces power through loss of 
information and can lead to serious bias (153).  Several authors have recommended 
avoiding categorisation or dichotomising of continuous variables (154-156), as 
models developed using categorised variables display poorer performance (157).  
Royston and Altman developed the concept of fractional polynomials as a flexible 
way of modelling a non-linear relationship between predictor and outcome variables 
(158).    Using multivariable fractional polynomials allows us to test for deviation from 
linearity using fractional polynomials to model non-linear effects.  This first involves 
transforming the variable to ensure the value is not less than zero and then applying 
a power function from a pre-determined set of (-3, -2, -1, 0, 1, 2, 3) (159).  
The output of the logistic regression analysis when using fractional polynomials can 
be obscure and difficult to interpret (152).  For this reason, FPs are not used in 
building the logistic regression model for HNC (in Chapter 6) as an easily-interpreted 
output is considered more important than a slight improvement in model 
performance (157).   
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However, categorisation of continuous variables has been avoided to prevent loss of 
data.  Categorisation results in poorer model performance (157) and is thought to be 
unnecessary, biologically implausible and an inefficient use of data (154, 157).  
However, in some cases clinical interpretation is simplified by categorisation: the 
‘Townsend deprivation index’ (160) is presented as a continuous variable, with the 
score commonly categorised into quintiles; one is most deprived and five is least 
deprived, to allow for more meaningful analysis and interpretation of results. 
4.4 Model Development 
4.4.1 Descriptive Analysis 
Individual variables were assessed using descriptive statistics.  Data are presented for 
cases and controls and separated by gender. 
Histograms were used to view data from continuous variables as a crude check for 
normality.  In cases of normally distributed data, a mean and standard deviation is 
presented and a two-sided students t-test was completed.  For skewed data, median 
and interquartile range is presented, along with results of a Mann-Whitney U test of 
significance at the 5% significance level.    
For categorical data, numbers and percentages are shown in each category.  A chi-
squared test was completed where appropriate with a Fisher’s Exact test used when 
the number per cell dropped below 5.  Again a 5% significance level was used. 
4.4.2 Planning Model Validation: Splitting the Dataset 
An important part of model development is internal and external validation of model 
performance and this is discussed in more detail in Sections 4.5, 6.6.2, and 6.6.3.  It 
involves quantifying a model’s performance (based on discrimination and calibration 
of the model) initially internally, i.e. within the data used to develop the model, 
followed by external validation in data not used to develop the model.  This accurate 
estimation of model performance allows us to draw meaningful conclusions 
regarding the model’s predictive accuracy (161).   
This can involve testing the reproducibility of the developed model on different 
samples from the same or similar populations, for example data collected from the 
same population at a different point in time or at a different geographical location.  
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Another form of external validation tests the transportability of the model into 
different populations; in this case a completely independent dataset is used, often 
including patients from entirely different populations.   
In order to be classed as completely external, the validation should be carried out on 
completely independent data, by researchers who did not develop the original 
model.  Completely independent data with sufficient numbers of events and 
containing information on all relevant predictors is difficult to find, thus many models 
that are developed are not tested externally (162). 
With very large datasets, such as the UK Biobank, splitting the dataset into 
development and validation sets is a recognised way of allowing the model to be 
tested ‘externally’.  The validation dataset should have a minimum of 100 events 
(163) and ideally closer to 200 (164).  A non-random split in the data is recommended, 
e.g. data could be split based on geographical location, sex, smoking-habits, or based 
on presence of particular diseases e.g diabetes (163).    
4.4.2.1 Geographical Split of the Dataset 
The UK Biobank data was collected at 22 main assessment centres around the UK.  
The prevalence of HNC is variable around the UK, therefore it was decided to split the 
dataset into development and validation datasets based on geographical location of 
assessment centres.  The data from assessment centres in the North West 
(Manchester, Liverpool, Bury and Stockport) were separated to become the 
‘validation dataset’, containing 157 cases of HNC.  Data from other centres were 
retained for the development dataset.  The North West is known to have a high 
prevalence of HNC, therefore it is useful to validate the prediction model in this 
subset of the population (149).  It is recognised that the North East also has a high 
incidence of HNC (see Section 2.4.3), however, the number of cases from this part of 
England within the dataset (n=92) is less than the North West (n=157) and does not 
reach the minimum 100 cases recommendation (163) (discussed in Section 4.4.2) for 
the validation dataset. 
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4.4.3 Multiple Imputation 
Missing data is a problem common to many studies.  It is possible to simply omit the 
data from the analysis (complete case analysis) but this risks losing potentially useful 
information.  If the data are not missing completely at random, i.e. there is an 
underlying reason for the missingness, one risks severely biasing the results by 
omitting observations with missing data (165).   
Multiple imputation (MI) is a method for mitigating this loss of information, which 
allows the retention of all available information, potentially reduces bias and 
improves efficiency in parameter estimation (166).   MI is a simulation-based 
procedure; each missing value is replaced by m>1 reasonable values, creating m 
complete datasets, which are then analysed using standard statistical 
procedures(166).  The model is developed on each imputed dataset and the model 
estimates and fit statistics are combined using Rubin’s rules (167, 168).   
 
4.4.4 Developing the Risk Prediction Model: Logistic Regression Analysis 
Risk prediction models are used to predict the risk of a future health outcome, in the 
case of HNC, in a presently healthy individual.  To examine the research question, a 
regression analysis is used.  If data are available on time-to-event, a Cox Regression 
can be used.  However, where data regarding time are not available, logistic 
regression is the preferred statistical tool for developing a prediction model. 
A binary logistic regression will be conducted to assess if the independent variables 
predict the dependent variable, “development of head and neck cancer – yes or 
no”.  Binary logistic regression is an appropriate statistical analysis when the purpose 
of research is to assess if a set of independent variables predict a dichotomous 
dependent variable (151).  This type of analysis can be used when the independent 
variables (predictors) are continuous, discrete, or a combination of continuous and 
discrete.  This method of analysis evaluates the odds of membership in one of the 
two outcome groups, based on the combination of predictor variable values.   
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Binary logistic regression analysis overcomes many of the assumptions of linear 
regressions.  For example, linearity between dependent and independent variables, 
normality and equal variances are not assumed, nor is it assumed that the error term 
(residuals) variance is normally distributed.  The major requirement is that the 
outcome variable must be dichotomous.  There should be no multicollinearity among 
the independent variables (i.e. the predictor variables should not be highly correlated 
with each other), there should be no outliers, and there should be a linear 
relationship between the log odds and the independent variable (151).   
4.4.5 Variable Selection 
4.4.5.1 Clinical Significance of Variables vs Univariable Screening 
Univariable screening is not recommended (169, 170); it involves testing all 
predictors individually, i.e. running a logistic regression model for each predictor 
variable, one at a time.  The statistical significance of each predictor is assessed and 
a decision is made whether or not to include the predictor in the final model (see 
below). 
Simply excluding all non-significant variables can wrongly rule out important 
predictors (171) but it is important to acknowledge that including non-significant 
variables may lead to reduced precision of estimation other effects, without 
necessarily adding validity.  In our case, lack of significance will not prevent the 
variable being included in the model, rather the clinical significance of the variable 
will be considered in conjunction with the statistical significance.  Highly correlated 
variables will not be included to avoid bias within the model (151).  Variables will be 
selected for the model if there is robust evidence of a causal association between the 
risk factor and HNC. Evidence from meta-analyses, systematic reviews or large 
observational studies, published in peer-reviewed journals, will be considered.   
4.4.5.2 Events per Variable (EPV) 
The relative number of cases (“Events”) to number of regression coefficients 
estimated (excluding the intercept) is known as the ‘Events Per Variable’ ratio.  This 
has been shown to be a key predictor of model performance (134).  When EPV is low, 
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the association between predictors and the outcome estimated by logistic regression 
can be inaccurate and biased (too extreme) (172, 173).  Models built within small 
datasets suffer the same problem (174).  10 EPV has been adopted as a minimum for 
performing binary logistic regression analysis (135) although more recent work shows 
that the evidence for this figure of 10 is weak as it is based on only three EPV 
simulation studies (173, 175, 176).  The risk of finite sample bias (over-optimistic 
estimates of the true association between predictor and outcome) is higher when 
small datasets are used to estimate logit coefficients (177).  This can be overcome by 
increasing the total sample size, whilst keeping EPV constant i.e. increasing the 
number of non-events or ‘controls’ (177).    
We ensured a minimum of ten events per variable (EPV) in order to reduce bias and 
increase reliability of parameter estimates(175).  We also used a minimum of 10 
controls per case. 
4.4.5.3 Variable Selection for the Final Model 
Selection of variables for the final model can be achieved through various methods, 
when developing a risk prediction model.  Fitting the full model, i.e. with no prior 
variable selection is one method.  More commonly, an element of automatic 
selection, either forward, backwards or stepwise selection is used (151).   
The aim is to develop a model that accurately predicts an individuals’ risk of 
developing head and neck cancer, using a parsimonious multivariable model.  This 
means only including variables (predictors) that improve the fit of the model. 
4.4.5.3.1 Forwards Selection 
Forward selection involves starting with no variables in the model and adding the 
most significant variable (from univariable analysis) first.  One then continues to add 
one variable at a time and test to see if they improve the fit of the model (151, 178).      
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4.4.5.3.2 Backwards Selection 
Backwards selection involves starting with the full model then removing the least 
significant variable (from univariable analysis) and retesting to determine the impact 
on model fit.  This process is repeated until the parsimonious model is achieved.  This 
method evaluates each predictor after accounting for other variables (179).   
4.4.5.3.3 Stepwise Selection 
Stepwise selection is a method that allows moves in either direction, dropping or 
adding variables at the various steps.  Backward stepwise selection involves starting 
off in a backward approach and then possibly adding variables back in if they later 
appear to be significant. The process is one of alternation between choosing the least 
significant variable to drop and then re-considering all dropped variables (except the 
most recently dropped) for re-introduction into the model.  This means that two 
separate significance levels must be chosen for deletion from the model and for 
adding to the model. The second significance must be more stringent than the first 
(151, 178). 
4.4.5.3.4 Forward Stepwise Selection 
Forward stepwise selection is also a possibility, though not as common. In the forward 
approach, variables once entered may be dropped if they are no longer significant as 
other variables are added (178, 180). 
The results of applying data-driven approaches may not be reproducible; it is 
important to always consider the clinically relevant variables for inclusion in the 
model, even if they do not appear to be significant (178).  
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4.5 Model Validation  
Assessment of model validity is a key requirement of a risk prediction model; it 
indicates the usefulness of the model in clinical practice.  This is discussed in detail in 
chapters 6 and 7. 
4.5.1 Apparent Validation 
Apparent validation involves using statistics, such as the Area under the Receiver 
Operating Curve (AUROC) (see 6.6.1) and calibration curve (see 6.6.2) to assess the 
performance of the model (discrimination and calibration) in the data in which it was 
developed. 
4.5.2 Internal Validation 
Internal validation involves assessing model performance within the existing dataset. 
There are different methods commonly used for internal validation: split-
sampling/cross-validation and bootstrapping are discussed in detail in 6.6.3.1 and 
6.6.3.2. 
Briefly, cross-validation involves splitting the dataset into development and 
validation sets, then developing the model in the development set and validating it 
in the validation set.  This process can be repeated several times, taking new random 
subsamples each time, to improve the stability of the cross-validation process (181).  
Bootstrapping replicates the process of sample generation from an underlying 
population by drawing samples with replacement from the original data set, of the 
same size as the original data set (182).  Models may be developed in bootstrap 
samples and tested in the original sample or in those subjects not included in the 
bootstrap sample (183).  This method has been shown to result in more accurate 
estimation of model performance (184, 185). 
   
75 
 
4.5.3 External Validation 
External validation tests the model on completely independent data and indicates 
how well the model adapts to different clinical situations.  In our case, the dataset 
has been split into development and validation sets based on geographical region.  
The model was built using the development dataset, which contains 702 cases of HNC 
and validated within the validation set, containing 157 cases of HNC from the North 
West of England. 
4.6 TRIPOD Guidelines 
The TRIPOD guidelines have been developed by a collaborative group of academics 
and clinicians, with the aim of improving the reporting of risk prediction models (134).  
Moons et al (135) cited 49 papers as examples of poorly-reported risk models, to 
demonstrate the need for guidelines.  Transparent reporting of the model 
development and validation process is vital to ensure the risk of bias can be 
accurately assessed and the usefulness of the model can be determined by 
researchers external to the development process (135).  This will also help 
policymakers decide whether to recommend the use of the model when developing 
clinical practice guidelines (135).  The TRIPOD checklist comprises 22 items covering 
the entirety of the publication of the model: title, abstract, introduction, methods, 
results, discussion, supplementary information and funding (134). The checklist 
encourages publication of coefficients for predictor variables (rather than simply 
odds ratios), so that the model can be tested in external data, by authors not involved 
with the development of the model.  TRIPOD guidelines have been followed in the 
development and validation of the model presented in Chapters 6 and 7.  The TRIPOD 
checklist is in Appendix 7, with links to the relevant sections of this thesis to 
demonstrate compliance with the guideline. 
 
4.7 Conclusion 
This chapter has described the methodology that is used in the development of a risk 
prediction model for predicting absolute risk of HNC.  The dataset is split based on 
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geographical region (Section 4.4.2.1) to allow for subsequent external validation of 
the model (Chapter 7).  The risk model is developed using logistic regression analysis 
and univariable screening and automated variable selection methods are avoided 
(Section 4.4.5.1).  Methods for assessment of model performance are discussed in 
more detail in Chapter 6.   
The next chapter (Chapter 5) describes details of the UK Biobank dataset and presents 
descriptive statistics for each of the predictor variables considered relevant to HNC.   
TRIPOD guidelines are followed throughout the development, validation and 
reporting of this risk prediction model. 
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Chapter 5 
Results: Descriptive Statistics 
 
5.1 Introduction 
The previous chapter described the methodology used to handle the large, UK 
Biobank, dataset and produce a working dataset for development of an HNC risk 
prediction model.  Section 4.4.2 also described how the dataset was split, based on 
geographic region, into development and validation datasets.  This is so that the final 
model may be validated in data from a cohort from the North West of England, which 
was not used to develop the model. 
This chapter contains a description of why these variables were selected, using 
clinical evidence and summary statistics to compare HNC cases with controls (section 
5.2).  A detailed description of the HNC cases can also be found in 5.3, with a 
breakdown of subtypes and outcome.  The variables considered for the risk model 
can be placed into the following categories: 
 Demographic information (section 5.2.1) 
 Social Deprivation (section 5.2.2) 
 Smoking (section 5.2.3) 
 Alcohol (5.2.4) 
 Diet and Exercise (5.2.5 and 5.2.6) 
 Medical History (5.2.7 and 5.2.8) 
 Sexual History (5.2.12) 
 Hormone-related (females only) (5.2.11) 
 Other risk factors (5.2.9, 5.2.10 and 5.2.12) 
5.2. The Results 
Sections 5.2.1 to 5.2.13 consider differences in demographic data, socio-economic 
status, smoking, alcohol, diet, exercise, medical history, baseline measures of current 
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health, engagement with screening programmes, breastfeeding, female-specific 
hormone risk factors, sexual history and other novel risk factors. 
5.2.1 Demographic Information 
The dataset contains 859 cases of Head and Neck Cancer (HNC) and 501,788 controls. 
Table 5.1 summarises the differences in demographics and socioeconomic factors 
between HNC cases and controls. 
534 cases are male (62.2%) and 325 are female (37.8%).   
228,644 controls are males (45.6%) and 273,144 are females (54.4%).   
Male to female ratio of cases is 1.64:1 and for controls 0.82:1 (p<0.001). 
The mean age of the cases is 58.6 years (female) and 58.8 years (male).  Controls were 
significantly younger:  56.3 years (female) and 56.7 years (male); p<0.001 for both 
genders. 
Most cases (90.8%) and controls (91.1%) were born in the UK, with less than 10% of 
participants born elsewhere. 
The UK Biobank contains both prevalent and incident cases of HNC: 552 (64.3%) were 
diagnosed prior to recruitment and 307 (35.7%) were diagnosed post-recruitment.  
The mean time to diagnosis post recruitment was 2.5 years (range 0 – 6.8 years).  The 
mean time between diagnoses and recruitment for prevalent cases was 7.14 years 
(range 0 to 37.9 years).   
The average period at risk per subject was calculated from date of birth to 7 years 
post-recruitment (the most recent available update on cancer registry linkage).  
Total person-time-at-risk was 31,932,329 years with a total of 859 cases.  This gives 
a rate of 0.027 per 1000 person-years.  The average period at risk was 63.5 years. 
 
5.2.2 Socio-Economic Deprivation 
Socio-economic deprivation has been strongly linked with male risk of HNC (35).  One 
marker of area-level deprivation is the Townsend Deprivation Score (160).  This score 
   
79 
 
is calculated from several measures of individual deprivation, from consensus data, 
such as car ownership, education, employment, number of persons per household 
and income.  It has the benefit that it can be calculated from routinely collected data 
(area postcode).  However, it has disadvantages over collecting individual measures 
of deprivation as the data used to calculate the Townsend score is often calculated 
from census data that may be over 12 years old (186).  It also assumes that persons 
living within the same electoral ward are socio-economically homogenous, which is 
unlikely to be true (186).  This makes the Townsend Score particularly inaccurate for 
mobile, inner-city populations.  In a study of alternative measures of health in relation 
to deprivation, annual household income and National Statistics Socio-Economic 
Class  (NS-SEC) (formerly Socio-Economic Group) were found to be two measures 
which account for the largest variation in self-reported health (186).      
Lower level of education has previously been found to confer increased risk of HNC 
in the INHANCE consortium (an international combined cohort study containing 
23,964 cases of HNC); OR 1.34 (1.04-1.73) (35).  Conway et al. also found that those 
with the lowest income had a 56% increased risk of HNC, when controlling for 
smoking, alcohol, diet, age and gender (OR 1.56 (1.29-1.88)) (35). 
Table 5.1 presents the socio-economic data for this UK Biobank data, separated by 
HNC cases and controls and gender.  Within the UK Biobank, 14% of male cases (n=76) 
live in the most deprived areas of the UK (Townsend Deprivation Quintile 5), 
compared with 9% of male controls (n=21,230) (p<0.001).   
There was no statistically significant difference in level of education between cases 
and controls for females or males, although male cases left full time education at a 
statistically significantly younger age than controls (see Table 5.1).  There was a 
significant difference in the employment status between cases and control, with 
significantly more males and female cases being retired and unable to work due to 
illness, compared to controls. This is likely to be explained by the older age of cases 
vs controls and the fact they have diagnosis of HNC. 
In the current study, 30% of male cases (n=138) reported an annual household 
income of <£18,000 in comparison to 20% of controls (n=41,652) (p<0.001).  Figures 
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are similar for female cases and controls, with 33% (n=86) of female cases living in 
households with <£18,000 annual income, compared to 24.8% (n=55,350) of controls.  
The lower income could be attributed to the fact cases tend to be older and are more 
likely to be retired or unable to work due to their illness, although other studies 
support lower income as a risk factor for HNC (35). 
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Table 5.1.  Demographic and Socio-economic Data: Differences between HNC Cases and Controls in the UK Biobank.  p value <0.05 is considered statistically significant.  Bold 
indicates a significant result. 
Variable     Head and Neck case Control p-value   
   Male Female Male Female   
Number 
  
534 325 228,644 273,144 <0.001 
 
 
% 
 
62.2 37.8 45.6 54.4 
  
             
Age at recruitment (mean years (SD)) 58.8 (6.86) 58.6 (6.82) 56.7 (8.20) 56.3 (8.00) Males <0.001 
           Females <0.001 
Townsend Deprivation Quintile 
 
N % N % N % N % 
  
 
1 
 
173 32.4 113 34.8 82,341 36.1 97,981 35.8 Males <0.001 
 
2 
 
107 20.0 75 23.1 53,724 23.5 65,897 24.2 Females 0.61 
 
3 
 
86 16.1 62 19.1 39,835 17.4 49,157 24.2 
  
 
4 
 
92 17.2 41 12.6 31,218 13.7 37,335 13.7 
  
 
5 
 
76 14.2 34 10.5 21,230 9.3 22,443 8.1 
  
Average total annual household income  
         
£ (before tax) < 18,000 
 
138 30.3 86 33.2 41,652 20.7 55,350 24.8 Male <0.001 
 
18,000 - 30,999 
 
112 24.5 90 34.8 49,253 24.4 58,746 26.3 Female <0.001 
 
31,000 - 51,999 
 
113 24.8 44 17.0 53,909 26.7 56,727 25.4 
  
 
52,000 - 100,000 
 
74 16.2 33 12.7 44,577 22.1 41,608 18.7 
  
  >100,000   19 4.2 6 2.3 12,190 6.1 10,719 4.8     
   
 
 
8
2
 
Table 5.1 continued. Demographic and Socio-economic Data: Differences between HNC Cases and Controls    
Variable Head and Neck case   Control   p-value  
 Male Female Male Female   
Country of Birth N % N % N % N %   
England 398 74.5 243 75.0    179,177  78.7   210,782  77.4 Males 0.04 
Wales 30 5.6 15 4.6       10,135  4.4     11,903  4.4 Females 0.33 
Scotland 60 11.2 28 8.6       17,996  7.9     22,105  8.1   
Northern Ireland 3 0.6 5 1.5         1,438  0.6        1,660  0.6   
ROI 7 1.3 5 1.5         2,112  0.9        2,842  1   
Elsewhere 36 6.7 28 8.6       16,883  7.4     22,972  8.4   
           
Education and Employment           
Age completed full-time education 16 (15 - 17) 16 (15 - 17) 16 (15 - 17) 16 (15 - 18) Male <0.01 
median (IQR)         Female 0.32 
Qualifications N % N % N % N %   
   University/College degree 149 37.9 86 35.7       76,502  41.4     84,475  38.1   
   A/AS levels or equivalent 38 9.7 38 15.8       23,283  12.6     31,976  14.4   
   GCSE's/O-levels 107 27.2 66 27.4       41,976  22.7     63,074  28.4   
   CSE or equivalent 25 6.4 13 5.4       12,269  6.6     14,588  6.6   
   NVQ/HND/HNC 49 12.5 13 5.4       20,516  11.1     12,159  5.5   
   Other professional qualifications 25 6.4 25 10.4       10,134  5.5     15,626  7.1   
           
Employment Status           
In paid employment or self-employed 250 47.3 136 42.6    137,739  61   149,112  55.2 Males <0.01 
Retired 187 35.3 149 46.7       71,242  31.5     95,436  35.3 Females <0.01 
Looking after home/family 1 0.2 9 2.8         1,283  0.6     12,619  4.7   
Unable to work due to sickness/disability 75 14.2 21 6.6         9,304  4.1        7,436  2.8   
Unemployed 16 3.0 0 0.0         5,360  2.4        2,890  1.1   
Doing unpaid/voluntary work 0 0.0 4 1.3            656  0.3        1,668  0.6   
Full or part-time student 0 0.0 0 0.0            461  0.2           883  0.3     
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5.2.3 Smoking  
Smoking is the single largest risk factor for cancers of the head and neck.  66.1% 
(n=353) male HNC cases in the UK Biobank are ever smokers (defined as current or 
former smokers).  50.7% (n=115,892) of male controls are ever smokers; p<0.001 56% 
(n=182) of female cases are ever smoker’s vs 40.1% (n=109,664) of controls; p<0.001.  
Full data are in Table 5.2. 
Consistent with previous reports, HNC cases report smoking more cigarettes per day 
than controls.  Current male smokers with HNC report smoking a mean of 20.7 
cigarettes per day compared to 17.1 for controls.  
Male and female HNC cases, who were smokers, began smoking at a younger age 
than controls, with males beginning around one year earlier (age 16.2 years) and 
females around three years earlier (age 15.8 years). 
Former smokers with HNC stopped at an older age than former smokers in the control 
group pointing to an overall increased duration of smoking among cases. 
Smoking duration was calculated as a new variable by subtracting age stopped 
smoking from age started smoking for former smokers.  For current smokers age at 
baseline – age started smoking was used to calculate smoking duration. 
Pack Years has been used as a measure of smoking exposure for many years, 
however, more recently smoking duration is believed to be a more accurate predictor 
of disease (187, 188).  Peto explains that a 55 year old person who begins smoking at 
age 15 and smokes 0.5 packs per day for 40 years has a greater risk of cancer than if 
they begin smoking at 45 years later but smokes 2 packs per day, even though they 
have smoked for 20 pack years (189).  In this study, pack years of smoking was 
significant, between cases and controls, in males and females.  Male cases had 
smoked for 37.5 pack years vs 25.9 in controls (p<0.001) and females 23.8 vs 20.1 
pack years; p=0.013.   
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5.2.3.1 Involuntary Smoking 
Involuntary, or passive, smoking has been difficult to study in relation to HNC due to 
difficulties in assembling large enough studies including sufficient numbers of never 
smokers.  Lee et al have published the findings from 6 case-control studies from 
within the INHANCE consortium, which contains 542 HNC who are never smokers and 
2,197 never-smoker controls.  They found an increased risk of head and neck cancer 
for those who were exposed to passive smoking in the home for greater than 15 years 
(OR 1.60; 1.12 -2.28; p-value<0.01).  The effect was only seen with this long duration 
of exposure and there was no overall increased risk for ‘ever exposure’ to passive 
smoke.  There have been other reports of an increased risk of HNC in adults who were 
exposed to passive smoke as children (190).  Troy et al. studied 858 cases and 806 
controls and found a 28% increased risk for head and neck cancer (OR 1.28 (95% CI 
1.01 – 1.63)) when controlling for current smoking and other commonly accepted risk 
factors (190).  The study may be subject to recall bias due to the nature of the 
retrospective data collection.  Our study found no difference in number of hours of 
smoke exposure at home or work, for non-smokers.  We did find a significant 
difference between male cases and controls in terms of number of smokers per 
household, however there were only 8 cases who reported >1 smoker in the 
household so the results are unreliable. 
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Table 5.2.  Smoking Related statistics for HNC cases and controls in the UK Biobank Dataset.  t-tests are used to test differences between continuous, normally distributed 
variables and chi-2 tests for categorical variables (with Fischer's Exact where indicated).  Significant p-values are shown in bold (<0.05 is considered statistically significant) 
                                          All   Head and Neck Cases Controls   p-value 
                                           n= 502,647  n=859  n=501,788     
     Male Female Male Female     
   N 534  325  228,644  273,144   <0.001 
   % 62.2  37.8  45.6  54.4     
               
Smoking Status N %  n % n % n % N %    
Never smoker 273,604 54.8  176 33.0 140 43.5 111,320 49.0 161,968 59.6  males <0.001 
Current Smoker 52,989 10.6  102 19.0 35 10.9 28,515 12.5 24,337 9.0  females <0.001 
Previous smoker 173,102 34.6  251 47.0 147 45.6 87,377 38.5 85,327 31.4    
               
No of smokers/household               
0 411,489 81.7  386 72.3 260 80.0 186,617 81.6 224,226 82.0  males 0.04 
1 41,294 8.2  48 9.2 27 8.2 16,890 7.4 24,329 8.9  females 0.94 
>1 5,373 1.1  8 1.5 3 0.8 2,294 1.0 3,068 1.1    
               
Hours of smoke exposure at home (for non-smokers)            
mean (SD) 0.5 
 
(4.5)  0.7  (4.1) 0.5  (3.7) 0.5 (4.4) 0.6  (4.6)  males 0.43 
N 463,475   441  289  203,372  247,269   females 0.81 
Hours of smoke exposure outside the home (for non-smokers)           
               
mean (SD) 0.5 
 
(2.6)  1.3  (5.6) 0.3  (1.0) 0.6  (3.0) 0.4  (2.1)  males 0.4 
N 463,475   409  264  191,847  229,253   females 0.81 
   
 
 
8
6
 
 
 
    
Table 5.2 continued.  Smoking-related Statistics for HNC cases and controls    
                 All   Head and Neck Cases Controls   p-value 
                    n= 502,647  n=859  n=501,788     
     Male Female Male Female     
 N %  n % n % n % N %    
Smoked at least 100 cigarettes in lifetime (occasional smokers only)          
Yes 60,475 44.0  65 66.3 38 51.4 29,392 49.1 29,949 41.7  males 0.002 
No 71,261 51.8  33 33.7 36 48.6 30,423 50.9 41,800 58.3  females 0.09 
Don't know 5,793 4.2             
               
Type of tobacco smoked                
Current Smokers               
Manufactured Cig 27,336 69.8  36 43.4 23 76.7 11,545 56.5 15,732 84.4  males 0.04 
Hand-rolled cig 9,158 23.4  36 43.4 7 23.3 6,326 31.0 2,789 15.0  females 0.41 
Cigars or pipes 2,668 6.8  11 13.2 0 0.0 2,552 12.5 105 0.6    
               
Former Smokers               
Manufactured Cig 107,507 88.8  159 74.3 99 94.3 54,247 82.8 53,002 96.4  males <0.001 
Hand-rolled cig 7,996 6.7  40 18.7 5 4.7 6,066 9.3 1,885 3.4  females 0.206 
Cigars or pipes 5,326 4.4  15 7.0 1 1.0 5,190 7.9 120 0.2    
None of above 138 0.1             
Prefer not to answer 34 0.0             
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Table 5.2 continued.  Smoking-related Statistics for HNC cases and controls    
All   Head and Neck Cases Controls   p-value 
n= 502647  n=859  n=501788     
     Male Female Male Female     
Age started smoking                
Current Smokers               
mean (SD)  17.9  16.2  (5.2) 15.8  (2.5) 17.5  (5.7) 18.3  (5.9)  males 0.04 
n  39,416  83  30  20,253  18,409   females 0.02 
               
Former Smokers  17.3  17.1  (4.7) 18  (4.0) 16.9  (3.5) 17.8  (3.84)  males 0.43 
n  122,239  211  104  65,306  54,729   females 0.51                
No. cigs/per day               
Current Smokers 
mean 
(SD) 15.5  20.7  (11.3) 13.6  (6.6) 17.1  (9.2) 14.1  (7.37)  males 0.00 
 n 52,989  70  30  17,657  18,407   females 0.71 
Former Smokers 
mean 
(SD) 19.1  24.6  (12.6) 17.4  (8.6) 21.2  (11.6) 16.7  (8.5)  males <0.001 
 n 173,102  197  102  59,850  54,473   females 0.38 
Age Stopped Smoking               
 
mean 
(SD) 39.8 (11.6) 45.8  (12.4) 42.7  (11.9) 40.1  (11.6) 39.6  (11.8)  males <0.001 
 n 122,239  212  104  65,258  54,739   females 0.01                
Ever Stopped for 6 months n %  n % n % n % n %    
No 67,005 55.8  127 61.7 62 59.0 37,356 58.3 29,460 54.6  males 0.33 
Yes 51,262 42.7  79 38.3 43 41.0 26,693 41.7 24,447 45.4  females 0.37 
Don’t know 1,787 1.5             
 
Table 5.2 continued.  Smoking-related Statistics for HNC cases and controls    
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All   Head and Neck Cases Controls   p-value 
n= 502,647  n=859  n=501,788     
     Male Female Male Female     
Time from waking to first cigarette              
 n %  n % n % n % n %    
<5 mins 5,212 14.0  15 24.6 5 17.3 2,838 16.1 2,263 12.4  males 0.05 
5-15 mins 13,648 36.8  25 41.0 17 58.6 6,478 36.9 6,781 37.2  female 0.08 
30m-1h 10,140 27.4  10 16.4 3 10.3 4,750 27.1 5,082 27.9    
1-2h 3,626 9.8  7 11.4 2 6.9 1,752 10.0 1,750 9.6    
>2h 4,218 11.4  4 6.6 2 6.9 1,729 9.9 2,343 12.9    
Don't know 221 0.6             
Total 37,065              
               
Smoking now compared to ten years previous             
               
More now 6,548 16.7  19 22.9 6 20.0 2,943 14.4 3,580 19.2  males 0.09 
About the same 15,661 40.1  31 37.3 14 46.7 8,511 41.7 7,107 38.2  females 0.56 
Less now 16,917 43.2  33 39.8 10 33.3 8,955 43.9 7,920 42.6    
Total 39,126              
               
Pack Years of Smoking               
               
mean (SD) 23.4 
 
(18.6)  37.5  (27.4) 23.8  (16.3) 25.9  (20.5) 20.1  (15.3)  males <0.001 
n 150,126   206  105  65,641  62,493   females 0.01 
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5.2.4 Alcohol 
Alcohol is known to increase permeability of the oral mucosa and may, therefore, 
increase exposure to smoke carcinogens.  Alcohol and smoking act synergistically to 
increase risk of oral cancer and this is discussed in the Introduction Chapter 1 (section 
1.2.1).   Alcohol alone is a risk factor for HNC; in non-smokers drinking 3 or more 
alcoholic drinks per day doubles an individual’s risk of HNC (OR 2.04 (95% CI 1.29-
3.21)) (191).  Purdue et al showed similar odds ratios for heavy drinkers of beer, wine 
or liquor, implying that quantity rather than type of alcohol is most relevant to risk of 
HNC (192).  In contrast to smoking, it appears that a high intake of alcohol over a 
shorter period confers greater risk of HNC compared to a low intake (1 drink per day) 
over a longer period (192). 
In the present study, 30% (n=163) of male cases report to drink alcohol on a daily 
basis compared to 25% (n=57,751) of male controls (p<0.001).  In contrast to this, 
12% of male cases report complete abstinence vs 6% of controls; this could be due to 
the effects of treatment for HNC or a decision to stop drinking following the diagnosis.  
Results are similar but not statistically significant, for females. 
Amongst male non-drinkers, 84% (n=54) report to be former alcohol-drinkers vs 55% 
of controls.  This supports the assumption regarding the diagnosis of HNC having an 
influence on the current alcohol status.  The majority of male and female cases report 
drinking less alcohol now compared to ten years previously and this was statistically 
significant between cases and controls; p<0.001 males and 0.031 for females. 
When the type of alcohol was studied, male cases were found to drink less wine 
(p=0.001) and more beer than controls.  Males cases consumed an average of 7.7 
pints of beer per week compared to 5 pints for controls (p<0.001).  Cases also 
consumed a greater number of measures of spirits per week compared to controls (3 
vs 2; p=0.001).  Male cases were also less likely to drink alcohol with meals (44% vs 
58%; p<0.001). 
These results are displayed in Table 5.3.
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Table 5.3. Alcohol: Differences between HNC Cases and Controls, in terms of alcohol status, frequency and type of alcohol consumed, in the UK Biobank.  
Significant p-values are shown in bold (<0.05 is considered statistically significant). 
Variable   Head and Neck Cancer Cases     Controls   p-value   
  Male Female   Male Female    
              
Alcohol Status  N % N %  N % N %    
 Never  11 2.1 13 4  6,458 2.9 16,065 5.9 Males <0.001  
Previous  54 10.1 26 8  8,074 3.6 9,961 3.7    
Current  469 87.8 286 88  213,350 93.5 246,377 90.4 Females <0.001  
              
Alcohol Frequency (Current)              
 Daily or almost daily  163 30.5 56 17.1  57,751 25.2 43,822 16 Males <0.001  
3-4 times per wk  109 20.4 71 21.9  59,443 26 55,840 20.3    
 1-2 times wk  123 23 72 22.2  59,011 25.8 70,117 25.7 Females 0.39  
1-3 times per month  33 6.2 36 11.1  20,326 8.9 35,479 13    
Special occasions only  41 7.7 51 15.7  16,819 7.4 41,119 15.2    
Never  65 12.2 39 12  14,532 6.4 26,026 9.5    
Missing  0 0 0 0  762 0.3 741 0.3    
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Table 5.3 continued.  Alcohol-related statistics comparing differences between HNC cases and controls     
Variable   Head and Neck Cancer Cases   Controls p-value 
  Male Female  Male  Female    
             
Alcohol usually taken with meals              
(only asked to those who drink alcohol)   N % N %  N % N %   
 No  161 55.9 40 26.1  50,744 42.4 30,721 23.4 Males <0.001 
             
Yes  127 44.1 113 73.9  68,869 57.6 100,784 76.6 Females 0.42 
             
Alcohol now compared to 10 years previously             
More now  44 9.4 38 13.4  28,039 13.2 47,504 19.5 Males <0.001 
             
About the same  134 28.6 120 42.4  78,088 36.8 94,371 38.7 Females 0.04 
             
Less now  291 62 125 44.2  106,107 50 102,131 41.8   
             
Former Alcohol Drinker (never drinkers only)             
 No  10 15.6 13 33.3  6,397 44.2 15,975 61.6 Males <0.001 
             
Yes  54 84.4 26 66.7  8,074 55.8 9,961 38.4 Females <0.001 
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Table 5.3 continued.  Alcohol-related statistics comparing differences between HNC cases and controls     
Variable  Head and Neck Cancer Cases    Controls   p-value 
   Male   Female  Male   Female      
             
For those who drink at least once per week:             
Weekly number of glasses red wine (125mL)  mean(sd) 3.39 (5.7)  3.59 (5.8)  4.43 (6.3)  3.38 (4.7)  Males <0.01 
  N 394  197  174,936  168,874    
           Females 0.51 
             
Weekly no. of glasses of  mean (sd) 1.71 (4.0)  3.18 (5.2)  2.01 (4.4)  3.32 (5.0)  Males 0.18 
 white wine or champagne (125mL)  N 393  197  174,858  168,687    
           Females 0.71 
             
Weekly pints of beer or cider  mean (sd) 7.70 (9.2)  1.04 (3.1)  5.31 (6.9)  0.62 (1.8)  Males <0.01 
  N 393  198  175,495  169,071    
           Females <0.01 
             
Weekly number of measures of spirits (25cl)  mean (sd) 3.03 (7.9)  2.38 (7.5)  2.22 (6.4)  1.47 (4.0)  Males 0.01 
  N 392  198  174,775  168,471    
           Females <0.01 
             
Weekly glasses of fortified wine (62.5mL)  mean (sd) 0.47 (3.8)  0.27 (1.0)  0.20 (1.3)  0.28 (1.2)  Males <0.01 
  N 392  197  175,199  169,133    
           Females 0.97 
             
Weekly glasses of other alcohol  mean (sd) 0.0 (0.0)  0.1 (0.3)  0.0 (0.6)  0.0 (0.5)  Males 0.48 
    N 121   58   59,200   56,313       
   
 
 
9
3
 
 
Table 5.3 continued.  Alcohol-related statistics comparing differences between HNC cases and controls       
Variable    Head and Neck Cancer Cases     Controls   p-value   
   Male   Female   Male   Female     
For those who drink maximum 3x/month:              
Average number of glasses of  mean (sd) 0.45 (1.3)  0.86 (1.3)   1.17 (2.1)  0.91 (1.7)  Males 0.09 
 red wine per month (125mL)  n 26  29   13,309  26,963    
            Females 0.89 
              
Average number of glasses of   mean (sd) 0.15 (0.5)  0.72 (1.1)   0.76 (1.4)  1.11 (1.7)  Males 0.03 
white wine/champagne per month (125mL)  n 26  29   13,300  26,918    
            Females 0.23 
              
Average number of pints of   mean (sd) 4.00 (6.7)  0.41 (1.0)   2.21 (3.5)  0.42 (1.2)  Males 0.01 
beer/cider per month  n 25  29   13,324  27,078    
            Females 0.99 
              
Average number of measures of  mean (sd) 0.36 (0.8)  0.58 (1.1)   0.84 (2.9)  0.70 (1.8)  Males 0.41 
 spirits per month (25cl)  N 25  29   13,273  26,925    
            Females 0.73 
              
Average number of glasses of   mean (sd) 0.04 (0.2)  0.38 (1.2)   0.14 (0.8)  0.17 (0.9)  Males 0.52 
fortified wine per month (62.5mL)   26  29   13,341  27,066    
            Females 0.20 
              
How many glasses of other   mean (sd) 0.00 (0.00)  0.00 (0.00)   0.09 (0.6)  0.12 (0.7)  Males 0.48 
alcoholic drinks per month?   n 26  29   13,354  27,098    
            Females 0.32 
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5.2.5 Diet  
Diet is known to be a risk factor for HNC.  Chuang et al have published evidence of 
the protective effect of fruit and vegetables on the risk of HNC (193).  This study used 
the international INHANCE consortium of studies with 14,520 cases and 22,737 
controls; Consuming fruit 7 or more times per week offered a protective effect of 48% 
(OR 0.52 (95% CI 0.43 – 0.62)) and vegetables OR 0.66 (95% CI 0.49 – 0.90).  In 
contrast, increased intake of red and processed meat conferred a greater risk of HNC: 
eating red meat on 7 or more occasions per week confers a 40% increased risk of HNC 
(OR 1.40 (95% CI 1.13 – 1.74)), similar to processed meat (OR=1.37 (95% CI 1.14-
1.65)). 
The data (Table 5.4) show that cases consume less fruit and raw salad/vegetables 
compared to controls.  On average, cases consumed less than two portions of fruit 
per day compared to controls, who reportedly consumed greater than two portions 
per day. Over a week this equates to a difference of around 3 portions.  This was 
statistically significant for males and females.   
Male cases are more likely to report never eating oily fish, beef or lamb than male 
controls.  Male cases are more likely to always add salt to their food (9.8%; n=52) 
compared to controls (5.2% n=11,818).   
 
5.2.6 Exercise 
Hashibe et al, in their study of risk factors for HNC within the Prostate, Lung, 
Colorectal and Ovarian  (PLCO) cancer cohort  (n=101,182), showed that physical 
activity for more than three hours per week offered a protective effect against HNC 
of around 40%  (OR 0.58  (95%CI 0.35-0.96))(194).   
The INHANCE consortium have reported similar effects, with a risk reduction of 22% 
with moderate physical activity compared to none (OR 0.78 (95%CI 0.66-0.91), in the 
2,283 cases and 5,674 controls studied (195). 
Moderate physical activity is defined, by the World Health Organisation, as 3-6 
Metabolic Equivalents (METs): “One MET is defined as the energy cost of sitting 
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quietly and is equivalent to a caloric consumption of 1kcal/kg/hour. It is estimated 
that compared with sitting quietly, a person's caloric consumption is three to six 
times higher when being moderately active  (3-6 METs) and more than six times 
higher when being vigorously active  (>6 METs)” (196). 
The present study confirms a difference between male cases and controls in terms of 
the number of days of moderate exercise per week.  20% of male cases report no 
moderate exercise compared to 13% of controls; p=<0.001.  Results are mixed, with 
the majority of male cases completing either no moderate exercise or exercising 
seven days per week (20% and 19.4% respectively).  Results for females were not 
statistically significantly different.  Results are presented in Table 5.4. 
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Table 5.4. Diet and Exercise: Differences between HNC Cases and Controls in the UK Biobank Dataset 
 Variable      Head and Neck Cancer Case     Control      
    Male   Females     Males   Females   p-value  
 Salt added to food   n % n %  N % n %   
  Never   253 47.6 205 63.3  121,881 53.4 155,668 57.1  Males   <0.001  
  Sometimes   146 27.4 79 24.4  64,550 28.3 75,881 27.8  Females             0.1  
  Usually   81 15.2 25 7.7  29,824 13.1 28,487 10.5   
  Always   52 9.8 15 4.6  11,818 5.2 12,554 4.6   
              
 Beef               
  Never   68 12.9 54 16.7  18,459 8.1 37,068 13.7  Males   <0.001  
  <1/week   195 37.1 144 44.4  101,233 44.6 125,602 46.3  Female             0.6  
  1/week   171 32.5 90 27.8  78,160 34.4 80,325 29.6   
  2-4/week   89 16.9 35 10.8  28,288 12.5 28,028 10.3   
  5-6/week   1 0.2 1 0.3  579 0.3 330 0.1   
  At least daily   2 0.4 - -  224 0.1 175 0.1   
              
 Bread (number of slices per week)             
  median (IQR)    12 (7 - 20)   8 (4.5 - 14)    14 (8 - 20)    10 (5 - 14)    Males   <0.001  
             Females             0.0  
 Bread type    n   %   n   %    n   %   n   %    
  White   202 41.4 67 22.3  73,221 33.0 54,614 20.8  Males   <0.001  
  Brown   56 11.5 31 10.3  30,643 13.8 29,874 11.6  Females             0.7  
  Wholemeal   219 44.9 189 63.0  111,054 50.1 160,206 62.2   
   Other    11 2.1 13 4.4  6,844 3.1 13,726 5.3     
   
 
 
9
7
 
  
 
 
 
Table 5.4 continued.  Diet and Exercise: differences between HNC cases and controls in the UK Biobank dataset     
Variable    Head and Neck Cancer Case     Control      
    Male   Females     Males   Females   p-value  
 Cereal (number of bowls per week)             
  median (IQR)    5 (2-7)   6 (3 -7)    5 (2-7)   5 (3-7)   Males             0.2  
             Females  
           
0.0  
 Cheese    n % n %  N % n %   
  Never   21 4.1 12 3.8  6,531 2.9 7,010 2.6  Males             0.4  
  <1/week   70 13.6 61 19.1  32,324 14.6 52,318 19.7  Females             0.4  
  1/week   112 21.8 72 22.6  46,092 20.7 58,552 22.1   
  2-4/week   253 49.0 127 39.8  106,018 47.7 114,255 43.1   
  5-6/week   43 8.3 37 11.6  22,844 10.3 23,581 8.9   
  At least daily   17 3.3 10 3.1  8,423 3.8 9,400 3.6   
              
 Coffee (number of cups per day including decaf)            
    2 (1-4)   2 (1-3)    2 (1-3)   2 (0 - 3)   Males             0.8  
             Females  
           
0.0  
 Coffee Type              
  Decaf   53 13.4 55 22.3  27,379 15.3 46,913 22.9  Males             0.4  
  Instant   243 61.4 143 57.9  106,286 59.4 108,328 52.9  Females             0.3  
  Ground   91 23.0 44 17.8  42,450 23.7 45,376 22.1   
  Other   9 2.3 5 2.0  2,760 1.5 4,373 2.1   
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Table 5.4 continued.  Diet and Exercise: differences between HNC cases and controls in the UK Biobank dataset     
 Variable     Head and Neck Cancer Case     Control      
    Male   Females     Males   Females   p-value  
 Cooked Vegetables (number of tbsp per day)          
median (IQR)    2 (2 - 3)   2 (2 -3)    2 (2 -3)   3 (2 - 3)   Males  
           
0.9  
            Females  
           
0.0  
             
 Oily Fish intake         n         %          n       %          n        %         n        %   
 Never               79           15.2              33           10.2             25,716           11.4            29,033           10.7   Males  
           
0.0  
 <1/week             182           34.9            107           33.0             78,377           34.6            86,266           31.8   Females  
           
0.8  
 1/week             172           33.0            117           36.1             82,456           36.4         105,796           39.0    
 2-4/week               77           14.8              63           19.4             37,226           16.4            48,058           17.7    
 5-6/week                 7             1.3                3             0.9               1,945             0.9              1,639             0.6    
 At least daily                 4             0.8                1             0.3                  712             0.3                 495             0.2    
             
 Non-oily fish intake             
Never              39             7.4              16             4.9             10,199             4.5            13,249             4.9   Males  
           
0.0  
<1/week            156           29.6              87           26.9             67,683           29.8            76,958           28.4   Females  
           
0.9  
1/week            238           45.1            170           52.5          112,835           49.8         135,216           49.8    
2-4/week              90           17.1              50           15.4             34,364           15.1            44,374           16.4    
5-6/week                3             0.6                1             0.3               1,190             0.5              1,194             0.4    
At least daily                2             0.4               0               0.0                       369             0.2                 438             0.2      
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Table 5.4 continued.  Diet and Exercise: differences between HNC cases and controls in the UK Biobank dataset
Processed Meat
Never 45           8.5          47           14.5        12,367         5.4          34,368         12.6        Males 0.0          
<1/week 101         19.1        118         36.3        48,674         21.4        103,488      38.0        Females 0.8          
1/week 152         28.7        93           28.6        67,777         29.8        78,050         28.7        
2-4/week 198         37.4        62           19.1        83,941         36.9        51,158         18.8        
5-6/week 24           4.5          5              1.5          11,689         5.1          3,952           1.5          
At least daily 10           1.9          -          -          3,079           1.4          1,016           0.4          
Salad and Raw Vegetables (no. heaped tbsp/day)
mean (sd) 1.8          (1.9) 2.2          (1.8) 2.0                (2.2) 2.5                (2.1) Males 0.0          
n 484         318         210,386      260,166      Females 0.0          
Fruit Mean no. pieces per day (SD) Males <0.001
N 501         317         217,226      265,479      Females <0.001
Lamb n % n % n % n %
Never 102         19.4        74           22.9        32,921         14.6        55,618         20.5        Males  <0.01
<1/week 244         46.4        168         52.0        128,399      56.7        152,982      56.5        Females 0.6          
1/week 156         29.7        75           23.2        56,388         24.9        55,716         20.6        
2-4/week 22           4.2          6              1.9          8,321           3.7          645               2.4          
5-6/week 1              0.2          -          -          196               0.1          125               0.1          
At least daily 1              0.2          -          -          136               0.1          105               0.0          
2.44 (1.58)2.11 (1.62)2.10 (1.36)1.69 (1.45)
Head and Neck Cancer Case Control
p-valueMale Females Males Females
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Table 5.4 continued.  Diet and Exercise: differences between HNC cases and controls in the UK Biobank dataset    
Table 5.4 continued.  Diet and Exercise: differences between HNC cases and controls in the UK Biobank dataset     
Variable    Head and Neck Cancer Case     Control      
    Male   Females     Males   Females   p-value  
 Type of Milk   N % N %  N % N %   
  Full cream   95 17.9 28 8.6  20,913 9.2 13,584 5.0  Males  <0.01  
  Semi-skimmed  314 59.1 195 60.2  154,758 67.1 167,705 61.5  Females  <0.01  
  Skimmed   85 16.0 67 20.7  36,683 16.3 63,795 23.4   
  Soya   14 2.6 15 4.6  5,592 2.5 14,035 5.2   
  Other   9 1.7 7 2.2  2,671 1.2 3,819 1.4   
  Never have milk  14 2.6 12 3.7  7,157 3.7 9,553 3.5   
              
 Pork               
  Never   106 20.2 74 23.1  31,173 13.8 55,158 20.4  Males   <0.001  
  <1/week   251 47.4 176 54.8  129,164 57.0 153,250 56.5  Females  0.5  
  1/week   147 28.2 67 20.9  55,748 24.6 55,180 20.4   
  2-4/week   19 3.3 4 1.3  9,885 4.4 7,228 2.7   
  5-6/week   1 0.2        0 0.0  327 0.1 142 0.1   
  At least daily   1 0.2        0 0.0  154 0.1 93 <0.1   
              
 Poultry               
  Never   45 8.5 29 8.9  8,822 3.9 16,759 6.2  Males  <0.01  
  <1/week   71 13.4 35 10.8  25,849 11.4 28,011 10.3  Females  0.4  
  1/week   188 35.0 112 34.5  84,290 37.1 95,091 34.9   
  2-4/week   212 40.0 143 44.0  103,370 45.4 126,091 46.3   
  5-6/week   90 1.7 5 1.5  4,497 2.0 5,464 2.0   
  At least daily   5 0.9 1 0.3  702 0.3 771 0.3   
              
Water 
 (no. glasses/day)  Median (IQR)    2 (1 - 4)   3 (2 -4)    2 (1 -4)   3 (2 -4)   Males  < 0.01  
   n  499 306  207,634 256,058  Females  0.4  
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 Variable   Head and Neck Cancer Case     Control      
    Male   Females     Males   Females   p-value  
 Moderate Exercise for at least 10 minutes          
 (number of days per week)            
          0            100           20.0              45           14.6             28,813           13.2            32,221           12.6   Males   <0.001  
                      1               25             5.0              30             9.7             18,657             8.5            19,578             7.7   Females       0.2  
                      2               72           14.4              39           12.6             31,701           14.5            37,988           14.8    
                      3               54           10.8              53           17.2             30,585           13.9            40,815           16.0    
                      4               46             9.2              38           12.3             20,571             9.4            26,546           10.4    
                      5               65           13.0              43           13.9             35,677           16.3            35,657           13.9    
                      6               42             8.4              15             4.9             14,412             6.6            11,967             4.7    
                      7               97           19.4              46           14.9             38,187           17.4            51,176           20.0    
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5.2.7 Medical History  
5.2.7.1 Diabetes 
The percentage of cases and controls with diabetes did not differ significantly, for 
males (6.8-7%) or females (3.1 -3.8%).  However, female cases with diabetes were 
diagnosed with diabetes at a significantly older age than female controls (61years vs 
54 years; n=8).  The low number of females with HNC and diabetes (n=8) limits the 
significance of this finding (see Table 5.5) 
Diabetes is associated with several other chronic health problems including an 
increased risk of cancers.  A pooled analysis of 12 case-controls studies within the 
INHANCE consortium (117) showed an increased risk of HNC for women with 
diabetes, particularly never smokers (OR 1.70 95% CI (1.25 – 2.32); n=39).  Overall, a 
diagnosis of type two diabetes conferred increased risk of 33% (OR 1.33; 95%CI 1.02 
– 1.73; n=118), when controlling for age, sex, education, centre, smoking, alcohol, 
BMI and race.  Information on treatment of diabetes was not available but it is known 
that around 80% of patients diagnosed with diabetes receive treatment, therefore 
the authors concluded that the effect of diabetes in the absence of treatment (i.e. 
undiagnosed diabetes) might be stronger than that observed in their study. 
Around 90% of patients with newly diagnosed diabetes in the UK are treated with the 
drug Metformin (197).  A recent systematic review has examined the effect of 
Metformin on the incidence of HNC and concluded that metformin reduces incidence 
of HNC, reduces recurrence of disease and improves overall survival of HNC patients 
(198, 199).   
The incidence of diabetes has doubled in the last twenty years.  It is estimated that 1 
million people are living with undiagnosed Diabetes in the UK.  Although the numbers 
of females with diabetes and HNC in our study are small (n=8), one could hypothesise 
that their later age at diagnosis implies they have lived with untreated disease for 
longer than the female controls, therefore being exposed to the damaging effects of 
uncontrolled hyperglycaemia for longer.  To investigate this, a prospective study 
would be required with blood glucose levels measured at intervals.    
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5.2.7.2 Cardiovascular Disease 
Male cases had a higher percentage of cases of heart attack (14.9% vs 11.8%), stroke 
(7.9% vs 4.4%) and angina (11.6% vs 8.8%) than male controls (see Table 5.5).  This is 
most likely to be due to increased age as there are no reports of an association 
between cardiovascular disease and increased risk of head and neck cancer.  It is 
known, however, that patients newly diagnosed with HNC have a higher 
cardiovascular risk score (Framingham) compared to the general population, mainly 
due to a lack of secondary prevention which could be achieved by treatment of 
hypercholesterolemia (200).  This may be due to shared risk factors between HNC 
and CVD, such as smoking and poor diet.     
We observed no statistically significant difference in systolic or diastolic blood 
pressure, or pulse, between cases and controls (see Table 5.5). 
 
5.2.8 Baseline Measures of Current Health 
 
5.2.8.1 BMI and Body Fat 
Body Mass Index has been investigated in relation to HNC risk, with mixed results 
(201).  A pooled analysis of 17 international studies appeared to show a protective 
effect of higher BMI against HNC amongst smokers and consumers of alcohol (BMI of 
>30; OR 0.38; 95% CI 0.30-0.49).   This protective effect was not observed for never 
smokers (OR 0.95 (95% CI 0.47 – 1.91) (201).  A similar tendency for leanness has 
been noted in other smoking-related malignancies such as lung and oesophageal 
(202).  
Within the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, 177 
individuals developed HNC.  BMI was extensively analysed, using current BMI and 
BMI at ages 50 years and 20 years; there was no association with HNC risk (194).    
In the present study, both BMI and body fat were statistically significantly lower in 
cases than controls (see Table 5.5).  Male cases had a mean BMI of 26.5 compared to 
27.8 in controls.  Female cases had a mean BMI of 26.1 compared to 27.1 for controls.  
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It is unclear if the BMI and body fat have reduced in cases due to difficulty eating 
secondary to development of oral cancer; to prove causation, a prospective study 
would be required. 
 
5.2.9 Engagement with Screening Programmes 
There were no statistically significant differences in reported engagement with 
bowel, prostate, breast and cervical screening between cases and controls (see Table 
5.6).    This is contrary to other data regarding screening behaviours; amongst the 
most socially deprived individuals, uptake of screening is known to be poor.  Only 
35% of those living in the most deprived areas engage with bowel cancer screening 
compared to 66% or persons living in affluent areas (203).  The UK Biobank questions 
asked if people had “ever” attended for screening, so it may be that people have 
attended on a small number of occasions but do not routinely participate.   
 
5.2.10 Breastfeeding 
The benefits of being breastfed as an infant are well documented (204, 205).  There 
is evidence of improved cognitive function, reduced risk of allergy (particularly 
asthma) and reduced risk of obesity.  However, despite reports of a reduced 
incidence of childhood leukaemia (206), a large meta-analysis of 5,000 subjects 
revealed no link between being breastfed as an infant and cancer incidence later in 
adulthood  (RR 1.07 (95% CI 0.89-1.28)), except for pre-menopausal breast cancer  
(RR 0.88  (95%CI 0.79 – 0.98)) (207). 
The present study reveals no statistically significant difference between reports of 
being breastfed as an infant between cases and controls, although in male cases the 
rate was higher than controls (79.8 vs 75.5%; p=0.057) (see Table 5.7). 
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Table 5.5.  Diabetes and Cardiovascular Status and BMI: Differences between HNC Cases and Controls.  p<0.05 indicates a statistically significant result; significant results 
are shown in bold 
  Variable     Head and Neck Cancer Case Control p-value 
    Males Female Male Female   
 Medical Conditions  n % N % N % n %   
 Diabetes             
  Yes  36 6.8 10 3.1 15,968 7 10,394 3.8 Males 0.82 
  No  495 93.2 314 96.9 211,266 93 261,547 96.2 Females 0.49 
              
 Age diabetes diagnosed            
  Median (IQR)  53 (47 - 60)  61 (56 - 64.5) 54 (46 - 60)  54 (46- 60) Males 0.69 
  N  34  8  15,615  8,943  Females 0.02               
 Vascular/heart problems  n(%)           
  Heart Attack  32 6.0 2 0.6 9,277 4.1 2,298 0.8 Male <0.001 
  Angina  25 4.7 7 2.2 6,910 3.0 4,397 1.6 Female 0.38 
  Stroke  17 3.2 3 0.9 3,488 1.5 2,712 1.0   
  HTN  141 26.4 86 26.5 59,070 25.8 60,889 22.3                 
 Age hypertension diagnosed          ranksum 
  median (IQR)  54 (46.5 - 58) 52 (45- 58) 52 (45-58)  52 (45-58) Males 0.23 
  N  168  69  64,463  56,525  Females 0.80               
 Age angina diagnosed           rank sum 
  median (IQR)  56 (51.1 - 59) 52 (50 - 60) 54 (48 - 59)  55 (50 - 60) Males 0.20 
  N  36  7  10,209  4,758  Females 0.66 
 Age heart attack diagnosed          ranksum 
  median (IQR)  56 (50 - 60)  42 (42-42) 53 (57-59)  55 (49-60) Males 0.13 
  N  30  1  9,017  2,151  Females 0.16 
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Table 5.5. continued. Diabetes and Cardiovascular Disease: Differences between HNC Cases and Controls.   P-values <0.05 are considered statistically significant and are 
shown in bold. 
 
  Variable     Head and Neck Cancer Case   Control   p-value 
    Males  Female  Male  Female    
              
 Blood Pressure            
              
 Systolic mean (sd)  144.2 (21.46)  138.5 (22.03)  142.7 (18.53)  137.2 (20.29)  Male 0.07 
  N  483  297           213,161         254,246   Female 0.29 
              
 Diastolic mean (sd)  83.7 (11.63)  80.3 (11.14)  84.0 (10.57)  80.7 (10.57)  Male 0.55 
  N  483  297           213,168         254,252   Female 0.54 
              
 Pulse mean (sd)  68.7 (12.04)  72.1 (11.67)  67.9 (12.04)  69.9 (11.07)  Male 0.41 
  N  163  99             78,158           92,363   Female 0.05 
              
              
 BMI mean (sd)  26.5 (4.40)  26.1 (5.08)  27.8 (4.25)  27.1 (5.20)  Male <0.001 
  N  530  323           227,002         271,687   Female <0.001 
              
 Body fat percentage            
  mean (sd)  24.4 (6.26)  35.7 (7.55)  25.3 (5.81)  36.6 (6.91)  Male <0.001 
  N  522  317           223,370         269,028   Female 0.03 
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Table 5.6. Differences in uptake of Screening between HNC Cases and Controls in the UK Biobank Dataset; p<0.05 indicates a statistically significant result.  Significant results 
are shown in bold. 
   
  Variable     Head and Neck Cancer Case   Control     p-value 
    Males Female Male Female   
              
 Attitudes to Screening  n % n % n % n %   
 Ever had bowel cancer screening (60y)          
   Yes 134 49.8 82 49.4           52,992  52.7      56,943  50.4 Males 0.32 
   No 135 50.2 84 50.6           47,274  47.3      56,103  49.6 Females 0.80 
              
 Ever had PSA test (males only)           
   Yes 169 34   66,002 30.6   Males 0.10 
   No 328 66   149,786 69.4     
              
 Ever had Breast screening (females >=50y only)         
   Yes   274 96.5   199,474 95.9   
   No   10 3.5   8,517 4.1 Females 0.63 
              
 Ever had cervical smear (females only)          
   Yes   321 99.1   265,543 97.7   
   No   3 0.9   6,344 2.3 Females 0.09 
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Table 5.7.  Differences between HNC Cases and Controls in terms of Breastfeeding in infancy; p<0.05 is considered statistically significant. 
Variable     Head and Neck Cancer Case   Control   p-value 
   Males   Female   Male   Female    
   n % N % n % n %   
             
Breastfed as baby            
 Yes  288 79.8 179 72.8         122,743  75.5   154,452  70 Male 0.06 
             
 No  73 20.2 67 27.2           39,927  24.5      66,085  30 Female 0.35 
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5.2.11 Female – specific Risk Factors 
The role of hormones, including hormone replacement therapy and menopause has 
been extensively reviewed in Chapter 3.   
Earlier age at menopause is a risk factor for oesophageal SCC. When controlling for 
smoking, however, the evidence for a role in HNC is less clear (99, 118).  There is some 
evidence for a protective role of hormone replacement therapy in HNC, but further 
evidence is needed (106).  In the present study, female cases were older than controls 
which may explain why there was a significantly higher percentage of cases who were 
post-menopausal (86.4 vs 72.1%) (see Table 5.8). 
This study showed no statistical difference between cases and controls for age at 
menarche, age at menopause, age at first live birth, number of lives births, use of oral 
contraceptive pill, use of hormone replacement therapy or experience of 
hysterectomy or bilateral oophorectomy.  Data on lactation history were not 
available; however, no studies investigating links between lactation history and HNC 
could be found, so this is unlikely to be relevant to the current study.   
The data are presented in Table 5.8. Hormone replacement therapy had been taken 
by 39.7% of cases and 38.2% of controls, for an average of 6 years.  This study 
suggests there is no protective effect of HRT in HNC (see Table 5.8). 
The concept of oestrogen deficiency as a risk factor for female HNC remains 
interesting as Bosetti showed a protective effect of later age at menopause  (OR 0.40  
(95%CI 0.30-0.70)) (108); equally Hashim et al found that menopause at less than 52 
years conferred greater risk of HNC  (OR 1.69 95%CI 1.06 – 2.71; n=476) compared to 
no history of menopause, when controlling for age, education, smoking, alcohol, BMI) 
(119).  
However, this UK Biobank study does not support a role for early menopause as a risk 
factor for HNC as there was no difference in age at menopause between cases and 
controls.  Given the differences between males and female cases with HNC (females 
tend to be older and there are more cases in never smokers), efforts to identify 
female-specific risk factors should continue.   
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Table 5.8.  Female-specific Hormone-related Factors: differences between HNC cases and controls in the UK Biobank Dataset.  Significant p-values (<0.05) are shown in bold. 
Variable Head and Neck Cases  Controls  p-value 
Age at recruitment 
mean (range) 58.6 (40-70)   56.4 (39-71)  <0.001 
N 325   273,144   
       
Menstruation       
Age at menarche (mean (SD)) 12.92   12.97  0.58 
N 314      
       
Menopause       
Post-menopausal N %  N %  
Yes 242 86.4  165,202 72.1  
No 38 13.6  64,057 27.9 <0.001 
 
Age at menopause       
Mean (std dev) 49.3   49.7  0.36 
N 228   154437   
       
Pregnancy       
Age at 1st live birth       
Mean (std dev) 27.8 6.55  29 6.34 0.18 
N 56   36,360   
       
Number of live births       
Mean (std dev) 1.82   1.82  0.99 
N 324   272,321   
 
Table 5.8 continued.  Female-specific hormone-related risk factors: Differences between HNC cases and controls 
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Variable Head and Neck Cases  Controls p-value  
Medications        
Ever taken oral contraceptive pill (OCP)                                                              N %  N %   
Yes 269 82.8  220,235 78.2   
No 56 17.2  51,489 18.9 0.47        
Ever used Hormone Replacement Therapy (HRT)       
Yes 129 39.7  103,824 38.2   
No 196 60.3  167,744 61.8 0.63        
Age Started HRT        
Mean (std dev) 47.5  47.4 0.87  
N 115  91,563        
Number of years on HRT        
Mean (std dev) 6.2  6.3 0.81  
N 94  73,347    
Operations        
Hysterectomy N %  N %   
Yes 25 8.6  19,900 8.3   
No 266 91.4  221,084 91.7 0.92  
Age at hysterectomy        
Mean years (std dev) 44.3 (7.68)   43.9 (8.0)  0.73  
        
Bilateral Oophrectomy N %  N %   
Yes 26 8.2  21,781 8.1   
No 291 91.8  246,767 91.9 1  
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5.2.12 Sexual History 
HPV infection accounts for over half of oropharyngeal cancers and almost all cervical 
cancers (31, 208).  In the USA, the incidence of oropharyngeal cancer now exceeds 
cervical cancer (209). 
Sexual behaviour is the main risk factor associated with oral HPV infections; lifetime 
number of sexual partners and age of sexual debut <18 years are strong indicators of 
risk of HPV infection (210-212).  The earliest evidence of infection has been found 2 
months following onset of sexual activity, and 62% of females were infected after 48 
months (212), which suggests vaccination would be most effective prior to the onset 
of sexual activity.  Gillison et al studied prevalence of HPV infection in the US 
population (n=5,579) and reported 6.9% of participants, aged 14-69 years, had oral 
HPV infection, with 1% carrying the high-risk strain HPV-16.  Age, male gender, 
number of sexual partners and positive smoking history were all independent risk 
factors for HPV infection (213).  Number of oral sexual partners has also be linked to 
higher risk of HPV infection (>10 oral sexual partners OR 5.2 (95% CI 1.1 – 25.0)) (214). 
In the UK, a vaccination programme for pre-adolescent girls has been in place since 
2008 and on 24th July 2018 the UK Government announced that this programme 
would be extended to adolescent males (215).  The Joint Committee on Vaccination 
and Immunisation commented that vaccination of boys would not be cost-effective 
if current NICE guidelines on assessment of cost-effectiveness of health interventions 
were applied.  However, using a system that reflects the long-term benefits of the 
programme did make vaccination of boys cost-effective.  The benefits of this wider 
vaccination programme will not be realised for at least 30 years but should contribute 
to a decline in the numbers of HPV-related oropharyngeal cancers (216). 
In this study, age at first sexual activity was statistically significantly lower in male 
cases (18.2 years vs 19.2 years; p<0.001) and male cases had a higher median number 
of sexual partners (6 vs 4; p<0.001) (see Table 5.9).  (Data were not available on 
number of oral sexual partners).  It is not immediately obviously why cases would 
have a higher number of sexual partners than controls.  However, age at sexual debut 
has been explored in relation to a number of factors related to socioeconomic status 
(217-219).  Sexual debut before 16 years is more frequent in people with no academic 
   
113 
 
qualifications than with academic qualifications and more frequent in those in lower 
occupations than managerial and professional occupations (220). 
Low parental educational attainment was significantly associated with earlier age at 
sexual debut (OR 2.58 95%CI 1.49 – 4.46), as was absence of either Mother (OR 2.43 
95% CI 1.22 – 4.83) or both parents (OR 2.28 95%CI 1.04 – 5.00) during childhood.  
Household income was not statistically significantly associated with age at sexual 
debut (218).  
The model development dataset contains 159 cases of oropharyngeal/tonsillar 
cancer/base of tongue cancer, out of a total 702 cases (22.6%).  Data are not available 
on HPV status of the HNC cancers in our dataset, however, based on estimates from 
the literature (31), around 83 (52% of 159) of these may be due to HPV infection, 12% 
of the total number of cases of HNC.  This justifies the consideration of sexual history 
in our model, however differences in sexual history are only evident in males and this 
will be considered when selecting variables for the final model.    
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Table 5.9.  Sexual History: Differences between HNC Cases and Controls in the UK Biobank Dataset.  P-values <0.05 are considered statistically significant and are shown in bold. 
Variable    Head and Neck Cancer Cases   Controls p-value   
   Male Female  Male Female   
              
Age first had Sexual Intercourse (years)           
              
  mean (sd) 18.2 (3.8) 19.0 (3.1)  19.2 (4.3) 19.1 (3.6) Male <0.001 
  n 452 285  199,406 235,378 Female 0.65 
              
Number of sexual partners            
  
median 
(IQR) 6 (3 - 15) 3 (1 -6)  4 (2 - 9) 3 (1 -5) Male <0.001 
  n 387 264  183,545 220,997 Female 0.47 
Ever had same-sex sex N % N %  N % N %   
 Yes     27 5.8 7 2.4  8,870 4.3 6,920 2.9  chi2 
            Male 0.10 
 No     435 94.2 281 97.6  197,325 95.7 235,063 97.1 Female 0.66 
              
Number of same-sex partners          Mann-Whitney U 
  
Median 
(IQR) 1 (1-8) 2 (1-7)  4 (1-18) 2 (1-3) Male 0.04 
  n 23 7  6,718 6,613 Female 0.46 
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5.2.13 Other Risk Factors for HNC 
Other risk factors for HNC have been less well-investigated.  Air pollution, sleep 
deprivation and snoring have been linked with other diseases including cancers.   
5.2.13.1 Snoring 
In this study, there was a statistically significant difference in self-reported snoring 
between cases and controls for both genders; cases were less likely to snore than 
controls (see Table 5.10). 
Snoring is a marker for sleep apnoea or Sleep-Disturbed Breathing (SDB).  Persons 
with SDB have an increased risk of dying from cancer than normal controls but a 
causation has not been proven (221):  Data from the Wisconsin Sleep Cohort Study, 
of 1,522 adults with 22 years follow up, found an increased risk of dying from cancer  
(HR 4.8) for those with severe SDB (7.3 per 1000 per years vs 1.54 per 1000 person 
years in the normal group) (221). The authors controlled for age, BMI, smoking and 
deprivation but acknowledge the small numbers in the severe SDB group.  Although 
this study is only exploring risk factors for HNC, rather than risk factors for mortality 
from HNC, these findings appear to be in contrast to our results, which show that 
cases are less likely to snore than controls. 
 
5.2.13.2 Air Pollution 
In the present study, there was no statistically significant difference in air pollution in 
the areas inhabited by HNC cases and controls (p>0.05), which appears to support 
the findings of Weinbayr et al (222) (see below); see Table 5.10. 
Air pollution is a risk factor for cancers, as identified in 2013 by the International 
Agency for Research on Cancer (223).   Weinmayr et al (222) have shown a link 
between long term exposure to PM2.5-Sulphates and Gastric Cancer, in a combined 
study of 10 European Cohorts in the ESCAPE study.  227,044 individuals were 
included, with 14.9 years follow up.  There were 763 cases of Upper Aerodigestive 
Tract Cancers (UADT), which included head and neck and oesophageal cancers and 
633 cases of gastric cancer.  The authors found no association with UADT but found 
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an increased risk of gastric cancer with increased exposure to PM2.5-Sulphates with a 
HR of 1.93 (95% CI 1.13 – 3.27) for every increase of 200ng/m3.   
Although air pollution is not implicated in as many cancers as more commonly 
accepted risk factors, such as smoking, the entire population is exposed therefore it 
may have a significant global effect.  Exposure to particulate matter of < 2.5 x 10-6 m 
in diameter  (PM2.5) is an established risk factor for lung cancer and are classified as 
a class I carcinogen (224). 
 
5.2.13.3 Sleep Deprivation 
The Office for Disease Prevention and Health Promotion has established a 
programme entitled “Healthy People 2020”; one of four core areas included in this 
programme is “Sleep Health”(225).  They have set a target that 70% of adults aged 
22 years or over should have 7 hours or more sleep in 24 hours.  This is in response 
to findings that lack of sleep confers increased risk of chronic diseases, including 
cancers.  Von Reusten et al published findings from the EPIC study (European 
Prospective Investigation into Cancer and Nutrition) which revealed that those 
sleeping for less than 6 hours per night have a 43% increased risk of cancers 
compared to those sleeping 7-8 hours per night (HR 1.43 (95% CI 1.09-1.87)).  This 
study included 23,630 individuals with average follow-up of 7.8 years (226).  
Our findings were contrary to this: sleep duration was slightly longer in male cases 
(7.2 hours) than controls (7.1 hours) (p=0.04).  There was no statistically significance 
difference in duration of sleep between female cases and controls (see Table 5.10).  
Sleep is a multifactorial phenomenon: male cases tended to be older and were more 
likely to be retired than controls, which may account for the slightly longer sleep 
duration.  Those with an established diagnosis of HNC may sleep longer as part of 
their recovery from treatment.  Sleep duration will vary throughout life and will 
depend on work and family commitments.  Consequently, this dataset is not ideally 
suited to assessing sleep deprivation as a risk factor for cancer and we are only 
provided with data at a single point in time, with no information of any history of 
chronic sleep deprivation.   
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Table 5.10.  Other Potential Risk Factors for HNC:  Exposure to air pollution and self-reported sleep duration and snoring in HNC Cases and Controls.  p<0.05 is considered statistically significant.  
Bold values indicate a statistically significant result. 
Variable Head and Neck case Control p-value 
 Male Female Male Female   
Air Pollution           
Nitrogen dioxide air pollution; 2010           
mean (SD) 27.35 (8.36)  27.03 (7.82) 26.8 (7.63)  26.7 (7.52) Males 0.08 
N 521  318  225216  269199  Females 0.40 
           
           
Particulate matter air pollution (pm10); 2010           
mean (SD) 16.3 (1.90)  16.2 (2.04) 16.2 (1.90)  16.2 (1.89) Males 0.25 
N 464  292  210239  250325  Females 0.85 
Particulate matter air pollution (pm2.5); 2010           
mean (SD) 10.07 (1.11)  10.04 (1.11)  10.0 (1.06)  9.98 (1.04)  Males 0.18 
N 464  292  210,239  250,325  Females 0.40 
Sleep Deprivation           
Sleep duration (average per night)           
mean number hours (SD) 7.23 (1.25)  7.28 (1.22) 7.13 (1.10)  7.17 (1.12) Males 0.04 
N 527  324  226,999  270,579  Females 0.08 
Snoring           
Yes 161 32.5 56 18.1 102,339 47.7 70,850 28.3 Males <0.001 
           
No 334 67.5 253 81.9 112,418 52.3 179,174 71.7 Females <0.001 
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5.3 Head and Neck Cancer Cases 
The detail of number of cases of four sub-types of HNC is considered here in the risk 
prediction model: oral, salivary gland, oropharyngeal and sinus cancers. Sections 
5.3.2-5.3.8 consider differences in age, smoking, lifetime number of sexual partners, 
household income, alcohol and exercise for these four sub-types.  For the justification 
for exclusion of laryngeal cancer, see section 4.3.4. 
Within the development dataset, there are 702 cases of HNC and 423,050 controls.  
Most cases are oral cancers (44.4%, n=311) followed by oropharyngeal/tonsil cancer 
(38.3%, n=269).  92 salivary gland cancers (13.1%) and 30 sinus cancers (4.2%) 
account for the remaining cases (see Table 5.11). 
5.3.1 HNC Sub-type and Sex 
The male:female ratio was elevated for oral and pharyngeal cancers but almost equal 
for salivary and sinus cancers.  The trend for male predominance was particularly 
strong for pharyngeal cancers and has been noted in other large studies (227). 
Table 5.11. Head and Neck Cancer Sub-types by Gender, within the UK Biobank Development Dataset 
Cancer Type Number of Cases   
 Male n (%) Female n (%) Total (%) M: F 
Oral 185 (59.3) 127 (40.7) 311 (44.3) 1.45:1 
Pharyngeal 193 (71.7) 76 (28.3) 269 (38.3) 2.54:1 
Salivary 48 (52.7) 43 (47.3) 92 (13.1) 1.11:1 
Sinus 14 (46.7) 16 (53.3) 30 (4.3) 0.88:1 
   Total: 702  
Controls 191 897 (45.4) 231 153 (54.6) 423,050 0.83:1 
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5.3.2 Age at Diagnosis 
Age at diagnosis was comparable for all sub-types of head and neck cancer (see Table 
5.12).  Over the last two decades, there has been a sharp rise in the incidence of 
oropharyngeal cancers in younger males, however in recent years it has been noted 
that this trend is slowing (31, 228).  There are increasing numbers of older individuals 
developing the disease (228).   There has been a drive to ensure treatment carries 
less morbidity than classic treatment for oral cancer, as survivors are likely to live 
with the consequences for longer due to their younger age at diagnosis.  However, 
there have been recent calls to review these so-called “de-escalation” trials in favour 
of more robust treatments, in recognition of the older patients now being diagnosed 
with oropharyngeal cancer (228, 229). 
 
Table 5.12  HNC Sub-types and Age at Diagnosis, by Gender (within the UK Biobank Model Development Dataset). 
Type of Cancer Age at Diagnosis 
 Male (mean/years) Female (mean/years) 
Oral 56.6 55.3 
Pharyngeal 55.4 54.9 
Salivary 52.6 50.0 
Sinus 55.3 57.9 
 
 
5.3.3 Smoking Duration amongst Ever Smokers 
Smoking duration was significantly longer for patients with oral vs other HNCs (see 
Table 5.13).  This is consistent with evidence that smoking is the major risk factor for 
oral cancers, whereas risk factors such as HPV infection may be more relevant for 
oropharyngeal cancers (192, 230, 231).  
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Table 5.13.  Smoking Duration for each sub-type of HNC considered, using data from the UK 
Biobank Dataset 
Type of Cancer 
Duration of Smoking 
(mean/years) 
Oral 34.1 
Pharyngeal 30.6 
Salivary 26.5 
Sinus 27.1 
P-value (ANOVA) = 0.03 
 
5.3.4 Lifetime number of sexual partners 
There is evidence to suggest a higher number of sexual partners increases risk for 
HPV-related oropharyngeal cancer (232).  Our data reveal a median of 10 sexual 
partners amongst male pharyngeal cancer patients compared to 4 for male oral 
cancer patients.  The difference is less notable amongst female head and neck cancer 
patients. See Table 5.14.  
 
Table 5.14.  Median Number of Sexual Partners for cases with each sub-type of HNC 
Cancer Type Median number of Sexual Partners 
(n) 
 
 Sex  
 Male Female Median (both 
genders) 
Oral 4 2 3 
Pharyngeal 10 4 8 
Salivary 3 3 3 
Sinus 5.5 4.5 5 
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5.3.5 Household income 
Household income can be used as a proxy for deprivation.  It may be a more reliable 
marker of individual levels of deprivation than Townsend or IMD scores (186), which 
also require calculation from the patient’s postcode.   The highest levels of low 
income were seen amongst patient with Oral cancers, consistent with previous 
reports (227, 233) (see Table 5.15).   
Table 5.15. Mean Annual Household Income for HNC cases, by anatomical sub-type. 
 
Cancer Type 
Annual Household Income (£) 
n (%) 
 < £18k £18 – 31999 £32-51999 £52-99999 >£100k/year 
      
Oral 93 (34.7) 77 (28.7) 57 (21.3) 36 (13.4) 5 (1.87) 
Pharyngeal 60 (26.7) 62 (27.6) 53 (23.6) 37 (16.4) 13 (5.8) 
Salivary 25 (32.9) 22 (28.9) 13 (17.1) 16 (21.1) 0 (0%) 
Sinus 6 (20.7) 10 (34.5) 8 (27.6) 2 (6.9) 3 (10.3) 
Controls 79798 (22.1) 90912 (25.1) 94907 (26.2) 75325 (20.8) 20784 (5.6) 
 
 
5.3.6 Frequency of Alcohol Consumption 
Reports of daily drinking were higher for all sub-types of HNC compared to controls, 
showing that this remains an important risk factor to consider in any risk prediction 
model.  The percentage of never drinkers was higher for all sub-types of HNC (see 
Table 5.16).  It is possible that patients decided to stop drinking following their 
diagnosis, as 88% of pharyngeal cancer patients and 60% of oral and salivary gland 
cancer patients claim to be previous drinkers (Table 5.17).   See 5.2.4 for a more 
complete discussion of alcohol consumption in HNC.  
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Table 5.16.  Frequency of Alcohol consumption by HNC Cases, by anatomic sub-type of HNC. 
Frequency of 
Alcohol 
Type of Cancer 
 Oral 
N(%) 
Pharyngeal 
N(%) 
Salivary 
N(%) 
Sinus 
N(%) 
Controls 
N(%) 
Daily 82 (26.3) 73 (27.1) 20 (22.0) 9 (30.0) 87,489 (20.7) 
3-4/week 66 (21.2) 57 (21.2) 20 (22.0) 4 (13.33) 96,932 (23.0) 
1-2/week 65 (20.8) 60 (22.3) 19 (20.8) 6 (20.0) 107,724 (25.5) 
1-3/month 29 (9.3) 17 (6.3) 7 (7.7) 4 (13.33) 46,929 (11.1) 
Special 
occasions only 
34 (10.9) 23 (8.6) 15 (16.5) 3 (10.0) 48,320 (11.5) 
Never 36 (11.5) 39 (14.5) 10 (11.0) 4 (13.33) 34,349 (8.1) 
 
Table 5.17.  Previous Alcohol Consumption in Current Never Drinkers, for HNC Cases, by anatomic 
sub-type 
  
Former Drinker  (if current 
never drinker) 
Type of Cancer 
 Oral  N(%) Pharyngeal  N(%) Salivary  N(%) Sinus  N(%) 
No 10 (38.5) 4 (11.8) 4 (40) 2 (50) 
Yes 26 (61.5) 34 (88.2) 6 (60) 2 (50) 
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5.3.7 Exercise 
There are greater levels of complete inactivity (i.e. zero days of exercise) amongst 
pharyngeal cancer patients (21% compared to 12.6% in controls) (Table 5.18).  
Exercise is known to be beneficial in helping to protect against several cancers and 
this evidence of reduced levels of exercise could be interesting to explore in greater 
detail (194, 195, 234). 
Table 5.18.  Number of Days on which HNC cases participate in Moderate Exercise, by sub-type of HNC. 
  
Moderate Exercise for at least 10 minutes (Number of Days per week) 
 Cancer Type 
 Oral 
N(%) 
Pharyngeal 
N(%) 
Salivary 
N(%) 
Sinus 
N(%) 
Control 
      
0 44 (15.2) 53 (21.0) 13 (14.8) 4 (13.3) 50,599 (12.6) 
1 19 (6.5) 15 (6.0) 6 (6.8) 2 (6.7) 32,461 (8.1) 
2 43 (14.8) 30 (11.9) 16 (18.2) 3 (10.0) 59,111 (14.8) 
3 36 (12.4) 28 (11.1) 10 (11.4) 5 (16.7) 60,335 (15.1) 
4 28 (9.7) 28 (11.1) 11 (12.5) 7 (23.3) 40,085 (10.0) 
5 41 (14.1) 32 (12.7) 13 (14.8) 4 (13.3) 60,274 (15.1) 
6 22 (7.6) 17 (6.8) 8 (9.1) 1 (3.3) 22,317 (5.6) 
7 57 (19.7) 49 (19.4) 11 (12.5) 4 (13.3) 75,330 (18.8) 
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5.4 Conclusions 
Many potential risk factors have been explored here covering patient demographics, 
medical history, smoking and alcohol, sexual history, hormone-related factors, and 
diet and exercise.  The evidence for the role of all the risk factors is discussed, 
however not all could be included in a risk prediction model.  The strongest evidence 
exists for smoking and alcohol, closely followed by number of sexual partners for 
HPV-related oropharyngeal cancer, diet and exercise, and social deprivation.  Low 
body mass index does not appear to represent a true risk factor for HNC but 
underlying reasons for the lower BMI of HNC patients are worthy of further 
investigation.  We have identified differences between patients with subtypes of HNC 
and between males and females in almost all identified risk factors, showing that 
Head and Neck cancer is a heterogenous disease in terms of its aetiology.   
Selection of variables for the final risk model will consider evidence from the 
literature as described, whilst maintaining the aim of developing a parsimonious 
model that can be utilised by general practitioners.   
Table 5.19 provides a summary of the pertinent risk factors described, with data for 
HNC cases and controls from the model development dataset.  Chapter 6 will describe 
the development of the risk prediction model for HNC. 
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Table 5.19.  Summary of Differences in Risk Factors between HNC Cases and Controls, with descriptive statistics, by gender, in the Model Development Dataset, within the 
UK Biobank.        P-values of <0.05 are considered statistically significant and are shown in bold. 
Variable Head and Neck Cancer Cases Controls p-value 
 Males Females Males Females  
Total Number 440 262 191,897 231,153  
Age at Recruitment (mean years (SD)) 58 (41-70) 59 (40-70) 56 (37- 72) 56 (39 – 71) <0.001 
Smoking Status    N(%)      
Never Smoked 143 (32.9) 119 (45.9) 93,885 (49.2) 137,805 (60.0)  
Ex-smoker 201 (46.2) 113 (43.6) 73,365 (38.5) 72,021 (31.3)  
Current Smoker 91 (20.9) 27 (10.4) 2,3449 (12.3) 20,021 (8.71) <0.001 
Smoking Duration (Mean (SD)) 32.8 (13.0) 29.3 (12.3) 26.5 (12.9) 25.2 (12.7) <0.001 
N 241 102 70,699 60,377  
Alcohol Status n (%)      
Never 9 (2.0) 12 (4.6) 5,421 (2.8) 13,846 (6.0) 
<0.001 Previous 46 (10.5) 22 (8.4) 6,765 (3.5) 8,317 (3.6) 
Current 385 (87.5) 228 (87.0) 179,059 (93.3) 208,335 (90.1) 
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Table 5.19 continued.   Differences between HNC cases and controls with in the Model Development Dataset, within the UK Biobank. 
Variable Head and Neck Cancer Cases Controls P-value 
   Males Females Males Females   
Current Alcohol Frequency         n 
(%) 
     
Daily or almost daily 136 (30.9) 48 (18.3) 49,388 (25.8) 38,101 (16.5) 
<0.001 
3-4 times per week 92 (20.9) 55 (21.0) 49,714 (26.0) 47,218 (20.5) 
1 – 2 times per week 94 (21.4) 56 (21.4) 48,936 (25.6) 58,788 (25.5) 
1 – 3 times per month 28 (6.4) 29 (11.1) 17,033 (8.9) 29,896 (13.0) 
Special occasions 35 (8.0) 40 (15.3) 13,988 (7.3) 34,332 (14.9) 
Never  55 (12.5) 34 (13.0) 12,186 (6.4) 22,163 (9.6) 
N 440 262 191,245 230,498  
Body Mass Index (BMI); 
mean(SD) 
26.4 (4.5) 26.1 (5.0) 27.8 (4.2) 27.0 (5.2) 
Males: <0.001 
Females: 0.004 
N 436 260 190,545 229,959  
      
Fruit (no. of pieces per day; 
mean(SD))  
1.7 (1.5) 2.1 (1.4) 2.1 (1.6) 2.4 (1.6) <0.001 
N 416 254 182,400 224,686  
      
Townsend Deprivation Quintile 
N (%) 
     
1 (least deprived) 142 (32.3) 90 (34.4) 69171 (36.1) 82,830 (35.9) Males: <0.001 
2 90 (20.4) 60 (22.9) 45201 (23.6) 55,750 (24.1) Females: 0.62 
3 69 (15.7) 47 (17.9) 33687 (17.6) 41,913 (18.2) 
 
4 77 (17.5) 37 (14.1) 26406 (13.8) 31,797 (13.8) 
 
5 (most deprived) 62 (14.1) 28 (10.7) 17166 (9.0) 18,563 (8.0) 
 
N 440 262 191631 230,853   
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Table 5.19 continued.  Differences between HNC cases and controls with in the Model Development Dataset, within the UK Biobank 
Variable Head and Neck Cancer Cases Controls P-value 
  Males Females Males Females   
Household Income per year (£) n (%)          
<18000 109 (28.4) 75 (35.1) 33,918 (19.8) 45,880 (24.1)  
18000-30999 100 (26.0) 71 (33.2) 41,177 (24.1) 49,735 (26.1)  
31000-51999 94 (24.5) 37 (17.3) 46,075 (26.9) 48,832 (25.6) <0.001 
52000-100000 64 (16.7) 27 (12.6) 38,807 (22.7) 36,518 (19.2) 
 
>100000 17 (4.4) 4 (1.9) 11,034 (6.5) 9,750 (5.1) 
 
N 384 214 171,011 190,715  
 
     
Moderate Exercise (at least 10 minutes) no. days/week 
0 80 (19.5) 34 (13.6) 23,823 (13.0) 26,776 (12.4)  
1 20 (4.9) 22 (8.8) 15,818 (8.6) 16,643 (7.7) 
Females: 0.681 
2 57 (13.9) 35 (14.0) 26,825 (14.6) 32,286 (14.9) 
3 41 (10.0) 38 (15.2) 25,771 (14.0) 34,564 (15.9) Males: <0.001 
4 41 (10.0) 33 (13.2) 17,353 (9.4) 22,732 (10.5)  
5 55 (13.4) 35 (14.0) 29,983 (16.3) 30,291 (14.0)  
6 35 (8.5) 13 (5.2) 12,135 (6.6) 10,182 (4.7) 
7 81 (19.8) 40 (16.0) 31,979 (17.4) 43,351 (20.0)  
N  410 250 183,687 216,825   
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Chapter 6 
 
Development of a multivariable risk 
prediction model for head and neck 
cancer in adults, using the UK 
Biobank 
 
6.1 Introduction 
The aim of this Chapter is to describe the development and performance of the first 
UK-based risk prediction model for head and neck cancer, using the UK Biobank 
dataset.  TRIPOD guidelines on development, validation and reporting have been 
followed and a summary of compliance is presented in Appendix 7.   
Chapter 5 described the study population and detailed descriptive statistics 
comparing over 230 candidate predictors.  The evidence to support the consideration 
of these candidate predictors was also presented. 
The methodology used to develop the model has been described in Chapter 4.  
Briefly, the model presented in this chapter has been developed using a nested case-
control study within the UK Biobank, a cohort of over 500,000 adults recruited from 
around the UK (see section 4.3.2) (235).  The outcome of interest is a diagnosis of 
head and neck cancer, with the model predicting absolute risk of head and neck 
cancer.  The dataset contains 859 cases of HNC, as confirmed by linkage with the UK 
Cancer Registries.  Given the large size of the dataset, the data obtained from the 
North West of England were split from the remainder, to allow geographical 
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validation of the model.  This formed a development dataset with 702 cases of HNC 
and a validation dataset with 157 cases. (see section 4.4.2.1 for a detailed discussion 
of the rationale for this methodology). 
The dataset contained some missing data and this was handled by multiple 
imputation using chained equations (166, 236).  The model was developed using 
logistic regression analysis, first considering the candidate predictors in a univariable 
(unadjusted) analysis (section 6.3) and subsequently in a multivariable model (section 
6.4).   Automated selection methods were avoided to ensure the clinical relevance of 
the model (169, 170).  The discrimination and calibration of the model is assessed in 
section 6.7 (179, 237).   
6.2. Candidate Variables 
From the initial list of 7,800 variables available within the UK Biobank dataset, a 
reduced list of 233 variables were considered to have some clinical relevance to HNC 
(Appendix 5).  These variables were explored in Chapter 5 and the literature was 
assessed for existing evidence to support their role as risk factors for HNC (section 
5.2).  From this investigation, a final list of twelve variables was created, each of which 
were explored in the univariable analysis (see box 6.1). 
Box 6.1.  Variables considered in the Univariable Analysis 
Age Gender 
Smoking Duration BMI  
Smoking Status Alcohol (frequency of consumption) 
Alcohol Status Exercise (number of days per week) 
Lifetime number of sexual partners Townsend Deprivation Score (groups 1-5) 
Annual Household Income Fruit (number of pieces consumed per day) 
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6.3 Univariable Analysis 
Each variable of interest was tested for an (unadjusted) association with the 
outcome, diagnosis of HNC.  The step was performed to detect associations, not to 
aid in variable selection: variable selection using univariable analysis has been shown 
to be an unhelpful step in model development, as variables which could have helped 
to stabilise the model may be excluded, even if they are not statistically significant 
(169, 170).  The results of the univariable analysis are shown in Table 6.1. 
 
Table 6.1. Univariable analysis of risk factors for head and neck cancer.  Risk factors (variables) are 
shown with their corresponding Odds Ratio and 95% Confidence Interval, related to risk of Head and 
Neck Cancer.  P-values are shown for each category, with <0.05 considered statistically significant. 
Variable Odds ratio 
(OR) 
95% Confidence Interval p-value 
Age 1.03 1.03 – 1.05 <0.001 
Gender                                          
Female 1.00 
  
 Male 2.02 1.74 – 2.36 <0.001 
Smoking Status                         
Never smoked 1.00   
Ex-smoker 1.91 1.62 – 2.25 <0.001 
Current Smoker 2.40 1.93-2.98 <0.001 
Smoking Duration 1.03 1.025 – 1.034 <0.001 
Alcohol Status    
Never drinker 1.00   
Previous drinker 4.14 2.53 – 6.75 <0.001 
Current drinker 1.45 0.93 – 2.24 0.093 
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Table 6.1 continued.   Univariable analysis of risk factors for head and neck cancer 
Variable Odds ratio 
(OR) 
95% Confidence Interval p-value 
Alcohol Frequency     
Daily 1.00   
3-4 times per week 0.72 0.58-0.90 0.003 
1-2 times per week 0.66 0.53-0.82 <0.001 
1-3 times per month 0.58 0.43-0.78 <0.000 
Special Occasions 0.74 0.56-0.97 0.027 
Never 1.23 0.96-1.59 0.107 
BMI 0.95 0.93 – 0.97 <0.001 
Fruit 0.79 0.76 – 0.84 <0.001 
Townsend Groups    
1 1.00   
2 0.97 0.79 – 1.20 0.798 
3 1.01 0.80 – 1.26 0.963 
4 1.28 1.03 – 1.61 0.029 
5 1.65 1.29 – 2.11 <0.001 
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Table 6.1 continued.   Univariable analysis of risk factors for head and neck cancer 
Variable Odds Ratio (OR) 95% confidence 
interval 
p-value 
Household Income (£ per year)   
<18,000 1.00   
18,000 - 30,999 0.82 0.66 – 1.00 0.055 
31,000 – 51,999 0.60 0.48 – 0.75 <0.001 
52,000 - 100,000 0.52 0.40 – 0.67 <0.001 
>100,000 0.44 0.28 – 0.69 <0.001 
Moderate Exercise (at least 10 minutes; number days/week) 
0 1.00   
1 0.57 0.40 – 0.82 0.002 
2 0.69 0.52 – 0.91 0.008 
3 0.58 0.43 – 0.77 <0.001 
4 0.82 0.61 – 1.10 0.183 
5 0.66 0.50 – 0.87 0.004 
6 0.95 0.68 – 1.33 0.788 
7 0.71 0.55 – 0.92 0.010 
Lifetime number of 
sexual partners 
1.00 1.00 – 1.00 0.321 
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In the univariable analysis, the following variables are significantly associated (at the 
5% level) with an increased risk of HNC (odds ratio >1):  increasing age, male gender, 
past or current smoking, increasing smoking duration, being a previous alcohol 
drinker or a current alcohol drinker and living in an area categorised as deprived or 
very deprived (Townsend Groups 4 and 5).   
Factors offering a statistically significant (5% level) protective effect (odds ratio <1) 
are:  increasing consumption of fruit, higher BMI and an annual household income of 
greater than or equal to £32,000 (compared to <£18,000).  
 
6.4 Multivariable Analysis 
 
6.4.1 Multivariable Model Development 
 
6.4.1.1 Selection of Variables 
Annual household income and Townsend groups are both measures of deprivation.  
Annual household income is a measure of individual-level deprivation, whereas the 
Townsend score is a measure of area-level deprivation (186).  Deprivation has been 
recognised as an important risk factor for head and neck cancer and has been 
discussed in Chapter 5 (section 5.2.2).  However, including two variables to measure 
the same risk factor is not necessary.  59.2% of patients with HNC living in the most 
deprived areas (Townsend group 5) had an annual household income of <£18,000, 
compared to only 16% of those living in the most affluent areas (data not shown).  
Despite this, the variables are only weakly correlated, as demonstrated by a 
Spearman’s correlation coefficient of 0.2086 (p<0.001).  For simplicity, Townsend 
groups were not included in the multivariable model as they are not simply calculated 
with freely available software.  Household income is self-reported by the patient and 
can be directly entered into the model.   
Alcohol status was also removed from the final model, as this does not reflect level 
of alcohol consumption.  Frequency of alcohol intake has been shown to be a reliable 
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and valid measure of alcohol consumption in a systematic review of population 
surveys (238) and avoids the need for the patient to recall exact numbers of drinks or 
calculate number of units.  Asking patients about alcohol intake on the previous day 
has been shown to be a more accurate measure of alcohol intake than overall 
frequency, as patients tend to underestimate how often they drink (239). However, 
these data were not available in our dataset.  The final multivariable model included 
variables for age, gender, smoking status, smoking duration, annual household 
income, frequency of alcohol consumption, BMI, exercise, number of pieces of fruit 
per day and lifetime number of sexual partners. 
6.4.1.2 Multivariable Results 
The data were split into North West (for model validation) and Rest of UK (for model 
development) (section 4.4.2.1).  The development dataset contains 329,005 
observations with 10 imputed datasets; section 4.4.3 discussed multiple imputation. 
Table 6.2 shows the Odds ratios with 95% confidence intervals for each variable, from 
the multivariable model developed. 
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Table 6.2. Multivariable Model of Risk Factors for Head and Neck Cancer.  Odds Ratios and 95% 
confidence intervals are presented, with p-values (<0.05 is considered statistically significant). 
Variable Odds Ratio P value 95% Confidence 
Interval 
     
Model Intercept  Coefficient:          
-6.094852 
<0.001 -7.12 -5.07 
     
Age 1.03 <0.001 1.01 1.04 
     
Male Gender 1.74 <0.001 1.44 2.10 
     
Smoking Status     
Previous 1.15 0.257 0.90 1.47 
Current 1.00 0.990 0.68 1.49 
     
Smoking Duration 1.02 <0.001 1.01 1.03 
     
Household income     
18,000 – 30,999 1.00 0.999 0.78 1.28 
31,000 – 51,999 0.85 0.262 0.65 1.13 
52,000 – 99,999 0.79 0.152 0.58 1.09 
≥100,000 0.72 0.201 0.44 1.19 
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Table 6.2 continued.  Multivariable model of Risk Factors for Head and Neck Cancer 
Variable Odds Ratio p-value 95% confidence 
interval 
    
BMI 0.94 <0.001 0.93 0.95 
    
Frequency of Alcohol Consumption    
3 – 4 times/wk 1.02 0.843 0.79 1.32 
1-2 times/wk 0.95 0.694 0.72 1.23 
1 -3 times per month 0.96 0.829 0.68 1.36 
Special Occasions 1.18 0.327 0.85 1.65 
Never 1.57 0.010 1.11 2.20 
     
Moderate Exercise (at least 10 mins; number days/wk)   
1 0.66 0.040 0.44 0.98 
2 0.71 0.045 0.52 0.99 
3 0.65 0.011 0.46 0.90 
4 0.81 0.250 0.57 1.15 
5 0.70 0.031 0.51 0.97 
6 0.74 0.173 0.48 1.14 
7 0.72 0.037 0.54 0.98 
     
Fruit                           
(number of pieces/day) 
0.86 <0.001 0.80 0.92 
Lifetime number of sexual partners    
 1.00 0.536 0.999 1.001 
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The results confirm that increasing age is a risk factor for HNC, with each year 
conferring an additional 3% risk (OR 1.03).  Males have a 75% higher risk of the 
disease, than women (OR 1.75).  As smoking duration increases, risk of HNC also 
increases by 2% per year (OR 1.02).   
Daily drinking was used as the baseline and ‘never drinking’ emerged as a risk factor 
for HNC (OR 1.57).  The remaining categories for frequency of alcohol consumption 
were not significant.  This will be discussed in section 6.9. 
Increasing consumption of fruit offers a protective effect against HNC (OR 0.86); 
every additional piece of fruit consumed per day offers a 14% protective effect.  
Moderate exercise on at least 1 day per week is associated with a protective effect; 
only exercise on 1, 2, 3, 5 or 7 days per week was found to have a statistically 
significant association (at the 5% level) with a reduced risk of HNC.  Increasing BMI 
also confers a protective effect (OR 0.94). 
Smoking status, lifetime number of sexual partners and household income were not 
statistically significant in the multivariable model. 
6.5. Individual Risk Prediction 
 
To calculate the probability of disease for an individual, using the model(s) described, 
a linear predictor must be calculated.  Let us consider a male, aged 65 years, who is 
a current smoker of 45 years, with an annual household income of <£18,000, who 
consumes alcohol 3-4 times per week, eats no fruit, never exercises and has 5 
previous sexual partners. 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + exp(𝑙𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟)
 
 
where linear predictor (log odds) = 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 +   𝛽1 𝑥1 + ⋯ + 𝛽𝑗 𝑥𝑗, where 𝛽 is the 
coefficient found in Table 6.2 and 𝑥 is the value of the associated variable. 
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In our case:  
log 𝑜𝑑𝑑𝑠 =  −6.094852 +  (0.0254 x 65)  +  (0.5554 x 1) +  (0.0025 x 1 )  +
 (0.0170 x 40)  +  (0.0001 x 1)  +  (0.0257 x 1 )  +  (0.0002 x 5 )  =  −3.180152 
Values for fruit and exercise are zero therefore are not seen in this equation. 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + exp(−3.180152)
= 0.03992 
 
This gives a percentage probability of head and neck cancer of 4%. 
6.6 Assessing Model Performance: Internal Validation 
 
Evaluating model performance is an important step in model development to predict 
how well the model will perform in external data (67).  Analysis and reporting of 
model performance is required as part of the TRIPOD guidelines for developing a 
multivariable prediction model (134, 240).  It is vital to know how well a model can 
discriminate between those who have the outcome of interest and those who do not, 
if the model is to be used in screening trials or in clinical decision making. 
The results of the internal validation can reveal problems in the model development, 
such as over-fitting or optimism (section 6.6.3) (136).  Correction of the model or 
recalculation of coefficients can then be undertaken prior to external validation 
(161). Obtaining external data in which to validate a model can be difficult and, if such 
data are available, it is important to maximise the opportunity by ensuring the model 
being tested is as robust as possible (161).  Essentially, the purpose of internal 
validation is to examine optimism in apparent performance, produce optimism-
adjusted performance and revise the developed model accordingly (136).   
Firstly, the apparent performance (discrimination and calibration) should be 
calculated and this is discussed in 6.6.1. and 6.6.2.   The problem of optimism is 
considered in 6.6.3, along with techniques to address this. 
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6.6.1 Discrimination 
Performance of a model refers to its ability to accurately separate those with the 
outcome from those who do not have the outcome of interest (discrimination) within 
a population.  For models with a binary outcome (as in this case), the Area Under the 
Receiver Operating Curve (AUROC) is used as a measure of discrimination (184).  This 
is equivalent to the c-statistic for Cox-regression models (241).  The AUROC plots the 
sensitivity (true positive rate) against ‘1-specificity’ (false positive rate).  A value of 
0.5 indicates the model is no better than chance at predicting the outcome, whereas 
a value of 1 signifies perfect discrimination.  Models are considered to show good 
discrimination if the AUROC is at least 0.7 and outstanding discrimination with an 
AUROC of at least 0.9 (242).  However, the ROC should be interpreted in the context 
of the literature available in the subject area in which the model was developed and 
consideration must be given to the calibration performance (134).  
6.6.2 Calibration 
Another important aspect of model performance is calibration.  This demonstrates 
how similar the predicted and observed risks are.  With a well-calibrated model, 𝑥 
out of 100 patients with a predicted risk of 𝑥% should experience the event (67, 243).   
Calibration can be presented graphically as a calibration plot, with predicted and 
observed event rate plotted for defined risk groups, together with 95% confidence 
intervals (134, 135). The closer the plots lie to the 45-degree line, the better the 
calibration.     
6.6.3 Optimism in Model Performance 
The apparent performance of models developed in small datasets, with a low number 
of events-per-variable, can be over-optimistic.   The model is built to fit the data in 
which it is developed, therefore it may not perform as well in external datasets (136).  
This is referred to as ‘overfitting’.  The best way to minimise optimism, or over-fitting, 
in risk models is to ensure one uses a dataset with enough events (i.e. patients with 
the outcome in question), in which to develop the model (175, 244).  Models 
developed in datasets with at least 20 events per variable have been found to display 
minimal optimism (245).  If large datasets are not available, there are techniques to 
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test and mediate for optimism, including cross validation and bootstrapping (181-
183, 185, 244).   
The UK Biobank development dataset contains 702 cases of head and neck cancer, 
and 23 variables have been considered in the final model.  This gives an EPV of 30, 
which minimising the risk of over-fitting and makes Leave One Out Cross Validation 
(LOOCV) and bootstrapping unnecessary (244, 245). Furthermore, the model 
developed will be validated in external data, not used to develop the model; the 
results are presented in Chapter 7. 
Measure of apparent discrimination and calibration are presented in section 6.7.  For 
completion, cross-validation and bootstrapping will be discussed in sections 6.6.3.1 
and 6.6.3.2. 
6.6.3.1 Cross Validation  
In situations where a relatively small dataset is available, it is considered wasteful to 
split the dataset into development and validation datasets (184).  It is better to use 
the full data to develop the model and then use cross-validation or bootstrapping 
techniques to obtain measures of internal validation (246).  Cross-validation involves 
splitting the data into N subgroups; the model is then developed in N-1 of the groups 
and tested in the remaining group.  This is repeated N times and the average 
performance is calculated (181).  Using 10 groups has been shown to produce the 
best results more efficiently, when compared to leave-one-out cross validation 
(LOOCV) (247).  LOOCV involves the same procedure detailed above, where N is the 
total number of participants in the dataset. 
6.6.3.2 Bootstrapping 
An alternative to cross-validation is bootstrapping.  This is another resampling 
procedure, in which samples of the same size as the original dataset are drawn with 
replacement from within, to create a new dataset (183, 185, 244).  The model is then 
developed in the bootstrap sample and tested in the original data.  The apparent 
performance is calculated in the bootstrap sample and tested in the original sample 
(test); optimism is calculated by subtracting the test performance from the apparent 
performance.  This entire procedure is repeated between 200 and 1000 times, 
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following which the average optimism is calculated (248).  Optimism-adjusted 
performance can then be calculated and if necessary, a shrinkage factor can be 
applied to the coefficients (249).  Bootstrapping has been shown to provide accurate 
estimates of model performance and is generally preferred to cross-validation 
procedures as it is considered more efficient use of data (67). 
6.7 Discrimination and Calibration of Multivariable Model using Standard Terms 
 
Apparent discrimination, as measured by the AUROC is 0.67 (95% CI 0.64 – 0. 69), see 
Figure 6.1.  This shows that the model is better than chance at predicting a case of 
HNC. 
 
Figure 6.1. Area Under the Receiver Operating Curve for Multivariable Model of Head and Neck Cancer 
Risk Prediction.   
Calibration was measured using expected:observed risk.  The calibration slope has a 
value of 0.99 and is shown in Figure 6.2:  The ‘Expected’ probability of a diagnosis of 
head and neck is calculated for each individual in the dataset.  The ‘Observed’ risk is 
calculated as the mean of the outcome variable (HNC).  The E:O ratio is simply the 
mean of the expected probabilities divided by the mean of the outcome variable.  A 
value close to one indicates perfect calibration.  A value less than one indicates that 
predictions are under-estimating risk and a value of greater than one indicates the 
predictions are over-estimating risk (67, 243).  Figure 6.2 shows calibration of ten risk 
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groups, demonstrating that performance is good across risk groups, as displayed by 
close-proximity to the 45-degree line.  Confidence intervals are shown and are 
narrow, indicating good calibration.  Most of the deciles are clustered close to the 
left side of the graph, indicating the very low risk of head and neck cancer in the 
general population.   
 
Figure 6.2.  Calibration Slope for Multivariable Risk Model for Head and Neck Cancer 
 
6.8 Discussion 
This chapter has presented the first risk prediction model for absolute risk of head 
and neck cancer, developed using the UK Biobank dataset. 
Logistic regression analysis has been used to develop the model.  The binary outcome 
of “Head and Neck Cancer: yes or no” lends itself to logistic regression; this method 
of analysis is flexible and produces a clinically meaningful output (odds ratios) (151, 
250). 
In the univariable analysis, increasing age, male gender, past or current smoking, 
increasing smoking duration, being a previous alcohol drinker or a current alcohol 
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drinker, and living in an area categorised as deprived or very deprived (Townsend 
Groups 4 and 5) were significant risk factors for head and neck cancer.  Increasing 
consumption of fruit, an annual household income of greater than or equal to 
£32,000 (compared to <£18,000) and increasing BMI were significantly protective 
against HNC.   
The multivariable model included variables for age, gender, smoking status and 
smoking duration, BMI, frequency of alcohol intake, household income (as a measure 
of deprivation), number of sexual partners, fruit intake and exercise.    
A multivariable model was built using untransformed continuous variables for ease 
of interpretation.  Increasing age, male gender, increasing smoking duration, and 
never drinking alcohol were found to be risk factors for HNC.  Moderate exercise, 
increasing BMI and increasing consumption of fruit were found to be protective.  The 
increasing incidence of HPV-related oropharyngeal cancers justifies the inclusion 
number of sexual partners in the risk model (20, 228), as number of sexual partners 
has been established as a risk factor for this sub-type of HNC (30). 
Increasing age, male gender and smoking are well established risk factors for HNC 
(194, 233, 251) and deprivation has also emerged as an important predictor of HNC 
(35, 227, 233), which justifies including household income in the model, as a proxy 
for individual-level deprivation (227, 252).  
 Alcohol is also a well-known risk factor for HNC and its effect is synergistic with 
smoking (192, 194).  It is surprising that the risk prediction model reveals ‘never 
drinking alcohol’ as a risk factor for HNC.  The dataset contains both prevalent and 
incident cases of HNC therefore it may be that changes in alcohol consumption 
following diagnosis of HNC has affected this result, i.e. it may be that cases have 
stopped drinking following their diagnosis of HNC.  For the never drinkers, 77% 
(68/88) are former drinkers, compared to 44% (15,082/34,212) of controls (data not 
shown), which supports this suggestion.  This reveals that current alcohol frequency 
may not be the most reliable predictor to use in a risk prediction model for HNC as it 
does not reflect lifetime use of alcohol.  Use of alcohol is known to change throughout 
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life (253), therefore it may be more appropriate to seek information about drinking 
habits both past and current to improve the model’s discriminative ability. 
Exercise and diets rich in antioxidants are known to be beneficial in prevention of 
HNC (193, 194, 233) and this is supported by the present model, with significant 
protective effects demonstrate for increasing fruit consumption and exercise on at 
least one day per week. 
BMI has been explored as a risk factor for HNC but no definite consensus has been 
reached as to its significance (201).  Section 5.2.8.1 discussed the relevance of BMI to 
HNC.  This model demonstrates that controls have a higher BMI than cases, implying 
that higher BMI is protective against HNC (OR 0.94).  However, this dataset contains 
information on patients who were free from HNC at recruitment and those with a 
previous diagnosis of HNC.  BMI may have been affected by the diagnosis itself, as 
HNC patients will frequently have periods of time where eating is difficult, which 
could result in weight loss (254).  Unintentional weight loss is reported as a presenting 
symptom in 26% of patients who go on to receive a diagnosis of HNC (255).  A 
prospective cohort with details of BMI in the years prior to diagnosis would be 
required to investigate this further. 
6.8.1 Model Performance 
 The AUROC was 0.67, which is reasonable.  The calibration was good with all risk 
groups lying close to the 45-degree line on the calibration curves.   
Resampling techniques were not used for internal validation as the EPV is high in 
these data, which minimises optimism in model performance statistics.  The true test 
of a model lies in its performance in external data, i.e. data in which the model was 
not developed, which is presented in Chapter 7. 
This is the first risk prediction model to be developed with HNC as an outcome, for 
the general population; therefore, it is impossible to discuss this apparent 
performance in the context of the current literature.   
One other risk model has been identified which predicts HNC in patients with current 
symptoms (256). This model is proposed for use in general practice as a tool for 
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guiding urgent referrals.  This model was developed using a UK-based dataset with 
397 cases and 4,318 controls.  The model has an AUROC of 0.77.  No calibration 
statistics are presented.  This model was externally validated, by the same authors, 
in a Scottish dataset of 2000 individuals with 232 cases of HNC(255).  The 
discrimination is good (C-statistic of 0.81); again, no measure of calibration is 
reported. 
Speight et al published an extensive Health Technology Assessment report, in 2006, 
on the cost-effectiveness of oral cancer screening in the UK, using a simulated 
population of 100,000 (257).  This incorporated some elements of risk modelling, 
although none that could be applied in general practice.  No performance statistics 
are presented.  The findings suggest that opportunistic screening of “high-risk” 
individuals could be cost-effective.  They define high-risk as males over the age of 40 
years, who smoke and consume alcohol.   
6.8.2 Absolute Risk of HNC 
Absolute risk is the risk of developing a disease within a given time period.  Absolute 
risk can be calculated by linkage with regional incidence data as in Cassidy et al 2008 
(188).  In this paper, regional lung cancer incidence data was obtained from North 
West Cancer Intelligence Service, in 5-year age categories and the intercept (𝛼) was 
calculated for each 5-year age group, using: 
𝛼 = ln (
𝑝
1−𝑝
) −  ∑ 𝛽𝑖𝑥𝑖, where 𝑝 =
𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 𝑝𝑒𝑟 100,000 𝑝𝑒𝑟𝑠𝑜𝑛𝑠
100,000
.   
The intercept is a function of the ratio of number of cases to number of controls and 
does not pertain to absolute risk; hence, the number of person-years at risk must be 
reported or, as in this example, a more complex method of calculation, using regional 
cancer data can be employed.  This will be discussed in Chapter 9 in relation to future 
aims.  
6.9 Conclusions 
The paucity of data on risk prediction in HNC highlights the need for the development 
of a validated risk prediction model.  There is great potential for use of this model for 
defining selection of patients for screening trials and this is discussed in Chapter 9.  
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Incorporation of biomarkers could further refine the predictive ability of the model 
(136, 258), and such a model could be applied to a known high-risk group of patients 
with a diagnosis of oral pre-malignancy in order  to predict malignant transformation 
and hence guide management decisions (see Chapter 8).  Potential for clinical 
application and future work will be discussed in Chapter 9.  
The model developed in this chapter shows reasonable discrimination and good 
calibration for prediction of head and neck cancer. The results of the external 
validation are presented in Chapter 7. 
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Chapter 7  
 
External Validation of a Risk 
Prediction Model for Absolute Risk 
of Head and Neck Cancer, using the 
UK Biobank 
 
 
7.1 Introduction 
The previous chapter presented the development of the first risk prediction model 
for absolute risk of head and neck cancer, using the UK Biobank dataset.  This chapter 
presents the validation of this model, using a subset of the UK Biobank dataset, 
containing persons living in the North West of England. 
Validation of risk prediction models is of paramount importance to investigate their 
reliability in different populations, referred to as ‘transportability’.  Ideally models 
should be validated in external datasets to confirm their reliability and predictive 
accuracy, before they are used in impact studies to assess their clinical usefulness 
(161, 163, 240).  
The North West of England is known to have a higher incidence of head and neck 
cancer than other parts of the UK (8, 149).  For this reason, the original dataset was 
split geographically, into development and validation sets, to tests its performance in 
a cohort known to have a higher risk of HNC.  It is not recommended to randomly 
split the data into development and validation sets (184), rather a geographical split 
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or time-dependent split is a better way of validating a model’s transportability to 
different populations (67, 161) (see section 4.4.2.1.) 
This chapter will present the methodology used for external validation (section 7.2), 
descriptive statistics for the validation cohort (section 7.3) and measures of model 
performance (section 7.4). Methods for improving model performance and the 
results of this will be presented in Section 7.5.  
7.2 Methodology 
 
The model for predicting risk of HNC, developed in section 6.4.1, contained variables 
for age, gender, smoking status and smoking duration, BMI, frequency of alcohol 
intake, household income (as a measure of deprivation), number of sexual partners, 
fruit intake and exercise.    
Firstly, the differences between cases and controls in the validation dataset are 
explored using descriptive statistics (t-test for continuous and chi-squared for 
categorical predictors) and compared to the development cohort (section 7.3).   
The linear predictor and predicted probability of head and neck cancer has been 
calculated for each individual in the validation dataset, using the log of the Odds 
Ratios found in Table 6.2 and the equation shown in section 6.5.  The c-statistic (area 
under the receiver operating curve, AUROC) has been used as a measure of the 
model’s ability to discriminate between cases and controls.  The calibration slope and 
calibration plot are used as measures of calibration.  Ten deciles of risk have been 
calculated to create risk groups, which are presented graphically as a calibration plot. 
Given that the model will always perform better in the data in which it is developed, 
it is sometimes necessary to recalibrate the model for the data in which it is to be 
used (161).  This can be achieved by updating the model intercept.  This is discussed 
in section 7.5 and the effects of this updating on the discrimination and calibration 
are presented.   
The model performance is assessed separately for males and females and separate 
calibration plots are presented.  Risk of HNC is significantly higher for males than 
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females (OR 1.75; see table 6.2), therefore it is important to determine if the model 
performs equally well for both sexes. 
 
7.3 The Validation Dataset 
This section will describe differences between the HNC cases and controls in the 
validation dataset.  These differences will be compared back to those found in the 
development dataset, which were presented in section 5.2.   
The validation set contains 78,895 individuals, with 157 cases of head and neck 
cancer.   
Table 7.1 presents the descriptive statistics detailing differences between cases and 
controls for all the variables used in the final model. 
7.3.1 Similarities and Differences between the Validation and Development 
Cohorts 
 
There are significantly more males than females with HNC.   Males with HNC are 
significantly older than male controls but this was not seen for females, which is 
different to the development data (Chapter 5.2.1).   There is a significant difference 
in the smoking status between cases and controls for males and females, which was 
also apparent in the development data (section 5.2.3).  Smoking duration was not 
significantly different, neither was frequency of alcohol consumption.  However, in 
the development dataset smoking duration was significantly different between cases 
and controls (section 5.2.3).  Household income was significantly lower for cases 
compared to controls, which was also the case in the development data (section 
5.2.2).  Participation in moderate exercise was greater for female controls compared 
to cases but this difference was not seen in males.  The opposite was seen in the 
development data: male cases reported less exercise than controls (section 5.2.6).  
Sexual history was not significantly different, however in the development data male 
cases reported statistically more sexual partners compared to controls (5.2.12).  Fruit 
consumption was higher for male controls compared to cases, but no significant 
difference was clear for females.  Fruit consumption was higher for both male and 
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female controls in the development dataset (5.2.5).  This demonstrates some 
differences between the development and validation datasets, which has the 
potential to demonstrate the performance of the developed model in a broader 
population than initially considered.  The prevalence of HNC in this population is 198 
per 100,000 compared to 165 per 100,000 in the development dataset, indicating the 
higher risk of disease in this population.   
 
   
 
 
1
5
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  Table 7.1  Descriptive Statistics for Risk Factors for Head and Neck Cancer in the Validation Cohort 
Variable  Head and Neck Cancer Case  Control p-value 
  Males Females  Males Females  
        
Number  
(N (%)) 
 94 (59.9) 63 (40.1)  36747 (46.7) 41991 (53.3) 0.001 
Age at recruitment (years) 
(mean (std dev)) 
 
 59.4 (6.5) 
 
 
57.0 (7.0) 
 
 
 56.7 (8.2) 
 
 
56.6 (8.0) 
 
 
Males 0.003 
Females 0.697 
Never  33 (35.1) 21 (33.3)  17,435 (47.8) 24,163 (57.8)  
Previous  50 (53.2) 34 (54.0)  14,012 (38.4) 13,306 (31.8) Males 0.012 
Current  11 (11.7) 8 (12.7)  5,066 (13.8) 4,316 (10.4) Females <0.001 
N (%)  94 (100) 63 (100)  36747 (100) 41991 (100)  
 
Smoking Duration (ever smokers) 
Mean years (SD) 
30.4 (14.5) 
 
25.8 (13.2) 
 
 27.4 (12.9) 
 
26.8 (12.7) 
 
Males 0.105 
Females 0.675 
N Missing (%)  10 (17) n=11 (26)  4,680 (25) 5,335 (30)  
Alcohol Frequency    N(%)        
Daily  27 (28.7) 8 (12.7)  8,363 (22.8) 5,721 (13.7)  
3-4 times/wk  17 (18.0) 16 (25.4)  9,729 (26.6) 8,622 (20.6)  
1-2 times/wk  29 (30.9) 16 (25.4)  10,075 (27.5) 11,329 (27.0) Males  0.126 
1 – 3 times/month  5 (5.3) 7 (11.1)  3,293 (9.0) 5,583 (13.3) Females 0.943 
Special Occasions only  6 (6.4) 11 (17.5)  2,831 (7.7) 6,787 (16.2)  
Never  10 (10.6) 5 (7.9)  2,346 (6.4) 3,863 (9.2)  
N (%)  94 (100) 63 (100)  36,637 (100) 41,991 (100)  
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Table 7.1 continued.  Descriptive Statistics of Risk Factors for Head and Neck Cancer within the Validation Cohort 
Variable  Head and Neck Cancer Case  Control p-value 
  Males Females  Males Females  
Household Income (£/year) 
N(%) 
       
<18,000  29 (40.3) 11 (24.4)  7,734 (25.3) 9,470 (29.2) Males 0.039 
18,000-31,999  12 (16.7) 19 (42.2)  8,076 (26.4) 9,011 (27.8) Females 0.229 
32,000 – 51,999  19 (26.4) 7 (15.6)  7,834 (25.6) 7,895 (24.3)  
52,000-99,999  10 (13.9) 6 (13.3)  5,770 (18.9) 5,090 (15.7)  
≥100,000  2 (2.8) 2 (4.4)  1,156 (3.8) 969 (3.0)  
                                 N missing(%)  22 (23) 18 (29)  6,177 (17) 9,556 (23)  
Moderate Exercise (10 mins; no. days/wk) N(%)      
0  20 (22.0) 11 (18.6)  4,990 (14.3) 5,445 (13.9)  
1  5 (5.5) 8 (13.6)  2,839 (8.1) 2,935 (7.5)  
2  15 (16.5) 4 (6.8)  4,876 (14.0) 5,702 (14.6) Males 0.325 
3  13 (14.3) 15 (25.4)  4,814 (13.8) 6,251 (16.0) Females 0.08 
4  5 (5.5) 5 (8.5)  3,218 (9.2) 3,814 (9.8)  
5  10 (11.0) 8 (13.6)  5,694 (16.3) 5,366 (9.8)  
6  7 (7.7) 2 (3.4)  2,277 (6.52) 1,785 (4.6)  
7  16 (17.6) 6 (10.2)  6,208 (17.8) 7,825 (20.0)  
                                N missing (%)  3 (3) 4 (6)  1,831 (5) 2,859 (7)  
Fruit intake (no. pieces/day 
(sd)) 
                                N Missing (%) 
 1.6 (1.4)                 
 9 (10) 
2.1 (1.3)  
0 (0) 
 2.1 (1.64)  
1,921 (5) 
2.4 (1.6)  
1,198 (3) 
Males 0.007 
Females 0.133 
Lifetime number of Sexual 
Partners (mean (sd)) 
                                   N Missing 
(%) 
 14.5 (20.2) 
 
24 (25%) 
4.2 (4.1) 
 
9 (14%) 
 11.0 (124.8) 
 
7,949 (22%) 
4.3 (10.3) 
 
8,195 (19%) 
Males 0.813 
Females 0.9185 
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7.4 Missing Data 
 
Missing data was noted as shown in Table 7.1: missing data for number of sexual 
partners and household income and smoking duration was highest, whereas all other 
variables had ≤6% missing data. 
Techniques for handing missing data were considered, including case-wise deletion 
or complete case analysis and multiple imputation.  Multiple imputation was 
discussed in Chapter 4, section 4.4.3 and was used on the development dataset to 
handle missing data.  Complete case analysis involves only using complete cases (i.e. 
with no missing data) in the analysis:  individuals with any missing data are were 
removed for the purposes of the analysis. 
In the validation dataset, complete case analysis was chosen due to the large size of 
the validation dataset and the fact that the variables with the highest amount of 
missing information were not statistically significant in the risk model (section 6.4.1).  
When the missing predictors do not have a significant effect on the outcome, 
complete case analysis is a simple and valid technique (259).  However, it is 
recognised that multiple imputation is a robust method for handling missing data and 
preferred by some authors (162).  60,240 individuals were available for complete case 
analysis.  Missing data is discussed in more detail in section 7.7.1. 
7.4 Calculation of the Linear Predictor 
 
The linear predictor (LP) was calculated for each patient in the validation dataset, 
using the coefficients obtained from the risk prediction model presented in 6.4.1 
(Table 6.2). The coefficient is the log of the odds ratio.  The LP is the log odds of each 
patient having the outcome of interest (151). 
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𝐿𝑖𝑛𝑒𝑎𝑟 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 =  −6.094852 (𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡) +  (. 0170573 ∗ 𝑠𝑚𝑜𝑘𝑖𝑛𝑔 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛) +
 (. 0001917 ∗ 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑥𝑢𝑎𝑙 𝑝𝑎𝑟𝑡𝑛𝑒𝑟𝑠) +  (−.1552106 ∗ 𝑓𝑟𝑢𝑖𝑡 𝑝𝑒𝑟 𝑑𝑎𝑦) +
 (−.322034 ∗ (𝑚𝑜𝑑𝑒𝑥10 == 7)) +    (−.299228 ∗ (𝑚𝑜𝑑𝑒𝑥10 == 6)) +  (−.3548187 ∗
(𝑚𝑜𝑑𝑒𝑥10 == 5)) +  (−.2049572 ∗ (𝑚𝑜𝑑𝑒𝑥10 == 4)) + (−.4371079 ∗ (𝑚𝑜𝑑𝑒𝑥10 =
= 3)) +  (−.332567 ∗ (𝑚𝑜𝑑𝑒𝑥10 == 2)) +  (−.4220539 ∗ (𝑚𝑜𝑑𝑒𝑥10 == 1)) +
 (. 4487275 ∗ (𝑎𝑙𝑐𝑓𝑟𝑒𝑞 == 6)) +  (. 1661107 ∗ (𝑎𝑙𝑐𝑓𝑟𝑒𝑞 == 5)) + (−.0385644 ∗
(𝑎𝑐𝑙𝑓𝑟𝑒𝑞 == 4)) +  (−.0528734 ∗ (𝑎𝑙𝑐𝑓𝑟𝑒𝑞 == 3)) +  (. 0257095 ∗ (𝑎𝑙𝑐𝑓𝑟𝑒𝑞 ==
2)) +  (−.3233918 ∗ (ℎ𝑜𝑢𝑠𝑒𝑖𝑛𝑐𝑜𝑚𝑒 == 5)) +  (−.2301338 ∗ (ℎ𝑜𝑢𝑠𝑒𝑖𝑛𝑐𝑜𝑚𝑒 == 4)) +
 (−.1571579 ∗ (ℎ𝑜𝑢𝑠𝑒𝑖𝑛𝑐𝑜𝑚𝑒 == 3)) +  (. 0001484 ∗ (ℎ𝑜𝑢𝑠𝑒𝑖𝑛𝑐𝑜𝑚𝑒 == 2)) +
 (. 0024737 ∗ (𝑠𝑚𝑜𝑘𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 == 2)) + (. 1402463 ∗ (𝑠𝑚𝑜𝑘𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 == 1)) +
 (. 5554884 ∗ 𝑔𝑒𝑛𝑑𝑒𝑟) +  (. 0254182 ∗ 𝑎𝑔𝑒) +   (−0.026872 ∗  BMI))  
 
The mean of the LP for the validation dataset is -6.737 (sd 0.607), based on 60,240 
observations.  The linear predictor was -6.095 (sd 0.523) for the development 
dataset, which is similar.  This allows us to compare the development and validation 
data and demonstrates that, on average, the risks are similar in the development and 
validation datasets.    
 
7.4 Model Performance 
7.4.1 Discrimination  
 
The c-statistic (area under the receiver operating curve) for the model in the 
validation data is 0.64 (95% CI 0.59 - 0.70), which shows that the model is better than 
chance at predicting the outcome (see Figure 7.1).  The performance is slightly worse 
than in the development data (AUROC 0.67 (95% CI 0.64 – 0. 69) – section 6.7).  This 
may be due to slight overfitting of the model in the development dataset, however 
this is unlikely to be due to the large sample size (n=329,005).  
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Figure 7.1. Area under the Receiver Operating Curve (AUROC) Graph demonstrating the Discrimination 
of the Risk Model in the Validation Dataset; C-statistic = 0.64 
 
7.4.2 Calibration 
 
The probability of head and neck cancer is very low, 0.00199 (n=78,895).  The mean 
expected probability is 0.00143 (n=60,240). 
Although this only equates to a difference of 0.00056, the expected:observed ratio is 
0.72.  Ideally the E:O would be 1, with no difference in the expected and observed 
probabilities.  However, with such low incidence, even small differences can appear 
large when viewed as a relative measure, such as E/O.  
The calibration slope is 0.83 (std error 0.14).  This suggests the model is slightly 
overfitted, with predictions being slightly too high in all risk groups.  
Ten risk groups were created, and a calibration plot generated (see Figure 7.2).  The 
risk is very low (<0.01% for all ten groups) and the observed and expected 
probabilities are quite close to the reference line. The model generally overpredicts 
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risk of head and neck cancer, as seen by many of the points lying above the reference 
line and as shown by the calibration slope of 0.83.   
 
 
Figure 7.2.  Calibration plot for Model Validation showing Expected and Observed Probabilities for Ten 
Risk Groups.  The 45-degree line indicates perfect calibration.  The points lie fairly close to this line 
indicating fairly good calibration of the model. 
 
7.5 Improving Calibration 
 
The problem of overfitting or optimism in model development was discussed in 6.6.3.  
In models developed in data with a low EPV or using data-driven techniques, such as 
automated selection of variables, one might expect significant overfitting (163).  
However, the present model was developed in data with an EPV of 30 and using 
clinical reasoning for variable selection to minimise this problem.  However, the 
calibration in the external validation is worse than the apparent calibration in the 
development data, which had a calibration slope of 0.99.  This is probably due to the 
fact that the prevalence of the outcome (HNC) is higher in the validation cohort 
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(section 7.3).  There is one option available to improve the calibration in these 
circumstances, which involves updating the model intercept, i.e. updating the 
baseline risk to reflect the higher outcome frequency (161, 260). This has been shown 
to improve calibration when models were under- or over-predicting risk (261).  
Another option when faced with a model which performs worse than desired is to 
develop a completely new model and reject the first model.  However, unless there 
have been significant concerns with the development of the initial model, it is 
recommended the model is simply updated, either by re-estimating the baseline risk 
(as in this case), or my re-estimating the effect estimates (161).  This prevents loss of 
scientific information and prevents a large number of models being developed, which 
generates confusion about which model should be used (161).   
The intercept is updated by fitting a logistic regression model with the original linear 
predictor (as an offset term) as the only covariate.  The new coefficient generated is 
the updated intercept. 
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The updated intercept in this validation data is -5.762 (95% CI -5.943 - -5.583).  The 
calibration slope is unchanged at 0.83 (sd 0.14) (see Figure 7.3) as is the 
discrimination as the ranking of the predictions is unchanged.   
Looking at the calibration plot, we can see the points now lie closer to the line of 
agreement (the 45-degree line), showing better agreement. 
 
 
 
 
 
 
 
 
 
 
Figure 7.3. Calibration Plot showing Expected and Observed Probabilities for Ten Risk Groups, 
following updating of the Model Intercept. 
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Figure 7.4 shows the calibration plots for the original model and the updated model overlaid. 
. 
 
Figure 7.4. Graph showing calibration of original model overlaid with calibration of model 
with updated intercept.  The expected:observed probabilities lie slightly closer to the 45-
degree line for some of the risk groups, with the updated model 
 
 
 
7.6 Calibration in Different Risk Groups 
 
Risk is different in subgroups of the population and therefore one might expect a risk 
model would perform differently in these subgroups (161, 260).  This model shows 
that male gender is a significant risk factor for HNC (6.4.1) and gender-specific risk 
factors for HNC have been explored in Chapter 3.  For this reason, model calibration 
has been tested separately for males and females. 
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7.6.1 Model Performance: Males 
 
The model performance was assessed in males within the validation cohort 
(n=27,364).  The E:O was 1.02 indicating good calibration.  The calibration slope was 
0.90, which is better than in the overall validation cohort.  The c-statistic is slightly 
improved but not significantly, at 0.65 (0.58 – 0.71).  Figure 7.5 shows the calibration 
plot.  All of the groups lie close to the 45-degree line.
 
Figure 7.5.  Calibration Plot of Risk Model for Head and Neck Cancer, with ten risk groups, for 
Males in the External Validation cohort. 
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7.6.2 Model Performance: Females 
 
The model was validated in females only, n=32,876 using the same methodology 
described in section 7.2.  The c-statistic is lower, at 0.61 (95% CI 0.52 – 0.69) and the 
calibration performance is also worse, with a calibration slope of 0.81, indicating that 
risk is under-predicted although, the E:O is 0.99, indicating good calibration overall.  
Figure 7.6. shows the calibration plot for ten risk groups of females in the validation 
dataset. 
 
 
Figure 7.6.  Calibration plot of risk model for Head and Neck Cancer, with ten risk groups, for 
females in the Validation dataset. 
 
7.7 Discussion 
 
The validation dataset contains 78,895 individuals with 157 cases of HNC and is drawn 
from a sub-group of the UK Biobank cohort.  Individuals recruited at sites in the North 
West of England are included in the validation cohort; the model was developed in 
the remaining data containing 329,005 observations with 702 cases of HNC (Chapter 
6). 
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The prevalence of HNC in the validation cohort is higher than that in the development 
cohort, which is consistent with reports of a higher incidence of HNC in the North 
West of England (8, 149).  Other than this higher prevalence of the outcome, the case-
mix is similar as demonstrated by comparisons between cases and controls in the 
development and validation cohorts (section 7.3).   
The ability of the model to discriminate between cases and controls is reasonable but 
there is scope to refine the model, to improve performance.  The c-statistic is 0.64 
for the overall cohort, 0.65 for males only and 0.61 for females only.   The calibration 
is good with the calibration plots showing points close to the 45-degree line, 
indicating the expected and observed probability of HNC is similar.  The calibration 
was not significantly improved by updating the model intercept. It may be that the 
only way to improve overall performance would be to include extra, as yet 
unidentified, novel variables that are more accurate predictors of disease than those 
currently included (161).  These risk factors may be molecular markers, which could 
preclude use of the model in general clinical practice.  This will be discussed in 
Chapter 9. 
 
7.7.1 Missing Data 
 
Collins recommends external validation studies should contain a minimum of 100 
events, and ideally 200 events, to ensure validity of the performance measures 
reported (164).  This validation dataset contained 157 cases, so the results of this 
validation study should be an accurate reflection of model performance in this data.   
Missing data was significant for three covariates (number of sexual partners, 
household income and smoking duration).   
It has previously been reported that missing data for income is frequently high in 
responses to surveys, around 10-15% (262).  One may assume that it is the personal 
nature of the questions surrounding income and sexual history that means patients 
are less likely to answer.  The questions were answered as part of a Computer-
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Assisted Self-Interview (CASI), as previously recommended when exploring sensitive 
information (263), in order to minimise the problem of missing data.   
Patients from the Liverpool Oral Medicine Patient Research Forum (LOMPRF) were 
asked to complete a short questionnaire regarding questions they would be willing 
to answer, for the purposes of determining their risk of HNC.  All patients (n=5) were 
willing to answer all questions posed (covering all variables included in the model), 
however questions were raised by two patients about the need for details of 
household income and sexual history.  Once an explanation had been given regarding 
the relevance of these factors to HNC, the patients said they would be willing to 
provide this information.  This informal, small, study does not provide the necessary 
evidence that patients would be willing to provide the details required for the risk 
model; a larger clinical utility study would be required.  If patients are not willing to 
answer the necessary questions, these variables could be removed from the model.  
Alternatively, one could work with a Public and Patient Involvement (PPI) group such 
as LOMPRF to determine if there are better ways of asking these questions and 
collecting the data.  Alternatively, real-time multiple imputation methods can be built 
in to computer software to overcome the problem of partial responses (264), 
assuming a web-based tool is being used.  
The reason for missing information regarding smoking duration, which is up to 30%, 
is due to the missing data for age started smoking (and age stopped smoking for 
former smokers).  Participants in the UK Biobank study were only asked for details of 
their age when they started (and stopped) smoking if they indicated they currently 
(or previously) smoke(d) “on all or most days of the week”.  Participants who reported 
to smoke ‘occasionally’ (n=14,455 for current smokers and n=71,472 for former 
smokers) or ‘just once or twice’ (n=80,991 for former smokers) were not asked for 
details of age at starting or stopping smoking.    Of these, 66,224 (40%) report to be 
‘ever’ smokers (i.e. have smoked at least 100 cigarettes in their lifetime).  Given the 
importance of smoking duration in other smoking-related cancer risk prediction 
models (for example the LLP model (188)), it would be important to ensure these 
data are thoroughly collected in any future studies. 
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7.7.2 Performance compared to Published Risk Models 
 
Whilst the performance of this model cannot be compared to similar models in the 
same field, due to the lack of such a model, the performance will be considered in 
relation to risk models in other smoking-related cancers (lung and oesophageal). 
7.7.2.1 Lung Cancer 
Risk prediction modelling in lung cancer has been established since the early-2000’s 
when Bach et al published their risk model for lung cancer risk prediction amongst 
smokers (265).  The c-statistic was 0.72.  Many other lung cancer risk models have 
been produced, including the Liverpool Lung Project (LLP) model in 2008 with a c-
statistic of 0.70 (188), which was updated in 2015 to the LLPi model which has a c-
statistic of 0.85 (266).  There is great variability in the apparent performance of the 
many lung models developed, with c-statistics ranging from 0.57 to 0.92 reported in 
the literature (267-272).  
7.7.2.2 Oesophageal Cancer 
A search of the literature revealed several risk prediction models for oesophageal 
cancer; the first were published in 2013 (43, 273) and several have been published 
between 2016 and 2018 with c-statistic ranging from 0.71 to 0.84 (70, 274-278).  One 
of these models was developed within the UK Biobank data and included 220 incident 
cases and 355,034 controls (70).  The model included variables for age, sex, smoking, 
body mass index, and history of oesophageal conditions or treatments.  The c-statistic 
is 0.80 but the model has not yet been externally validated.   
The models with better performance tended to have a disease-specific risk factor 
incorporated (275, 277), such as ‘known oesophageal disease’, as in this latter model 
(70) or genetic markers in the model of Dong et al (275). 
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7.8 Conclusion 
 
The model developed provides a firm foundation on which to begin the discussion on 
risk modelling in HNC.  The model demonstrates moderate discriminative ability and 
good calibration; its performance is consistent with models developed for predicting 
risk of other smoking-related cancers, but it is noted that several of these models out-
perform the present model.  This is likely to be because of the presence of disease-
specific risk factors and genetic markers in the better models.  The HNC model could 
be refined and updated to improve the performance, by including disease-specific 
risk factors or molecular biomarkers, if they can be identified.  Chapter 9 will discuss 
the need for further validation studies in truly independent data and for clinical 
impact studies to determine the model’s true potential in improving patient 
outcomes. 
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Chapter 8 
 
The Link with Oral Epithelial 
Dysplasia  
 
 
 
The work in this Chapter was published as an Editorial in Oral Oncology 
(Appendix 8). 
Field EA, McCarthy CE, Ho MW, Rajlawat BP, Holt D, Rogers SN, Triantafyllou A, Field 
JK, Shaw RJ.   
Editorial:  The management of oral epithelial dysplasia.  The Liverpool algorithm. 
Oral Oncol. 2015 Oct;51(10):883-7. doi: 10.1016/j.oraloncology.2015.06.015. Epub 
2015 Jul 18. 
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8.1 Introduction 
The work described in this thesis demonstrates the increasing incidence of HNC in 
the UK (chapter 2), explores novel gender-specific risk factors for HNC (chapter 3) and 
presents the first risk prediction model for HNC, developed and validated in a large 
UK dataset (chapters 4-7). 
Risk prediction models have an important role to play in primary prevention efforts 
in many cancers, particularly HNC.  If high-risk individuals can be accurately identified, 
targeted prevention efforts can be implemented.  Patients with a diagnosis of Oral 
Dysplasia (oral pre-cancer) are known to be at high risk of developing oral cancer 
compared to the general population (279).  Liverpool University Dental Hospital, 
manages a cohort of around 250 patients with histologically confirmed oral dysplasia; 
the malignant transformation rate has been reported as 25% over 5 years (280, 281). 
There is potential for a risk prediction model to inform treatment and follow-up 
decisions (282).  This chapter discusses the diagnosis of Oral Pre-malignancy (Oral 
Dysplasia) and reviews the current management strategies.   
8.2 Oral Epithelial Dysplasia (OED) 
 
8.2.1 Background and Current Management of Oral Epithelial Dysplasia 
 
Oral epithelial dysplasia (OED) is a potentially malignant disorder of the oral mucosa, 
which may appear as a white patch, red patch or mixed red and white patch on any 
area of the oral mucosa (see Figure 8.1).  The clinical appearance is described in 
section 8.2.3.1.   
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Figure 8.1. Clinical photograph of a homogenous, white dysplastic lesion on the lateral border (side) of the tongue, 
extending to the ventral (underside) surface.   
These premalignant lesions undergo malignant transformation to oral cancer in 5.0-
36.4% of cases (6, 279, 282-287). 
A biopsy is required to confirm the diagnosis of OED.  The lesion is graded 
histologically as mild, moderate or severe.  Severe oral epithelial dysplasia has been 
found to transform to oral cancer in up to 50% of cases (288).   
Ho M et al (2012) studied a cohort of 91 patients with histologically-confirmed OED 
from Liverpool University Dental Hospital.  The authors reported a mean time to 
transformation (MTT) following diagnosis of 40 months, with 12% transforming 
within 2 years and 22% at five years (279).  Ho PS (2009) reported malignant 
transformation of 24% (8 of 33) cases of OED over 38 months (6).   
Prevention of malignant transformation is the primary aim of management.  Failing 
this, detection of malignant transformation at the earliest possible opportunity, to 
allow minimally invasive treatment, is desirable. 
OED may be managed by surgical excision (laser or scalpel), laser ablation or, less 
commonly, photodynamic therapy, cryotherapy or non-surgical treatments 
(discussed in 8.2.4.2).  Close-monitoring with intervention in the event of a suspicious 
change in clinical appearance is offered in some cases and is discussed in 8.2.4. 
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The decision to proceed with treatment (as opposed to close monitoring) would 
ideally be based on a validated risk prediction model showing that the patient is at 
high risk of developing oral cancer. In clinical practice, because no such model is 
available, the decision is based on grade of dysplasia seen on histological examination 
and clinical risk factors for malignant transformation such as smoking status, site, size 
and appearance (279, 282).  Feasibility of surgery, in terms of patient acceptance, 
anticipated quality of life following surgery, medical status of the patient and local 
factors such as requirements for reconstruction, are also major considerations. 
Recurrence of lesions following surgery is reported in 4-17% of cases  (289-292) (see 
section 8.2.4.1), therefore close follow-up is required.  Length of follow-up and 
intervals between appointment are variable between clinicians and there is a need 
for consensus guidelines to inform clinicians how to manage these patients (279). 
Management decisions are challenging, and at present the only guidelines in place 
regarding management of OED form part of the British Association of Head and Neck 
Oncologists (BAHNO) UK Head and Neck Cancer Multidisciplinary Management 
Guidelines (231). These guidelines advise on the “targeted use of biopsy and 
histopathological assessment, along with advice on reduction of environmental 
carcinogens (tobacco use and alcohol), followed by surgical excision of the lesion 
where the size of the lesion and subsequent function allows”.  Long term surveillance 
is recommended.   
In the United Kingdom, primary care practitioners receive guidance from the National 
Institute for Health and Clinical Excellence (NICE) regarding referral of patients with 
suspected cancer (293), which have been summarised in the “Mouth Cancer Referral 
Guidelines for Dentists” by Cancer Research UK (294).  These guidelines apply for 
patients with unexplained or persistent lesions of the oral mucosa; therefore, most 
patients with OED will be managed in secondary or tertiary care settings, following 
referral from primary care. 
At Liverpool University Dental Hospital, a tertiary Regional OED clinic was created in 
recognition of the difficulties faced in managing patients with this condition.  These 
clinics are intended to harness the combined expertise of both Oral and Maxillofacial 
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Surgery and Oral Medicine specialists to ensure patients receive the highest standard 
of care.  This format also minimises delay to definitive treatment, which often 
includes surgery.     
8.2.2 Current Methods for Diagnosis of OED 
 
8.2.2.1 Histopathological Examination 
Despite many studies into alternative methods, routine histopathological 
examination of a biopsy specimen remains the gold standard for diagnosis of OED.  
The 2005 WHO Classification of Tumours defined the features of OED in the hope of  
reducing intra- and inter-observer variability amongst histopathologists in reporting 
of OED (295-297).  Presently, dysplasia is categorised as mild, moderate and severe, 
however studies have shown variability between specialist oral and maxillofacial 
pathologists in their interpretation of the architectural and cellular changes within 
the epithelium that lead them to their diagnosis (297, 298). 
It has been suggested that a binary system, categorising lesions as ‘low risk’ and ‘high 
risk’, would be helpful in reducing inter-observer variability (298).  It was also 
suggested that this may help in avoiding confusing messages to clinicians, such as 
reports stating “mild with focally moderate dysplasia”, which can be difficult to 
interpret clinically (298).  This binary system has been shown to correlate well with 
clinical outcomes, with only 15% of lesions categorised as ‘low risk’ undergoing 
malignant transformation, compared to 80% of ‘high risk’ lesions.  Sensitivity and 
specificity of the binary system is reported as 84.9% and 85% respectively.  Crucially, 
this method of reporting avoids the category of ‘moderate dysplasia’, for which 
treatment decisions can be particularly challenging.(298)    
The use of toluidine blue, bio-optical imaging and cytological examination of brush-
biopsy specimens are under intensive research  (299-305), but as yet none of these 
methods are able to reliably replace routine histopathology.   Toluidine blue is 
discussed below in view of the encouraging results indicating its ability to detect 
lesions more likely to progress to oral cancer.(282). 
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8.2.2.2 Toluidine Blue 
Toluidine blue (Tolnium chloride) or TBlue is a dye with a high affinity for cells rich in 
nucleic acids (such as (pre)-malignant cells of the oral mucosa).  It has been used in 
studies (301, 306, 307) to aid detection of dysplastic lesions and carcinoma of the oral 
mucosa.  Sensitivity rates for detection of carcinoma are high (76 - 100%), however 
the figures are lower for detection of dysplasia (45-94%).  Specificity is quite low, 
ranging from 39 to 45%(307).  Detection rates improve with increasing severity of 
dysplasia (307).  It has been proposed that Tblue detects ‘molecularly-positive’ 
lesions, as it stains nucleic acids, its retention being linked to loss of heterozygosity 
at various loci on tumour suppressor genes (300).  That is, it is thought to stain high 
risk lesions that are likely to progress, even in the absence of histopathological 
features of dysplasia (282).  Rock et al found that 22 out of 83 “TB-positive” lesions 
progressed to oral cancer against 34 out of 266 TB-negative lesions.  This implies that 
lesions which stain positive for TB are more than twice as likely to progress to oral 
cancer (OR 2.65; 95%CI 1.45 – 4.83).  This is attractive, as it may help to guide 
management and follow up of lesions but needs to be confirmed by a randomised 
control trial.  The ease of application and immediate, chair-side result favours its use 
and results are easy to interpret, however further evidence is required regarding its 
use in detecting dysplasia.  Its use is supported for detection of carcinomas and in 
biopsy site selection, as well as in mapping out a lesion prior to excision (308, 309). 
 
8.2.3 Predictors of Malignant Transformation of OED 
One of the main challenges in the management of OED is predicting which lesions will 
progress to invasive carcinoma.  Factors including non-smoking status, lateral tongue 
site and non-homogenous appearance have been shown to be associated with higher 
rates of malignant transformation, along with female gender, larger size of 
lesion(>200mm2) and non-homogenous appearance, as described previously (6, 279, 
282). 
8.2.3.1 Clinical Appearance 
Dysplastic oral lesions may present as leukoplakia (white patches), erythroplakia (red 
patches), erythro-leukoplakia (mixed red and white patches), verrucous lesions 
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(usually thick, white lesion) or ulcers/erosions.  Lesions may be homogenous (uniform 
in appearance) or non-homogenous (mixed appearance); it has been shown that 
speckled lesions (areas of erythro-leukoplakia) are more likely to be dysplastic and to 
undergo malignant transformation (286, 310).  
Leukoplakia is a clinical diagnosis, defined as ‘a white plaque of questionable risk 
having excluded (other) known diseases or disorders that carry no increased risk of 
cancer’ (295) and does not confirm the presence of dysplasia.  Unfortunately, authors 
differ in their use of the term ‘leukoplakia’ which can make the results of studies 
ambiguous; some incorrectly use it to infer dysplasia.  Studies reporting on malignant 
transformation of oral leukoplakia  display a wide range of malignant transformation 
rates: 0.13-17.5%  over a period of 6 months to 30 years (286, 310).  There is 
variability between studies in the diagnosis of the disease, the population studied, 
the treatment modality and the follow-up arrangements, which is likely to account 
for the large range in malignant transformation rates.  When comparing malignant 
transformation rates of OED between studies, one should be aware of the method 
used to diagnose oral dysplasia, so that similar studies can be compared.   
Around 90% of red lesions (erythroplakia) show evidence of severe dysplasia or 
carcinoma on histology(311).  Holmstrup et al (312) reported a 7-fold increase in 
malignant transformation in non-homogenous leukoplakia (i.e. mixed red and white 
lesions), therefore it is usual for these lesions to be treated more aggressively than 
their homogenous counterparts (312).  Treatment almost always includes surgery 
and this is discussed below (section 8.2.4.1). 
An annual malignant transformation rate of leukoplakia of 1.4-7% has been reported, 
with the highest rate of malignant transformation occurring in the first 2 years (6, 
286, 310).  Size of lesion has also been found to predict malignant transformation, 
with lesions over 200mm2 found to transform more often than smaller lesions (279, 
312). 
The lateral tongue is the most common site for oral leukoplakia, followed by buccal 
mucosa. Ho et al found that 80% of lesions on the lateral tongue occurred in non-
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smoking patients (279). These lesions transform more frequently than lesions 
elsewhere on the oral mucosa (279, 286, 289).   
8.2.3.2. Grade of Dysplasia 
Grade of dysplasia has been found to be strongly associated with malignant 
transformation, with lesions showing a higher grade of dysplasia more likely to 
transform to invasive carcinoma (285, 287, 289, 313).  Lesions showing no evidence 
of dysplasia may also transform (285), which highlights the need for careful follow up 
of all patients with areas of change on the oral mucosa.  Mild dysplasia shows less 
than 5% transformation, and moderate and severe dysplasias have transformation 
rates of 3-15% and 7-50% respectively (288).  Amagasa et al (314) found that time to 
malignant transformation was reduced for lesions with higher grades of dysplasia. 
Liu et al (289) showed an increased risk of malignant transformation for lesions 
histologically confirmed as dysplastic, with high grade lesions more likely to 
transform compared to low grade (OR 2.78).  This finding is supported by Lee et al 
(313) who found a 2.30-fold increased risk of malignant transformation in lesions 
showing moderate/severe dysplasia compared to mild dysplasia.   
The effect of field cancerization is well-known and it has been demonstrated that 58% 
of patients with a unilateral oral squamous cell carcinoma displayed evidence of 
histologically abnormal tissue on the contralateral side, which appeared clinically 
normal (315).  This is consistent with a report by Lee et al (313)  that for 41% of their 
patients who developed Oral Squamous Cell Carcinoma (OSCC), the cancer developed 
at a different site to the original leukoplakia for which they were being treated. 
8.2.3.3 History of Oral Cancer 
Previous history of oral cancer is a risk factor for malignant transformation of 
dysplastic lesions:  Lee et al (313) showed that 63.6% of patients with previous cancer 
experienced malignant transformation of a dysplastic lesion compared to 25.4% of 
those with no previous history.   Management of these patients is also likely to be 
more aggressive and include excision or laser ablation of new lesions as they develop.   
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8.2.3.4 Smoking Status 
Non-smoking patients have been found to be at higher risk of malignant 
transformation compared to ever-smokers.  Ho et al (279) reported that non-smokers 
were 7.1 times more likely to undergo malignant transformation than heavy smokers 
(>20 pack years).  Rock et al published results in 2018 of their study of 444 patients 
with OED in Canada (282) and reported an increased risk of malignant transformation 
for dysplastic tongue lesions; 44 of the 85 tongue lesions in non-smokers progressed 
to oral cancer (OR 7.3; 95% CI 1.7-31.1).  The wide confidence intervals cast some 
doubt on the validity of the overall result. 
That non-smokers appear to be at higher risk of malignant transformation contrasts 
with the commonly accepted fact that smoking is a risk factor for oral cancer.  The 
increased risk of malignant transformation in non-smokers may be due to underlying 
(epi-)genetic differences.  Oral dysplasia that has developed in the absence of classic 
carcinogens suggests an alternative aetiology such as unique genetic mutations or 
replicative errors, which may confer increased risk (282). 
 
8.2.3.5 Molecular Markers of Malignant Transformation 
Various molecular markers of malignant transformation have also been explored 
(316-318). Loss of Heterozygosity (LOH) and methylation of p16 will be discussed 
briefly.  Rock et al have previously developed a prediction model for progression of 
OED based on LOH-status alone (319).  Their cohort contained 44 cases of oral 
dysplasia which progressed to oral cancer out of 296 total cases.  They have shown 
that LOH in a dysplastic lesion in a non-smoker confers a greatly increased risk of 
malignant transformation (HR 60.7 (95% CI 7.1 – 514.5)) and conclude that LOH 
“should be an important consideration in the management of OED”.  The addition of 
methyl groups to tumour suppressor genes (methylation) reduces their activity:   
27.1% of lesions showing evidence of p16 methylation underwent malignant 
transformation compared to 8.1% of un-methylated p16 cases (OR 4.6) (320).  
Molecular markers should be considered in any future risk prediction model for oral 
epithelial dysplasia. 
   
178 
 
8.2.4 Management Decisions in OED 
 
Section 8.2.1 discussed the current management of OED and the brief guidelines 
provided within the UK National Multidisciplinary Guidelines for Head and Neck 
Cancer (231).  The value of clinical photographs for surveillance is recognised, with 
72% of Consultant Oral and Maxillofacial Surgeons photographing lesions at the 
patient review appointments.  However, only 26% of these specialists would always 
biopsy a potentially premalignant oral lesion, although 99% would biopsy a speckled 
patch (321). Clinicians must decide whether to monitor a lesion for signs of 
progression, prior to definitive surgical intervention vs proceeding directly to surgical 
excision.  Patients with multiple lesions, larger lesions and lesions present at high risk 
sites (lateral border of tongue/floor of mouth), are considered to be at high risk of 
malignant transformation and may therefore be offered intervention, rather than 
active surveillance (279).   These decisions are made based on best-available evidence 
and potentially would benefit from the use of a risk prediction model, together with 
clinical acumen.  For lesions thought to be at low risk of progression, e.g. a mildly 
dysplastic lesion in a low-risk site, active monitoring is a realistic management plan 
(322).  Active monitoring may include clinical examination, photographic recording 
and surveillance biopsies.  
Management of moderate dysplasia varies between clinicians and may include a 
period of monitoring followed by resection if changes are noticed.  Other clinicians 
recommend excision of all areas of leukoplakia, due to reports of malignant 
transformation of non-dysplastic areas of leukoplakia many years after initial 
diagnosis (322).  Without conclusive evidence to support or reject the use of surgical 
excision of dysplastic lesions, it remains common practice to excise lesions showing 
histopathological evidence of severe dysplasia or carcinoma in-situ, as they would be 
considered at high risk of malignant transformation (323). 
8.2.4.1 Surgical Management of Oral Epithelial Dysplasia 
Some authors recommend excision of all areas of leukoplakia (322), with the aim of 
preventing malignant transformation. In complete contrast, it has been suggested 
that surgical excision of hamster tongue mucosa treated with carcinogen promotes 
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malignant transformation (324), although this has not be shown in humans.  In the 
absence of good quality evidence that surgical intervention helps to prevent 
malignant transformation, it is necessary to consider the need for multicentre, 
randomised control trials with long follow-up periods, to accurately determine the 
outcome of surgical intervention.   
Despite the current lack of RCTs into surgical intervention, it remains the most 
commonly used intervention in treating oral epithelial dysplasia. When treatment is 
advised, this may include laser ablation, laser resection or conventional scalpel 
excision(285).   
8.2.4.1.1 Scalpel Excision  
Scalpel excision remains a common treatment for dysplastic oral mucosal lesions.  
Studies over the last 10-15 years show a mean recurrence rate of 11.9% and 
malignant transformation rate of 4.6% for lesions that are excised (see Table 8.1) 
(325-329).   
Laser resection offers the advantages over scalpel excision of: haemorrhage control, 
improved visibility, shortening of operative time, decreased post-operative pain and 
swelling, minimal scarring and good post-operative tissue mobility (330).  Recurrence 
rates from studies into laser treatment of OED range from 7.7 to 38.1%. (331-333).
   
 
 
1
8
0
 
Table 8.1. Studies of Surgical interventions in Oral Epithelial Dysplasia.  The results for recurrence rate and malignant transformation rate, following surgery, are shown for 
each study 
 Author and Year Type of Treatment % Recurrence % Malignant Transformation amongst 
treated cases 
Jaber 2010 (325) “Surgery” or  “drug therapy” or 
“other” 
16.7 4.7 
Holmstrup 2006 (312) Scalpel Excision 13.5 12.4 
Kuribayashi 2012 (327) Scalpel Excision following 
application of Lugols Iodine 
15.1 1.9 
Thomas 2012 (328) Scalpel excision 4.2 4.1 
Pandey 2001 (329) Surgical Excision 10.1 0 
Jerjes 2012 (334) Laser excision and/or ablation 19.5 10.4 
Van der Hem 2005 (335) Prophylactic laser treatment 9.9 1.1 
Ishii 2003 (330) Laser treatment 29.3 1.2 
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8.2.4.2 Other Methods of Treatment 
8.2.4.2.1 Photodynamic Therapy 
Photodynamic therapy (PDT) has also produced positive results in the treatment of 
oral leukoplakia in short-term studies, although recurrence within 6 months was 
reported in one case (290).  Jerjes reported a complete response with PDT in 81% of 
treated lesions, malignant transformation in 7.5% of cases and progressive disease in 
a further 7.5% (336). 
8.2.4.2.2 Chemoprevention 
Several authors have investigated the use of chemoprevention in the management 
of oral dysplasia.  Vitamin A and beta carotene were explored as part of a double-
blind, placebo-controlled, randomised control trial (291) and it was demonstrated 
that 52% of lesions regressed with a regime of oral vitamin A, whilst 33% of lesions 
regressed with beta carotene.  Only 10% regressed in patients taking placebo.  This 
response was not maintained following cessation of the therapy, with up to 66% of 
responders relapsing. 
Epstein et al (292) used topical bleomycin in the management of oral dysplasia and 
demonstrated a decrease in clinical size and in grade of dysplasia compared to 
placebo.  Whether or not this translated to a decreased rate of malignant 
transformation is not clear.   
13-cis-retinoic acid and oral lycopene have also shown promising short-term results 
(337, 338), however reports of adverse reactions and early relapse limit their clinical 
usefulness.  
The most recent Cochrane review regarding management of oral leukoplakia 
concluded that there is insufficient high-quality evidence to support the use of non-
surgical interventions for treatment of oral epithelial dysplasia (339).  Only 2% of Oral 
and Maxillofacial (OMFS) consultants reported ever using chemopreventive agents 
for patients with oral premalignant lesions (321). 
A UK-based multicentre, double-blind, placebo-controlled, randomised control trial 
of Sodium Valproate for high-risk oral epithelial dysplasia, has been funded by the 
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Medical Research Council (ISRCTN12448611) (340) .  This trial is due to open in 2019 
and will recruit 110 patients with high risk oral dysplasia.  Patients will receive either 
4 months of Sodium Valproate or placebo, following which the histological and 
molecular changes will be assessed.   Interest in Sodium Valproate as a 
chemopreventive agent in HNC was raised following publication of the Kang study 
(341): over 400,000 US Veterans, of which 27,000 were taking sodium valproate, 
were recruited.  Results showed a significant protective effect against HNC for those 
veterans taking sodium valproate for greater than 3 years (HR 0.66 (95%CI 0.48-
0.92)). 
8.2.4.3 Follow-up 
Currently there is no international / national consensus for exact duration of follow-
up or follow-up intervals for monitoring of dysplastic lesions (342).   Some suggest 
lifelong follow-up at intervals of no more than 6 months (322), due to the potential 
for malignant transformation many years following the initial diagnosis of dysplasia. 
However, this has to be considered in terms of clinical resources; a risk assessment 
model would be extremely useful to select high risk individuals for follow up in 
secondary care, with low risk individuals discharged back to the Dentist for lifelong 
follow up.  Evidence from Taiwan, of 2229 male patients with Oral Leukoplakia 
showed a five year and ten year malignant transformation rate of 5% and 9.56% 
respectively, demonstrating the need for vigilance, even after the first five years 
(343).  
One survey of 189 UK OMFS Consultants (321) reports that 96% would follow up a 
patient with severe dysplasia but that only 70% would follow up moderate dysplasia. 
Thus, in the UK we already have an agreement to focus on the highest risk patients, 
but this could be improved with a validated risk model.  This indicates that clinicians 
regard grade of dysplasia as an important predictor for malignant transformation and 
plan their follow up of patients on that basis. 
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8.2.5 Risk Prediction for Oral Epithelial Dysplasia 
 
There are no current risk prediction models in clinical use for Oral Epithelial Dysplasia.  
Decisions on management are based on clinical and histological predictors. Attempts 
have been made to develop a risk model of malignant transformation: Lee et al (313) 
used a dataset containing 70 patients with OED with median 7.2 years follow up, with 
22 cases of malignant transformation.   They considered a total of 12 variables in their 
Cox regression model, of which three were significant at the 5% level.  Age >60, 
positive cancer history and moderate/severe dysplasia (vs mild dysplasia) were found 
to be risk factors for transformation.  Unfortunately, no discrimination or calibration 
statistics were presented, and the model has not been internally or externally 
validated.  This model is underpowered to detect variables significantly associated 
with the outcome, given the small number of cases that progressed to cancer (n=22).  
Using the rule of ten events per variable, only 2 variables should have been 
considered, which demonstrates the need for a larger dataset in which to develop 
this model. 
8.3 Discussion 
Patients with Oral Epithelial Dysplasia have a significantly increased risk of developing 
oral cancer compared to the general population (25% vs 0.2%) (281, 341).  There is a 
need for consensus guidelines, based on the available evidence, for the management 
of OED. Ideally, management decisions should be based on a robust and properly-
validated risk prediction model.  No such risk model exists at present and a large 
dataset is required to achieve this aim. OED is diagnosed by clinical examination and 
histopathology, which remain the gold standard for diagnosis considering current 
evidence. With further development of the technologies discussed in this chapter, 
this may change in the future.   
The forum in which patients are managed may be significant for patient outcome: 
Liverpool University Dental Hospital has a specialist oral pre-malignancy clinic, which 
involves clinicians from the specialities of Oral Medicine, Oral and Maxillofacial 
Surgery and Oral Pathology.  This group has shown that patients managed within this 
multidisciplinary dysplasia clinic, whose lesions undergo malignant transformation, 
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present with lower stage tumours (T1) in comparison to patients presenting with oral 
cancer from general practice or elsewhere (281).  This permits more limited surgical 
intervention (wide local excision), when compared to higher stage tumours, which 
may be treated with more invasive surgery plus adjuvant radiotherapy with or 
without concurrent chemotherapy.   There is also a survival advantage, with 100% 5 
year survival reported, in the group of patients (n=23) who developed oral cancer, 
from dysplasia, having first been managed within the tertiary care clinic (281). 
The fourth World Workshop on Oral Medicine (WWOM IV) review of the 
management of oral epithelial dysplasia (344) concluded that there is a lack of RCTs 
assessing the effectiveness of surgical intervention in preventing malignant 
transformation.  However, surgery (laser or scalpel) remains the most appropriate 
treatment option for many patients.  Laser ablation can also be considered for larger 
areas where surgical removal may not be compatible with function.  The use of 
toluidine blue in identification of high risk lesions, selecting biopsy sites and helping 
to ensure clear margins is increasing and good results are emerging (282, 299, 301, 
307) as discussed in 8.2.2.2. 
Alternative modes of management such as chemoprevention have been explored 
and clinical trials are currently been undertaken,  however high quality evidence is 
required before chemopreventive options can be considered in the management of 
OED (344). Regular and long-term follow up is required for all patients with OED; at 
least 5 years follow up by specialists is suggested.  The location of this follow up may 
include tertiary dysplasia clinics, oral medicine clinics, and OMFS departments at 
district general hospitals. Patients will need to be individually assessed to determine 
the most appropriate location for follow-up.   Due to the potential for late malignant 
transformation, all patients discharged from specialist care will require lifelong 
surveillance in General Dental Practice; patients should be re-referred in the event of 
a change in the clinical appearance of the lesion.   
It is questionable whether more aggressive management is justified for patients with 
particular risk factors (e.g.  non-smoking patients). In the absence of RCTs the 
evidence does point to a high risk of malignant transformation for dysplastic lesions 
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on the lateral tongue of non-smoking patients (279, 282).  An ambition for the future 
will be to create a risk model for malignant transformation of dysplastic lesions, which 
will then need to be utilised in a RCT, with the aim of eventually offering a 
personalised treatment plan for patients with OED.  Development of a dysplasia risk 
model will require a dataset with sufficient numbers of cases of OED, progressing to 
oral cancer, requiring a multicentre study.  Ideally the model will include molecular 
markers, necessitating a prospective study. 
8.4 Conclusion 
The evidence presented here has highlighted the need for a risk prediction model to 
aid decision making, with the aim of improving outcomes for patients with this 
potentially malignant disease.  Chapter 9 provides conclusions and proposals for 
future work following the development and validation of the risk model for head and 
neck cancer in chapters 6 and 7. 
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Chapter 9  
 
Conclusions and Further Work 
 
9.1 Introduction 
Head and Neck Cancer is a debilitating disease affecting 12,000 people in the UK 
every year and over 500,000 individuals globally (345).  The incidence is rising, 
particularly in subgroups of HNC related to HPV infection (31).  Risk prediction models 
offer an exciting opportunity to enhance patient care in HNC.  There is potential to 
reduce morbidity and mortality associated with HNC through targeted screening of 
high-risk individuals, hopefully leading to earlier detection of disease and the 
possibility of less invasive treatments (257).  There is potential for a risk calculator to 
be used in clinical trial design to enable recruitment of sub-groups of patients with 
the highest risk of disease.  Using a risk prediction tool in general dental practice could 
offer an exciting opportunity to educate patients regarding their risk habits, based on 
a personalised risk score.   
This thesis has discussed the increasing incidence of HNC in the UK, explored novel 
risk factors for HNC in females and described the development and validation of the 
first risk prediction model for absolute risk of HNC in a UK population, using the UK 
Biobank dataset.  Oral pre-malignancy has also been discussed, as this condition 
affects a group of individuals with a particularly high risk of developing HNC.  This 
chapter draw conclusions from the work presented in chapters 2 and 3 (sections 9.2 
and 9.3) and will discuss the potential for further external validation (section 9.5) and 
testing of the risk prediction model for HNC (presented in Chapter 6) in feasibility and 
impact studies (section 9.6).  Options for implementation of the risk model in HNC 
clinical trials and as a tool for the dental team to guide patient counselling on risk 
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behaviours are discussed in 9.7 and 9.8, including the potential to translate this work 
into Oral Pre-malignancy. 
9.2 Incidence of Head and Neck Cancer  
The incidence of HNC increased from 12.2 to 15.9 per 100,000 between 2002 and 
2011, in the UK (149).  However, at sites strongly associated with HPV-infection (the 
oropharynx, tonsil and base of tongue), the incidence of cancers doubled.  This trend 
has been reported by others (31, 346) and in July 2018 the UK Government 
announced that the HPV vaccination programme would be extended to include boys 
(216) to address the issue of HPV-related oropharyngeal cancers.  The HPV 
vaccination should significantly reduce the incidence of HPV-related HNC, however, 
this effect will not be demonstrated for several decades due to the lag time between 
initial infection and presentation with HPV-related oropharyngeal cancer (216).   
9.3 Novel Risk Factors 
Smoking, alcohol and particularly the combination of the two are well-established 
risk factors for HNC (22).  Increasing age and male gender are also known to increase 
the risk of disease.  However, there is increasing acceptance that lack of fresh fruit 
and vegetables and lack of exercise are risk factors for HNC.  Closely related to this is 
the problem of social deprivation; areas of significant deprivation in the UK have rates 
of HNC three-times the national average (8).  However, not all patients conform to 
the stereotype of a HNC patient by being an older male with a long history of smoking 
and drinking alcohol.  Work in this thesis has demonstrated an increasing incidence 
of oral cancer in older females (Chapter 2).  There is also a known cohort of non-
smoking female patients with oral pre-malignancy, who suffer a higher rate of 
malignant transformation compared to their smoking counterparts (279, 282).  This 
raised the question as to whether hormone-related risk factors were specific to 
females.  The systematic review presented in Chapter 3 demonstrated a lack of 
studies addressing this issue but confirmed an increased risk of oesophageal cancer 
for women entering menopause before the age of 45 years; similar but less significant 
results were noted for HNC.  Hormone related risk factors (early menopause and 
hormone replacement therapy) were not found to be significantly different between 
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cases and controls when assessed in the UK Biobank data (Chapter 5).  However, in a 
pooled analysis of 11 HNC studies, with 1572 cases of HNC, HRT offered a significant 
protective effect (OR 0.58 (95% CI 0.34-0.77)), which justifies further exploration of 
hormone-related risk factors in female HNC (347).   
9.4 Improving Model Performance 
Chapter 6 presented the development and performance of a risk prediction model 
for HNC using the UK Biobank dataset.  The final model included variables for age, 
gender, smoking duration and smoking status, frequency of alcohol consumption, 
lifetime number of sexual partners, daily consumption of fruit, moderate exercise and 
annual household income.  This model was developed using a nested case-control 
study within the UK Biobank, which contains 702 cases of HNC and 423,752 controls.  
The model performance was moderate in terms of its ability to discriminate between 
cases and controls (c-statistic 0.67) but displayed good calibration.  The model was 
validated in a sub-group of individuals from the North West of England, known to 
have a higher incidence of HNC (8).  The performance of the model in this external 
validation was reasonable, with a c-statistic of 0.64.  
9.4.1 Limitations of the Model and the Data 
The addition of further HNC-specific risk factors could potentially improve the 
discriminative ability of the current model.  Certainly, the addition of molecular 
biomarkers has been shown to improve performance of other cancer risk prediction 
models (275, 348).  There is increasing evidence of a role for biomarkers, present in 
saliva, which are associated with increased risk of HNC, specifically lactate 
dehydrogenase (349), sialic acid (350) and presence of HPV in oral rinses (351).  As 
technology develops and chairside analysis of saliva for relevant biomarkers becomes 
possible, the model could be updated.      
It was surprising to note that those currently ‘never’ drinking alcohol were at higher 
risk of HNC than daily drinkers (Table 6.2).  This may be explained by looking at the 
univariable analysis of alcohol status (Table 6.1), which revealed that ‘previous 
drinkers’ were at higher risk of HNC than current drinkers and never drinkers.  It is 
possible that those currently not drinking have stopped consuming alcohol for health-
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related reasons, for example alcoholic liver disease.  It is not possible to capture a 
picture of lifetime consumption of alcohol from the UK Biobank data and this is a 
limitation of the study.  However, we did note that a statistically significantly greater 
number of male and female cases report drinking “less alcohol now than 10 years 
previously”, compared to controls (see Table 5.3).  This could be due to the diagnosis 
of HNC, as discussed in 5.3.6. 
The Biobank data contains both prevalent and incident cases of HNC (see section 
5.2.1).  Both were included in the model development and validation data.  It would 
be possible to include only incident cases to remove any bias introduced from 
including prevalent cases.  Patients may have changed their alcohol or smoking habits 
due to the diagnosis of HNC which could result in artificially lower effect estimates 
for these variables.  Data on lifetime smoking and alcohol can help to overcome this, 
however, lifetime alcohol consumption was not captured within the Biobank data.  
Smoking duration was used within the model to reflect lifetime exposure to cigarette 
smoke.   
Household income is lower in the HNC cases than controls and this may be explained 
due to the fact a greater percentage of cases are retired compared to controls 
(section 5.2.2); therefore, a different measure of socio-economic deprivation could 
be considered for future models, such as Index of Multiple Deprivation (IMD).  IMD 
data was not available in the Biobank.  Townsend deprivation index was available, 
but this was not selected for the final model as it cannot be simply calculated from a 
postcode.  Lifetime number of sexual partners could be removed from future 
iterations of the model as this is only relevant to oropharyngeal cancers (see sections 
1.2.4 and 5.2.12) due to the association with Human papillomavirus.   
Due to the heterogeneous nature of HNC and differences in risk profiles between 
patients with the difference sub-types of HNC, it would be sensible to consider 
individual risk models for the different sub-types.  However, many of the subtypes 
are extremely rare and it would require a dataset much larger than the UK Biobank 
in order to develop a robust model. 
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This study calculated absolute risk of head and neck cancer, with an average person-
time at risk of 63.5 years (see section 5.2.1).  A model for 5-year or 10-year risk could 
be considered, and regional cancer incidence data could be used to facilitate absolute 
risk calculation over this period, as described in section 6.8.2. 
9.5 External Validation Studies 
Many risk prediction models have been developed but few are validated in external 
data and even fewer have been assessed for their clinical impact on patient outcomes 
(264, 352).  It is recognised that the model developed in this thesis will require further 
validation in data external to the UK Biobank.  INHANCE  (International Head and 
Neck Cancer Epidemiology Consortium) is a collaborative group of HNC researchers 
that contains over 30 member studies with greater than 30,000 cases of HNC and 
over 40,000 controls (353).  We will seek to collaborate with individuals within this 
consortium to validate this HNC risk prediction model.  Discussions regarding data 
sharing are underway. 
Head and Neck Cancer 5000 is a UK based cohort study of 5000 patients with a 
diagnosis of HNC (354), who were asked to provide details on lifestyle, including 
sexual history, at baseline.  Researchers are encouraged to apply for access to this 
data, therefore this could provide a valuable UK-based dataset for validation of the 
model, assuming comparable controls are available. 
9.6 Impact Studies 
Many risk prediction models are developed with the ultimate aim of having a positive 
impact on patients, whether through guiding decision-making (264) or reducing the 
burden of disease through screening (355).  Section 9.6.1 will briefly discuss models 
which have been successfully developed and implemented to demonstrate this is a 
realistic possibility for a HNC risk model.  Section 9.6.2 and 9.6.3 discuss a framework 
for moving forward following the model development phase. 
9.6.1 Successful Development and Implementation of Risk Prediction 
Models in Lung Cancer 
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Lung cancer risk prediction models have been developed, validated and tested in 
screening trials; the use of such models has been found to be beneficial in selecting 
high-risk patients for screening (356). Selecting high-risk individuals, using risk 
algorithms, improves cost-effectiveness of screening for lung cancer and reduces the 
risk of false positive diagnoses (357, 358).  The PLCOm2012 model (Prostate, Lung, 
Colorectal and Ovarian modified risk prediction model) has been developed (359) and 
externally validated (360-363) and has now been adopted for use in selection of high-
risk individuals for the Cancer Care Ontario pilot study of lung cancer screening (356, 
364).  Individuals with a greater than 2% risk as defined by the PLCOm2012 model are 
invited for low-dose CT screening (356). 
The Liverpool Lung Project modified risk prediction model (LLPv2) (365) has also been 
externally validated (360-362) and used in the UKLS trial (United Kingdom Lung 
Cancer Screening Trial) (366).  UKLS is a randomised controlled trial of low dose CT 
screening for lung cancer against usual care (no screening).  4055 patients were 
recruited to the pilot study; patients were classified as high-risk (and therefore 
eligible for inclusion) if they had a >5% chance of lung cancer as determined by the 
LLPv2 model (52).  46 (2.1%) participants were diagnosed with lung cancer and over 
85% were detected at an early stage (Stage I or II).   The LLPv2 is also used in the 
Liverpool Healthy Lung Project, funded by Liverpool Clinical Commissioning Group 
(367) through which patients with a greater than 5% risk of lung cancer are invited 
for LDCT scan via their GP. 
This demonstrates that with proper development, validation and impact studies, risk 
prediction models can be a valuable tool in clinical trials and screening programmes. 
9.6.2 The Process following Model Development 
 
Developing and validating this HNC risk prediction model is only the first step towards 
achieving the aim of reducing the incidence of head and neck cancer.   
A model that performs well in validation studies could be expected to perform well 
in clinical practice. However, just because a model exists does not mean that a 
clinician will choose to use it or that it will improve decision-making, or indeed health-
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outcomes (264).  These potential pitfalls can be addressed systematically through 
feasibility studies, clinical utility studies and ultimately impact studies.  This involves 
significant time and monetary costs so one must be confident that the model in 
question is ready for implementation in clinical practice (264, 352, 368, 369).   
The model should be externally validated in at least one external dataset and ideally 
within the population that the impact study will be performed.  This allows 
coefficients to be recalculated to fit the population in which it is to be used if 
necessary.  One should also be confident that the aim of the model is realistic; for 
example, if the aim is to reduce the incidence of HNC through targeted screening of 
high-risk individuals, one should be sure that there is evidence to support this.  
Appropriate software would also need to be developed to allow the risk model to be 
combined with existing programmes in clinical practice (369). 
The way in which the model is introduced to clinical practice is of paramount 
importance and should be done in consultation with the clinicians involved.  The 
model can be presented to clinicians in a directive or assistive format (264).  In the 
directive format, the clinician is given a direct recommendation from the model 
output, e.g. to order a diagnostic test.  In the assistive format, the clinician is 
presented with a probability of the outcome for that individual and can make their 
own decision about how that should be interpreted.  The directive format is preferred 
by clinicians and has been shown to improve patient outcomes, compared to the 
assistive format (264).  When applying this to screening programmes, patient choice 
will also be a factor, as any screening programme carries the risk of uncertain 
diagnoses and inaccurate results.  Patients should be fully appraised of the role of the 
risk model in selecting them for screening, and the potential risks and benefits of the 
screening offered (370, 371).  
9.6.3 Study Design 
To test the effect of a risk model on decision making or outcome, a clinical trial is 
required.  This may take the form of a cluster cross-over RCT, in which certain clusters 
use the model and others do not, following which the group initially using the model 
becomes the control group and vice versa.  Closely related to this is the ‘parallel 
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group’ design, where parallel groups either use the model or act as controls.  In this 
case, it is very important to study the decision making of clinicians in each group prior 
to the trial, so that one can account for any differences at baseline. Alternatively, a 
before-after study design can be used, where the effects of the risk model on decision 
making (or other outcome) are compared before and after model implementation 
(352, 368).    
Studying the effect of a model on the health-outcome in question can require very 
long studies, especially if the outcome is rare, as is the case with HNC.  In this 
situation, it is reasonable to study the effect on decision-making initially.  This can be 
achieved through clinical trials as described above, however, decision analytic studies 
can be used prior to committing to expensive RCTs (368, 372). These studies model 
the effects of the risk prediction model on decision making and outcome, based on 
the model’s predictive accuracy and the effectiveness of the intervention proposed, 
within pre-existing datasets.  If there is no effect on decision-making in the decision 
analysis, it would be hard to justify a trial to study change in outcome.  Decision 
analytic modelling also forms an important part of Health Economic Evaluations 
(HEE), which considers the cost of an intervention (for example, screening) in relation 
to improvement in quality of life.  HEE for prediction models are rare and there is a 
need for guidance in this area (368). 
Wallace et al proposed a framework for the implementation of a clinical prediction 
model, as follows (369): 
1. Exploratory phase: explore how well the model performs in external 
validation. 
2. Preparation for impact analysis: Conduct a feasibility study to investigate 
clinician-acceptance of the model and consider potential barriers to 
implementation. 
3. Experimental phase:  Monitor the use of the model in clinical practice 
(through a trial). 
4. Long-term implementation phase: examine if a model is used long-term and 
the methods used to achieve this. 
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The model developed here in this thesis could be externally validated in large, existing 
datasets to confirm its predictive accuracy.  Software could be developed to integrate 
the model into existing software programmes in general dental and medical practice.  
A decision-analysis study could be completed to model the effect of the risk model 
on clinicians’ decisions to screen high-risk individuals for oral cancer.  Pending the 
results of such analysis, a cluster RCT could be designed to test the use of the model 
in general practice.   
9.7 Implementation: Counselling on Risk Behaviours 
General Dental Practitioners are required to screen all patients for oral cancer (373).  
However, only 51% of the adult population of the UK visit a Dentist each year (374).  
Whilst it may not be necessary to use a clinical risk calculator in General Dental 
Practice to guide screening of high-risk individuals, as all patients will undergo an oral 
examination, using a personalised risk score could support discussions between 
dental professionals and patients regarding risk behaviours, such as smoking and 
alcohol consumption.  It could also provide an opportunity for the dental team to 
discuss health promoting behaviours, such as eating fresh fruit and vegetables and 
taking regular exercise.  There is evidence from an RCT that use of a risk score when 
providing smoking cessation advice results in longer term success with smoking 
cessation (375).  The effects of this would hopefully be more wide-reaching than the 
effect on incidence of HNC alone, due to the damaging effects of smoking and alcohol 
on general health.  This provides an exciting opportunity to implement what is 
already being done in relation to lung cancer (375) into General Dental Practice.  
Feasibility and impact studies would be required to test whether the HNC risk model 
is well-received by clinicians and patients, and the impact on smoking cessation rates 
and other risk behaviours. 
 
9.8 Translation to Oral Pre-Malignancy 
Finally, risk prediction modelling could offer huge benefits in guiding the 
management of oral pre-malignancy and in the design of clinical trials.   
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The management of oral pre-malignancy is currently based on clinical and histological 
diagnosis, with no use of risk prediction scores to guide the clinician.  Although many 
molecular markers, which may predict malignant transformation, are under 
investigation, none are currently being used to guide patient management.  Nikitakis 
et al reviewed the current literature on molecular markers associated with 
progression of oral dysplasia to oral cancer, in 2018 (376).  They concluded that “a 
combined panel embracing all of these parameters (molecular markers) and an 
algorithm to provide quantitative scoring should be developed” (376). 
A large prospective dataset would be required to develop such a model and external 
data would be required to validate the model.  This is likely to require a multicentre, 
national or international study, of significant duration.  The model should then be 
tested for its clinical usefulness and ultimately for its effect on the incidence of HNC.     
9.8.1 Risk modelling in Clinical Trials 
In addition to the potential for guiding management decisions and improving 
outcomes for patients with Oral Epithelial Dysplasia, there is potential for a risk 
prediction model to be used in clinical trials.  Phase II trials are feasibility trials, usually 
involved in testing novel drugs or other interventions.  Rather than comparing 
outcome between index and control groups, one can predict survival in both groups 
based on usual standard of care (using the risk model) and compare this to the 
observed survival (or other outcome measure).  This helps to control for the 
differences between trial patients in each group (372). 
Phase III trials are expensive, and it is desirable to recruit patients at highest risk of 
poor outcome, to increase the expected event rate and hence minimise sample size 
requirements.  Exposing low-risk patients to potentially toxic drugs or the 
inconvenience of screening and risk of false positive results would not be ethical, 
which further supports the need for recruitment of high-risk patients.  These high-
risk patients can be identified through use of a risk model, which helps to provide a 
definitive cut off point for inclusion criteria (372).   
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9.9 Concluding Remarks 
Risk prediction modelling is currently under-utilised in HNC research.  There is great 
potential to build, validate and implement risk calculators in many areas of HNC 
clinical practice. The work presented in this thesis should stimulate discussion 
between clinicians and academics about future work in this area.  The model 
developed could be refined, validated and implemented to inform recruitment of 
high-risk individuals to clinical trials, guide the dental team when counselling patients 
on risk behaviours and be explored as a tool for screening of high-risk individuals.  
There is potential to translate this work to Oral Pre-malignancy, to allow the 
development of personalised treatment plans, based on the individual’s’ risk of 
developing oral cancer, calculated using a properly developed and validated risk 
prediction model.  
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Appendix 1.  Chapter 2: Incidence of Head and Neck Cancers in England, by Sex: 2002-2011 
Table A1.1 Incidence of Head and Neck Cancer and sub-types, per 100,000 persons, for males and females from 2002-2011, in England 
Year Value Cancer Type 
  
Head and Neck Cancer  OPSCC  Oral Cancer  Laryngeal Cancer 
Total Male Female  Total Male Female Total Male Female Total Male Female 
2002 
 
Incidence 12.2 17.4 7.4  1.8 2.7 1.0 5.2 6.6 3.8 3.4 5.7 1.2 
N 6,082 4,215 1,867  899 654 245 2,582 1,611 971 1,674 1,374 300 
2003 
 
Incidence 13.1 18.4 7.9  2.0 3.1 1.0 5.6 7.2 4.1 3.4 5.7 1.2 
N 6,532 4,505 2,027  1,004 756 248 2,809 1,756 1,053 1,698 1,380 318 
2004 
 
Incidence 13.1 18.6 7.8  2.1 3.1 1.1 5.5 7.0 4.1 3.4 5.8 1.1 
N 6,554 4,563 1,991  1,040 761 279 2,771 1,730 1,041 1,693 1,424 269 
2005 
 
Incidence 13.2 18.6 8.1  2.2 3.4 1.1 5.6 7.0 4.3 3.4 5.8 1.2 
N 6,700 4,617 2,083  1,119 835 284 2,831 1,733 1,098 1,729 1,432 297 
2006 
 
Incidence 14.3 20.1 8.6  2.5 3.9 1.2 6.0 7.7 4.5 3.3 5.6 1.2 
N 7,272 5,033 2,239  1,284 969 315 3,083 1,920 1,163 1,708 1,405 303 
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Table A1.1 continued.  Incidence of Head and Neck Cancer and Sub-types (per 100,000 persons) for Males and Females 2002-2011, in England 
 
Year Value 
 
                           Cancer Type  
 
 
 
 
  
  Head and Neck Cancer                 OPSCC            Oral Cancer        Laryngeal Cancer  
Total Male Female  Total Male Female Total Male Female Total Male Female  
2007 
 
Incidence 14.1 19.9 8.5  2.5 3.9 1.3 6.0 7.7 4.4 3.3 5.7 1.1  
N 7229 5012 2217  1304 974 330 3098 1942 1156 1714 1436 278  
2008 
 
Incidence 15.1 21.1 9.2  2.7 4.3 1.2 6.6 8.1 5.0 3.5 5.9 1.2  
N 7799 5364 2435  1415 1089 326 3394 2066 1328 1798 1492 306  
2009 
 
Incidence 15.4 21.7 9.4  3.0 4.5 1.5 6.6 8.4 4.9 3.4 5.9 1.1  
N 8034 5550 2484  1549 1156 393 3469 2161 1308 1797 1496 301  
2010 
 
Incidence 15.9 22.1 9.9  3.4 5.2 1.7 6.7 8.4 5.1 3.5 5.9 1.2  
N 8355 5711 2644  1794 1339 455 3524 2167 1357 1837 1529 308  
2011 
 
Incidence 15.9 22.1 9.8  3.3 5.1 1.6 6.9 8.7 5.1 3.5 5.8 1.3  
N 8424 5788 2636  1772 1338 434 3647 2271 1376 1848 1506 342  
 
p-value <0.001 0.003 0.004  <0.001 0.003 0.003 <0.001 0.005 0.004 0.32 0.40 0.40  
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Appendix 2.  Further Results from Chapter 2. 
Table A2.1.  Incidence per 100,000 persons of HNC in England, in each 5-year age category, from 2002-2011. 
 
 
  
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Age Cat M F M F M F M F M F M F M F M F M F M F 
40-44 2.1 0.5 2.2 0.6 1.9 0.8 2.8 0.5 2.9 0.7 2.9 1.2 2.7 0.9 3.0 0.9 3.2 0.9 2.8 0.9 
45-49 5.2 1.2 5.4 1.4 5.5 1.4 5.3 1.6 6.2 1.6 6.5 1.9 7.2 2.0 6.2 2.1 7.6 2.2 7.3 2.0 
50-54 6.6 2.2 7.6 2.1 7.5 2.3 10.2 2.5 8.7 2.9 11.3 2.2 10.7 2.9 12.8 3.6 12.0 3.7 12.5 3.5 
55-59 8.3 2.9 10.0 2.9 9.2 2.7 9.8 2.7 11.1 3.4 10.0 3.5 14.1 3.3 15.1 4.5 17.2 5.0 17.6 5.2 
60-64 7.7 2.6 9.7 2.5 9.7 3.7 10.1 2.4 11.9 3.3 11.2 3.5 10.5 3.3 12.2 4.4 16.9 5.9 16.2 4.8 
65-69 6.2 2.0 6.4 2.0 7.6 2.7 9.2 2.3 8.8 2.6 10.0 2.5 13.1 2.6 11.3 3.6 13.3 3.9 13.6 3.9 
70-74 6.0 3.1 6.8 2.7 6.0 2.0 6.6 2.7 6.7 1.9 7.1 3.2 10.0 2.8 9.6 3.1 10.8 3.7 12.5 3.5 
75-79 5.4 1.3 4.5 1.9 6.5 2.1 5.4 2.5 8.0 2.3 5.9 1.8 7.4 2.5 7.4 3.0 7.7 2.4 7.9 2.6 
80-84 4.5 1.9 4.1 1.4 5.3 2.7 5.7 2.8 6.3 1.5 5.2 1.6 4.3 1.5 6.2 1.6 8.2 2.7 5.9 2.3 
85+ 5.6 2.2 3.8 1.2 5.9 1.5 2.4 1.6 5.4 1.7 3.5 2.4 4.2 1.7 3.2 1.1 4.3 1.6 4.8 1.8 
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Appendix 2 continued. Further Results from Chapter 2. 
Table A2.2.  Incidence per 100,000 persons, of OPSCC in England, in 5 - year age categories, from 2002-2011 
 
  
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Age Cat M F M F M F M F M F M F M F M F M F M F 
40-44 2.1 0.5 2.2 0.6 1.9 0.8 2.8 0.5 2.9 0.7 2.9 1.2 2.7 0.9 3.0 0.9 3.2 0.9 2.8 0.9 
45-49 5.2 1.2 5.4 1.4 5.5 1.4 5.3 1.6 6.2 1.6 6.5 1.9 7.2 2.0 6.2 2.1 7.6 2.2 7.3 2.0 
50-54 6.6 2.2 7.6 2.1 7.5 2.3 10.2 2.5 8.7 2.9 11.3 2.2 10.7 2.9 12.8 3.6 12.0 3.7 12.5 3.5 
55-59 8.3 2.9 10.0 2.9 9.2 2.7 9.8 2.7 11.1 3.4 10.0 3.5 14.1 3.3 15.1 4.5 17.2 5.0 17.6 5.2 
60-64 7.7 2.6 9.7 2.5 9.7 3.7 10.1 2.4 11.9 3.3 11.2 3.5 10.5 3.3 12.2 4.4 16.9 5.9 16.2 4.8 
65-69 6.2 2.0 6.4 2.0 7.6 2.7 9.2 2.3 8.8 2.6 10.0 2.5 13.1 2.6 11.3 3.6 13.3 3.9 13.6 3.9 
70-74 6.0 3.1 6.8 2.7 6.0 2.0 6.6 2.7 6.7 1.9 7.1 3.2 10.0 2.8 9.6 3.1 10.8 3.7 12.5 3.5 
75-79 5.4 1.3 4.5 1.9 6.5 2.1 5.4 2.5 8.0 2.3 5.9 1.8 7.4 2.5 7.4 3.0 7.7 2.4 7.9 2.6 
80-84 4.5 1.9 4.1 1.4 5.3 2.7 5.7 2.8 6.3 1.5 5.2 1.6 4.3 1.5 6.2 1.6 8.2 2.7 5.9 2.3 
85+ 5.6 2.2 3.8 1.2 5.9 1.5 2.4 1.6 5.4 1.7 3.5 2.4 4.2 1.7 3.2 1.1 4.3 1.6 4.8 1.8 
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Appendix 2 continued. Further Results from Chapter 2. 
Table A2.3.  Incidence per 100,000 of Oral Cancer in England, in five-year age categories, from 2002-2011 
 
 
 
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Age Cat M F M F M F M F M F M F M F M F M F M F 
40-44 3.5 1.2 3.5 1.5 2.8 1.3 3.5 1.5 3.4 2.0 3.1 1.1 4.1 2.0 3.6 2.8 3.7 2.4 3.4 1.4 
45-49 7.6 2.6 6.6 4.0 6.5 3.1 6.5 3.3 7.4 3.2 6.7 3.6 6.8 4.0 7.1 3.1 7.4 3.2 8.5 3.1 
50-54 12.4 4.5 12.4 5.0 12.3 6.8 12.6 5.7 12.6 5.8 15.2 6.2 13.9 6.7 13.0 6.2 13.6 6.7 13.1 7.1 
55-59 16.2 6.1 17.1 7.5 16.6 7.1 15.3 6.1 18.4 7.6 20.0 7.9 19.2 7.8 21.3 8.4 20.7 9.7 22.3 8.8 
60-64 18.1 8.4 21.9 8.0 20.6 8.4 20.2 10.2 21.7 8.4 23.4 8.8 22.6 9.8 22.8 10.3 26.4 9.5 26.5 10.2 
65-69 19.5 8.3 22.2 9.7 17.8 9.9 21.6 11.2 24.4 10.3 23.1 10.5 25.1 11.8 26.8 13.5 26.5 12.9 24.0 13.6 
70-74 18.9 11.6 21.1 12.2 23.3 11.0 20.8 12.1 21.0 13.4 22.2 11.1 22.7 15.5 26.6 12.3 25.1 15.3 26.9 15.9 
75-79 19.8 12.8 24.7 11.0 23.8 12.9 22.8 12.3 23.6 12.5 21.1 15.4 26.3 14.1 29.1 15.5 23.6 16.8 24.7 17.1 
80-84 25.7 14.8 21.2 14.4 24.4 15.9 23.0 16.7 26.8 17.8 20.3 16.7 29.6 19.6 23.4 16.4 25.1 18.9 25.8 20.9 
85+ 28.7 15.7 24.5 20.5 27.2 17.6 25.9 19.0 25.7 22.6 25.5 18.2 25.2 23.1 23.7 22.6 25.2 21.9 30.0 19.7 
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Appendix 2 continued. Further Results from Chapter 2. 
Table A2.4.  Incidence, per 100,000 persons, of Laryngeal Cancer in England, in five-year age categories, from 2002-2011 
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Age Cat M F M F M F M F M F M F M F M F M F M F 
40-44 1.2 0.4 1.2 0.4 1.3 0.2 1.0 0.3 1.3 0.3 0.8 0.2 0.8 0.5 1.4 0.4 1.4 0.3 1.0 0.2 
45-49 3.2 0.5 3.9 0.7 2.6 0.5 3.1 0.9 3.6 0.9 3.0 0.3 4.0 0.4 2.9 0.6 3.0 0.6 3.3 0.8 
50-54 7.5 1.2 6.9 1.6 6.9 1.6 7.1 1.6 7.2 2.3 7.7 1.7 7.2 1.8 6.6 1.4 7.5 1.4 5.2 1.7 
55-59 13.5 2.8 13.7 2.0 13.0 1.5 13.1 2.1 11.4 1.9 12.4 2.0 10.9 1.9 12.7 1.9 12.7 2.6 12.6 1.8 
60-64 18.1 2.6 16.0 3.8 19.2 3.4 18.6 3.3 19.4 3.9 15.2 3.0 18.4 3.6 17.8 2.5 16.9 2.9 15.6 3.2 
65-69 20.8 4.1 20.0 4.3 19.8 3.3 20.1 3.2 21.8 3.6 22.9 3.1 20.6 3.2 20.3 3.9 22.5 4.4 20.9 4.1 
70-74 24.8 4.2 22.8 4.3 22.9 3.5 21.9 3.1 20.3 2.4 24.4 3.6 23.9 4.0 26.0 4.7 23.3 3.8 22.7 4.6 
75-79 22.9 3.7 26.2 4.1 28.3 4.6 24.2 5.3 22.5 3.6 21.8 3.1 24.2 3.0 23.5 3.3 24.6 3.5 24.7 4.6 
80-84 23.4 5.0 25.3 4.3 26.1 3.1 27.9 4.1 22.6 4.4 22.4 4.5 23.9 4.6 24.2 4.5 21.2 3.5 24.0 4.7 
85+ 18.6 3.2 23.0 3.3 22.8 3.2 25.9 2.7 22.9 3.2 28.2 2.9 27.1 3.2 18.1 2.7 21.6 3.1 26.2 3.3 
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Appendix 3.  Chapter 3 – Data Collection Sheet for Systematic Review 
Table A3.1. Data Collection Sheet for Systematic Review in Chapter 3 
Study Number 1 2 3 4 5 6 7 8 
Year  
       
First Author  
       
Country  
       
Study Type  
       
Aim of Study  
       
Inclusion criteria  
       
Exclusion Criteria  
       
Number in cohort  
       
Follow up time for Cohort studies  
       
Number Cases  
       
Controls  
       
Loss to follow up  
       
Age (mean) Cases   
       
Controls 
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Table A3.1 continued. Data Collection Sheet for Systematic Review in Chapter 3 
 Study 
Number 
 
1 2 3 4 5 6 7 8 
Male:Female Ratio Cases  
       
Controls  
       
Age at Menopause Cases  
       
Controls  
       
Use of HRT Cases  
       
Controls  
       
Duration of HRT Cases  
       
Controls  
       
Type of HRT Cases  
       
Controls  
       
Smoking Cases  
       
Controls  
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Table A3.1 continued. Data Collection Sheet for Systematic Review in Chapter 3       
Study Number  1 2 3 4 5 6 7 8 
Alcohol Cases  
       
Controls 
 
 
       
          
SES measure used 
 
 
       
SES results Cases  
       
Controls  
       
Newcastle Ottawa Score  
       
Comments  
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Appendix 4.   
Material Transfer Agreement for 
UK Biobank Data 
 
 
 
  
The Material Transfer Agreement 
received from the UK Biobank can 
be found inserted here. 
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Appendix 5.  Full list of Variables 
Considered Contained in the 
Development Dataset 
 
General Exercise 
Encoded anonymised participant ID 
Number of days/week of moderate physical 
activity 10+ minutes 
Sex 
Number of days/week of vigorous physical 
activity 10+ minutes 
Year of birth Place of Birth 
Month of birth Place of birth in UK - north co-ordinate 
Date of attending assessment centre Place of birth in UK - east co-ordinate 
UK Biobank assessment centre Screening-related Variables 
Age at death Ever had bowel cancer screening 
Date of death Ever had prostate specific antigen (PSA) test 
Underlying (primary) cause of death: ICD10 
Ever had breast cancer screening / 
mammogram 
Contributory (secondary) causes of death: ICD10 Ever had cervical smear test 
Ethnic background Early-life and Family History 
Weight Adopted as a child 
Age when attended assessment centre Part of a multiple birth 
Age at recruitment Maternal smoking around birth 
Country of Birth (non-UK origin) Father still alive 
Home location at assessment - east co-ordinate 
(rounded) 
Fathers age at death 
Home location at assessment - north co-
ordinate (rounded) 
Mother still alive 
Pulse rate Number of full brothers 
Number of children fathered Number of full sisters 
Handedness (chirality/laterality) Mothers age at death 
Skin colour Number of older siblings 
Hair colour (natural, before greying) Birth weight 
Facial ageing Illnesses of father 
Country of birth (UK/elsewhere) Illnesses of mother 
Length of mobile phone use Illnesses of siblings 
Weekly usage of mobile phone in last 3 months Non-accidental death in close genetic family 
Usual side of head for mobile phone use Socio-Economic Variables 
Sleep duration Age completed full time education 
Snoring Qualifications 
Medical History Current employment status 
Blood clot, DVT, bronchitis, emphysema, asthma, 
rhinitis, eczema, allergy diagnosed by doctor 
Job code – deduced 
Medication for cholesterol, blood pressure, 
diabetes, or take exogenous hormones 
Current employment status - corrected 
Medical History continued Socio-Economic Variables 
Diastolic blood pressure, automated reading Townsend deprivation index at recruitment 
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Appendix 5  continued. Full list of Variables in the Model Development Dataset 
Systolic blood pressure, automated reading Average total household income before tax 
Body mass index (BMI) Home area population density - urban or rural 
Body fat percentage Particulate matter air pollution (pm10); 2010 
Number of self-reported non-cancer illnesses Particulate matter air pollution (pm2.5); 2010 
Number of operations, self-reported Nitrogen dioxide air pollution; 2010 
Number of treatments/medications taken Nitrogen oxides air pollution; 2010 
Overall health rating Smoking-related Variables 
Long-standing illness, disability or infirmity Current tobacco smoking 
Had major operations Past tobacco smoking 
Diabetes diagnosed by doctor Smoking/smokers in household 
Fractured/broken bones in last 5 years Exposure to tobacco smoke at home 
Other serious medical condition/disability 
diagnosed by doctor 
Exposure to tobacco smoke outside home 
Taking other prescription medications Light smokers, at least 100 smokes in lifetime 
Had other major operations Age started smoking in former smokers 
Age high blood pressure diagnosed Type of tobacco previously smoked 
Age diabetes diagnosed Number of cigarettes previously smoked daily 
Age angina diagnosed Age stopped smoking 
Stomach/abdominal pain for 3+ months Ever stopped smoking for 6+ months 
Age hay fever, rhinitis or eczema diagnosed 
Number of unsuccessful stop-smoking 
attempts 
Age asthma diagnosed Likelihood of resuming smoking 
Operative procedures - main OPCS Age started smoking in current smokers 
Diagnoses - main ICD10 Type of tobacco currently smoked 
Interpolated Year when non-cancer illness first 
diagnosed 
Number of cigarettes currently smoked daily 
(current cigarette smokers) 
Interpolated Age of participant when non-
cancer illness first diagnosed 
Time from waking to first cigarette 
Non-cancer illness code, self-reported Difficulty not smoking for 1 day 
Medication for cholesterol, blood pressure or 
diabetes 
Ever tried to stop smoking 
Mouth/teeth dental problems Wants to stop smoking 
Vascular/heart problems diagnosed by doctor Smoking compared to 10 years previous 
Medication for pain relief, constipation, 
heartburn 
Previously smoked cigarettes on most/all days 
Heel bone mineral density (BMD) T-score, 
automated (left) 
Why stopped smoking 
Age heart attack diagnosed Why reduced smoking 
Age emphysema/chronic bronchitis diagnosed 
Number of cigarettes previously smoked daily 
(current cigar/pipe smokers) 
Age deep-vein thrombosis (DVT, blood clot in 
leg) diagnosed 
Age stopped smoking cigarettes (current 
cigar/pipe or previous cigarette smoker) 
Age pulmonary embolism (blood clot in lung) 
diagnosed 
Smoking status 
Gestational diabetes only Ever smoked 
Facial pains for 3+ months Pack years of smoking 
Spells in hospital 
Pack years adult smoking as proportion of life 
span exposed to smoking 
Illness, injury, bereavement, stress in last 2 
years 
Alcohol-related Variables 
Female-Hormone Related Variables Alcohol intake frequency 
Age when periods started (menarche) Average weekly red wine intake 
Female Hormone continued Alcohol continued 
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Appendix 5. continued.  Full List of Variables in the Development Dataset 
Had menopause 
 
Average weekly champagne plus white wine 
intake 
Number of live births Average weekly beer plus cider intake 
Birth weight of first child Average weekly spirits intake 
Age at first live birth Average weekly fortified wine intake 
Age at last live birth Alcohol usually taken with meals 
Ever had stillbirth, spontaneous miscarriage or 
termination 
Alcohol intake versus 10 years previously 
Ever taken oral contraceptive pill Reason for reducing amount of alcohol drunk 
Age started oral contraceptive pill Former alcohol drinker 
Age when last used oral contraceptive pill Alcohol consumed 
Ever used hormone-replacement therapy (HRT) Red wine intake 
Age at hysterectomy Rose wine intake 
Bilateral oophorectomy (both ovaries removed) White wine intake 
Pregnant Beer/cider intake 
Age started hormone-replacement therapy 
(HRT) 
Fortified wine intake 
Age last used hormone-replacement therapy 
(HRT) 
Spirits intake 
Age at menopause (last menstrual period) Other alcohol intake 
Ever had hysterectomy (womb removed) Alcohol drinker status 
Time since last menstrual period Diet-related Variables 
Length of menstrual cycle Cooked vegetable intake 
Number of stillbirths Salad / raw vegetable intake 
Number of spontaneous miscarriages Fresh fruit intake 
Number of pregnancy terminations Dried fruit intake 
Age of primiparous women at birth of child Oily fish intake 
Age at bilateral oophorectomy (both ovaries 
removed) 
Non-oily fish intake 
Cancer-related Variables Processed meat intake 
Number of self-reported cancers Poultry intake 
Cancer diagnosed by doctor Beef intake 
Cancer code, self-reported Lamb/mutton intake 
Interpolated Year when cancer first diagnosed Pork intake 
Interpolated Age of participant when cancer 
first diagnosed 
Cheese intake 
Date of cancer diagnosis Milk type used 
Type of cancer: ICD10 Spread type 
Age at cancer diagnosis Bread intake 
Reported occurrences of cancer Bread type 
Histology of cancer tumour Cereal intake 
Behaviour of cancer tumour Cereal type 
Type of cancer: ICD9 Salt added to food 
Sexual History Tea intake 
Age first had sexual intercourse Coffee intake 
Lifetime number of sexual partners Coffee type 
Ever had same-sex intercourse Water intake 
Lifetime number of same-sex sexual partners Major dietary changes in the last 5 years 
 Variation in diet 
 Breastfed as a baby 
 Never eat eggs, dairy, wheat, sugar 
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Appendix 6.  Rules applied for 
Managing Variables 
 
Category Criteria for removal of variable/data 
point 
Missing Data >40% missing data 
Duplicate Cancer Diagnosis Same histological type of cancer recorded 
at same sub-type within 1 week of 
original diagnosis 
Repeated Measures All variables representing repeated 
measures (i.e. data not collected at first 
visit) 
Irrelevant Variables Remove all variables not listed in 
Appendix 5. 
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Appendix 7.  TRIPOD Checklist 
Topic Checklist Item Section in Thesis Page Number 
Title and Abstract    
Title Identify the study as developing and/or 
validating a multivariable model, the target 
population and the outcome to be predicted 
Title Page – Chapter 6 
Title Page- Chapter 7 
127 
147 
    
Abstract Summary of objectives, study design, 
setting, participants, sample size, predictors, 
outcome, statistical analysis, results and 
conclusions 
6.1 127 
    
Introduction    
Background and Objectives Explain medical context and rationale for 
development/validation of the model 
1.4 12-13 
 Specify the objectives, including whether the 
study describes development, validation or 
both 
1.4 12-13 
Methods    
Source of data Describe the source of the data 
Specify the key study dates (start and end of 
accrual) 
4.3.2 62-3 
    
 
 
 
 
 
Appendix 7. TRIPOD Checklist   
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Topic Checklist Item Section in Thesis Page Number 
Participants Specify key elements of the study setting, 
including number and location of centres. 
Describe eligibility criteria 
Details of treatment received, if relevant 
4.3.2.2 63 
    
Outcome Clearly define the outcome that is predicted 
by the prediction model, including how and 
when assessed 
 
Report any actions to blind assessment of 
the outcome 
4.3.4 66-7 
    
Predictors Clearly define all predictors used including 
how and when they were measured 
 
Report any measures to blind assessment of 
predictors 
4.3.2.3 64-5 
    
Sample Size Explain how the study size was arrived at 4.3.2.2 64 
    
Missing Data Describe how missing data were handled 
with details of any imputation method 
4.4.3 69 
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Topic Checklist Item Section in Thesis Page Number 
Statistical Analysis Methods Describe how predictors were handled 
 
Specify the type of model, any predictor 
selection and method for internal validation 
 
For validation, describe how the predictors 
were calculated 
 
Specify all measures used to assess model 
performance and, if relevant, to compare 
multiple models 
4.3.5 
 
 
4.4.5.3 and 4.5.1 
 
4.3.2.3 
 
 
7.2 
67 
 
 
72 & 73-4 
 
64-5 
 
 
148 
    
Risk Groups Provide details on how risk groups were 
created, if done 
N/A N/A 
    
Development vs Validation For validation, identify any difference from 
the development data in setting, eligibility 
criteria, outcome and predictors 
7.1 147 
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Topic Checklist Item Section in Thesis Page Number 
Results: Participants Describe the flow of participants through 
the study, including the number of 
participants with and without the outcome 
Describe the characteristics of the 
participants (basic demographics, clinical 
features, available predictors), including the 
number of participants with missing data for 
predictors and outcome 
 
For validation, show a comparison with the 
development data of the distribution of 
important variables (demographics, 
predictors and outcome). 
 
 
 
Table 5.19 
 
 
 
 
 
 
Table 7.1 
 
 
 
124-26 
 
 
 
 
 
 
151-52 
Results: Model Development Specify the number of participants and 
outcome events in each analysis. 
 
If done, report the unadjusted association 
between each candidate predictor and 
outcome 
6.1 
 
 
Table 6.1 
127 
 
 
130 
    
Results: Model Specification Present the full prediction model to allow 
predictions for individuals (i.e. all regression 
coefficients, and model intercept) 
Table 6.2 135 
    
Results: Model Performance Report performance measures with CI’s for 
the prediction model 
7.4.1 154 
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Topic Checklist Item Section in Thesis Page Number 
Results: Model updating If done, report the results from any model 
updating 
7.5 156 
    
Discussion    
Limitations Discuss any limitations of the study  6.8.1 144-46 
    
Interpretation For validation, discuss the results with 
reference to performance in the 
development data and any other validation 
data 
 
Give an overall interpretation of the results, 
considering objectives, limitations, results 
from similar studies, and other relevant 
evidence 
 
 
7.7.1 
 
 
 
 
 
7.8 
 
 
161 
 
 
 
 
 
164 
    
Implications Discuss the potential clinical use of the 
model and implications for future research 
9.7 and 9.8 190-91 
    
Other information    
Supplementary information Provide information about the availability of 
supplementary resources, such as web 
calculator and datasets 
n/a n/a 
    
Funding Give the source of funding and the role of 
funders for the present study. 
n/a n/a 
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